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ABSTRACT

Bartolowits, Matthew David Ph.D., Purdue University, December 2015. Discovery of molecules
that modulate protein-protein interactions in the context of human proliferating cell nuclear
antigen-associated processes of DNA replication and damage repair. Major Professor: Vincent Jo
Davisson.

Integral to cell viability is the homotrimeric protein complex Proliferating Cell Nuclear
Antigen (PCNA) that encircles chromatin-bound DNA and functionally acts as a DNA clamp that
provides topological sites for recruitment of proteins necessary for DNA replication and damage
repair. PCNA has critical roles in the survival and proliferation of cells, as disease-associated
dysregulation of associated functions can have dire effects on genome stability, leading to the
formation of various malignancies ranging from non-Hodgkin’s lymphoma to skin, laryngeal,
ocular, prostate and breast cancers. Here, a strategy was explored with PCNA as a drug target that
may have wider implications for targeting protein-protein interactions (PPIs) as well as for
fragment-based drug design. A design platform using peptidomimetic small molecules was
developed that maps ideal surface binding interaction sites at a PPI interface before considering
detailed conformations of an optimal ligand. A novel in silico multi-fragment, combinatorial
screening approach was used to guide the selection and subsequent synthesis of tripeptoid ligands,
which were evaluated in a PCNA-based competitive displacement assay. From the results, some of
the peptoid-based compounds that were synthesized displayed the ability to disrupt the interaction
between PCNA and a PIP box-containing peptide. The IC50 values of these compounds had similar
or improved affinity to that of T2AA, an established inhibitor of PCNA-PIP box interactions. The
information gained here could be useful for subsequent drug lead candidate identification.
As a second goal of this study, the known anti-tumor agent, EGFR antagonist, gefitinib,
was chemically modified and incorporated into subcellularly-targeted peptoid-peptide hybrid
complexes. It is hypothesized that targeting this agent into the nucleus of tumor cells can allow for
bypassing mechanisms of drug resistance observed in various tumor types, particularly triple

xx

negative breast cancer. Enhanced cellular and nuclear uptake was observed with the drug
conjugates. Furthermore, some of the compounds demonstrated the ability to selectively
downregulate STAT3 phosphorylation, while not affecting the phosphorylation of ERK1/2, and
had enhanced antiproliferative activity in gefitinib-resistant cells. Further studies are needed to
assess the mechanism of action of these molecules, but they hold promise as agents that can be used
to treat drug-resistant cancers.

1

1. INTRODUCTION

DNA is the repository in which genetic information is stored in every living cell, and its structural
integrity is vital to proper cellular function and survival. At any given time, cells are being exposed
to exogenous and endogenous agents that cause as many as tens of thousands to one million DNA
lesions per day [1,2]. If the resulting damage is not repaired, it gives rise to genetic instability, and
possibly disease [3–9]. Additionally, DNA damage has been observed to be a major factor in
cellular senescence and aging [10,11]. In response to these damaging events, a complex process is
initiated that comprises the detection and repair of DNA lesions. These make up what is referred to
as the DNA damage response (DDR).
The DDR as a whole is composed of a number of distinct mechanisms that are activated in
response to specific types of DNA damage. DNA lesions can arise from numerous sources, with
examples such as replication errors during DNA synthesis, UV-induced linkages or radiation/chemically-induced DNA double strand breaks (DSBs) [6]. Damage induced by exogenous agents
can result in an unpredictable pattern of DNA lesions, potentially due to decreased efficiencies of
the DNA repair process, particularly in the context of DNA damaging chemotherapies [6,12]. In
general, cells that have defective mechanisms of DDR display enhanced sensitivity to DNAdamaging agents, and these defects can ultimately lead to disease. The major processes of damage
repair and their associated signaling mechanisms have been extensively studied [6,13–15], and
what is becoming clear are the implications for dysregulation of the DDR.
A number of human diseases, both inherited and non-inherited, have been associated with
an accumulation of DNA lesions. Parkinson’s, Huntington’s and Alzheimer’s diseases, in addition
to ataxia, have been associated with an increased amount of DNA damage in neurons [9,16].
Infertility [17,18], metabolic syndrome [19,20] and heritable diseases such as Fragile X, diabetes
mellitus type 2, Creutzfeldt-Jakob, amyotrophic lateral sclerosis and Leigh syndrome are also
caused by deficiencies in the DDR [21–23]. Perhaps most notoriously, cancer arises from genome
instability induced by large numbers of DNA lesions. Correspondingly, the majority of agents
classified as carcinogens operate by causing DNA damage, many times resulting in mutations that
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can negatively impact numerous cellular signaling and checkpoint pathways [24]. Individuals can
also have predispositions to cancer based on inherited defects in gene products involved in the
DDR, and a patient’s outcome can be further complicated due to these same defects enabling
neoplastic lesions to progress into malignancy [25,26]. Ultimately, these conditions highlight the
importance of proper cellular response to inflicted DNA damage, as well as the careful maintenance
of multiple genome stability pathways.

1.1

Regulation of Protein Repair Complexes at Sites of DNA Damage

Evoking an appropriate cellular response to DNA damage involves a complex series of events
including the sensing and recognition of damage, subsequent signaling and repair of those lesions.
There are various pathways that act to repair various types of exogenous and endogenous agentinduced damage in humans. The protein MGMT reverts the mutagenic O6-methylguanine lesion
back to guanine, and is able to prevent mismatch errors during the replication and transcription of
DNA [27]. When damage occurs that leads to breaks in a single strand of DNA, three major
mechanisms, base excision, nucleotide excision and mismatch repair, are elicited [28]. These
mechanisms function by using the opposite intact strand of DNA as a template, removing a
damaged nucleotide and replacing it with the proper complementary nucleotide. Single strand
breaks are the most common type of DNA damage that occurs [29], so efficient repair of these
lesions is essential for cell survival.
Alternatively, DNA DSBs are particularly troublesome since they can result in
rearrangements of the genome. DSBs are repaired by three different mechanisms, homologous
recombination (HR), non-homologous end joining (NHEJ) and microhomology-mediated end
joining (MMEJ) [6]. HR and NHEJ are the primary repair pathways invoked in mammalian DSB
repair [30], though MMEJ does occur at relatively reduced levels. NHEJ, in particular, is a versatile
system that exhibits a high degree of structural tolerance of DNA end substrate configurations.
Owing to its importance, individuals that lack normally functioning NHEJ are sensitive to ionizing
radiation, and are also severely immunodeficient [31].
Separate from the other mechanisms of DDR, translesion synthesis (TLS) is a process of
DNA damage tolerance that enables DNA replication machinery to replicate past lesions. In
general, if replication is initiated before a site of DNA damage is repaired, it can lead to the
replication machinery stalling at the damage locus, ultimately leading to cell death. TLS involves
the recruitment of specialized DNA polymerases that can bypass the site of the lesion, allowing
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DNA synthesis to continue [32]. The switching out of regular polymerases for specialized ones is
mediated, among various other factors [33], by RAD6/18-mediated ubiquitination of Proliferating
Cell Nuclear Antigen (PCNA) [34]. While this damage tolerance mechanism aids cell survival, due
to the nature of these specialized polymerases being error prone, undesired consequences, such as
the formation of cancer, can potentially result, particularly if numerous DNA lesions continue to
accumulate in a cell’s genome [35].
As a protective measure, upon DNA damage cell cycle checkpoints become activated; this
allows the cell to repair DNA lesions before continuing to divide. Typically, the type of damage is
recognized and the appropriate signaling pathway is initiated, resulting in the formation of repair
complexes at sites of lesions [15]. The proteins that initially detect lesions can be classified as
“sensors”; this class is made up of DNA scaffolds such as the Rad9-Rad1-Hus1 (9-1-1) complex,
replication protein A (RPA), phosophoinositide-3-kinase (PI3K) members ATM, ATR and DNAPK, and the aforementioned PCNA [6]. Each of these recognizes and interacts with a number of
mediatory proteins; this leads to the transduction of amplified signals towards effectors that affect
processes such as cell cycle regulation, transcription, DNA repair, chromatin remodeling and
apoptosis. In this way, the scaffold proteins act as sites of recruitment, forming complexes that
regulate the essential functions associated with the DDR [15].

1.1.1

Targeting Cancer-Specific Defects in DNA Repair Pathways

The significance of genome maintenance, and subsequent cancer prevention, in the DDR is
highlighted by the observation that genes that encode components of DNA repair pathways are
among the most frequently mutated genes in cancer [36]. Studies have shown that as tumorigenesis
progresses, cancer cells tend to inactivate the DDR and overcome senescence, potentially indicating
that abrogating portions of DDR signaling pathways is necessary for malignant transformation
[25,26,37–40]. This likely explains why defects in the DDR are typically seen in human tumors
and why genomic instability is increasingly being seen as a hallmark of cancer [36,40].
Though hundreds of mutations may be present in a given cell’s genome, only a select few
of these may be necessary to induce carcinogenesis [41]. These “driver” mutations cause some sort
of key dysregulation in a cell’s growth control, and are the cause of specific cancers being
‘addicted’ to these oncogenic drivers. With the increase in knowledge of the mutational landscape
of cancer genomes, function-oriented classification of cancer-associated genes has increased. As a
result, the ability to classify tumors based on their unique repertoire of DNA repair deficiencies has
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Explored in combination therapy with various
DNA-damaging agents, growth factor
receptor inhibitors and enhanced radiotherapy
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Type of Cancer or Model Cell Line
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Sensitization to ionizing radiation, PARP
inhibitors and methyl methanesulfonate

Sensitization to etoposide and doxorubicin

Explored in combination therapy with various
DNA-damaging agents and topotecan

Application

Table 1.1
Examples of Small Molecule Inhibitors of DDR-Associated Pathways in Cancer in Phase I/II/III or Pre-Clinical Trials
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improved. Targeting these cellular defects has been a goal of drug development against cancer.
Many current and traditional chemotherapies make use of a single drug to treat a specific type of
cancer. However, these strategies have not always proven to be effective in the short- or long-term
due to cellular toxicity and development of resistance [42]. Because mammals have evolved
complex networks of parallel and overlapping pathways to repair diverse types of genotoxic
lesions, it is likely that targeting multiple pathways simultaneously is necessary for a robust,
sustained response to drug therapy.

1.1.1.1 Using Small Molecules to Target Processes of DNA Damage Repair

Three major classes of inhibitors exist that target processes of DNA repair: protein-protein
interaction (see Table 2.1), DNA-protein interaction and enzyme-based inhibitors [5,43,44]. While
enzyme inhibition has had success in treating certain diseases, many traditional chemotherapies
and molecularly-targeted agents including protein kinases inhibitors have not provided sustained
clinical efficacy by themselves [45–49]. Compounds such as DNA damaging agents often display
initial benefit in cancer patients, but tumors eventually become resistant to these drugs due to
various factors, including upregulation of the DDR [50]. As a result, new strategies are being
explored for the treatment of disease including new rational therapeutic drug combinations [42].
A potential approach toward overcoming certain cellular mechanisms of drug resistance is
to simultaneously target multiple pathways associated with DNA replication and damage repair. A
number of small molecules in pre-clinical or clinical trials have been developed that target DDRassociated pathways such as cell cycle checkpoints, NHEJ, homologous recombination and baseexcision repair (Table 1.1) [44]. These compounds are typically used in combination with other
types of chemotherapeutics, and show enhanced sensitization to ionizing radiation, DNA damaging
agents and growth factor receptor inhibition [44]. Ultimately, this strategy may prove to be far more
efficacious, and in many cases, necessary in the treatment of cancer.

1.2

Considerations of Protein Subpockets in Fragment-Based Drug Design

(The following section is reproduced with permission from Bartolowits, M., and Davisson, V.J.
(2015) [51]; © 2015 John Wiley & Sons A/S. doi: 10.1111/cbdd.12631.)

Fragment-based drug design (FBDD) is an important strategy in both industry and academia for
the discovery of novel ligands and aids the progression toward lead compounds [52]. It is based on

6
the idea that through the use of low molecular weight chemical fragments, which typically only
bind weakly to their intended target, higher affinity lead ligands can be obtained by combining or
‘growing’ these small compounds into larger drug-like molecules. Due to high levels of diversity
between biological targets, incorporating FBDD as a high-throughput screening tool can have
significant advantages over traditional higher molecular weight chemical libraries [53]. The
approach considers factors such as compound availability, ease of synthesis, large chemical space,
and limits on steric “bulkiness”, which may otherwise preclude many higher molecular weight
ligands from recognizing non-covalent enthalpically-driven affinity factors (e.g. hydrogen bonding,
etc.) at a target binding site. Indeed, FBDD can prove to be robust for rational fragment
identification in the absence of 3D structural data [54]. However, FBDD still faces several
challenges, such as the general lack of accountability for ligand specificity or selectivity [55,56],
and the fact that key interactions and geometry of an original fragment hit may need to be changed
when incorporated into a lead compound [57]. Furthermore, the role of ligand-dependent receptor
conformations has been largely untested.
A number of reviews have discussed recent advances in fragment-based drug design and
how these tools can be used to improve the lead design process [55,58–65]. Yet, relatively few
evaluations have appeared which address the importance of small localized environments in a
protein binding site, and how microenvironments ultimately drive ligand binding and observed
effects such as drug non-specificity. The field of drug discovery has long struggled with the
accurate prediction of a drug’s cross-pharmacologic profile [66–69] and side effects. However,
recent advances offer avenues toward understanding the significance of protein “subpockets”—the
physical chemical and geometric properties surrounding an individual residue. Traditional methods
of computational analysis to find binding sites have sought to identify the similarity between
proteins based on inherent sequence conservation or overall structural similarity. However, the
localized chemical environments to be sampled by chemical fragment screens are potentially vast.
Further development of generalized methods for discovery of similar protein-ligand binding sites
and predicting the interaction profile of molecular fragments remains of high interest [70].
Recently, multiple methods have been developed that compare proteins based on localized
environments within binding sites, or the chemical environment around protein-bound ligands
derived from PDB database crystal structures. These methods take one of two general approaches:
1) proteins are compared and binding sites organized based on their structural or chemical
similarities, or 2) data from known ligand-protein interactions are used to identify potentially
similar sites in other proteins that could bind equivalent chemical fragments. This review aims to
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provide an overview of the background and emerging computational approaches that can define,
and take into account, the significance of protein subpockets in the design of new chemical probes
and pharmaceuticals. Many of these same tools offer methods which can also enhance
understanding of drug activity. The relevance of new methodological insights to fragment-based
drug discovery and the implications for lead development when considering factors such as nonspecificity and side effects are also considered.

1.2.1

Protein Fragment Recognition in Drug Design

1.2.1.1 Concept of Shared Subpockets

In many modern cases of structure-based drug discovery, structural information for a target in
question drives the ligand development process [71,72]. The RCSB protein data bank (PDB) [73]
currently contains more than 89,000 structures solved by X-ray crystallography, with more than
10,000 others solved through other means (NMR, electron microscopy, etc.). This knowledge
database, which continues to expand, is a vital tool for understanding the general structures of target
proteins and the topology of target ligand binding sites. Among “sibling” members of a protein
subfamily, binding sites may have a moderate-to-high level of overall similarity, such as the ATP
binding sites in the large family of protein kinases [74]. Although, even in cases where two
arbitrarily selected proteins have overall dissimilar ligand-binding sites, they may still bind the
same chemical fragments if they share similar or equivalent topological features at the subpocket
level (see Figure 1.1 for an example). This explains why two binding sites with substantially
different sequences can bind identical chemical fragments, such as the case with the
trifluoromethyl- and sulfonyl-binding subpockets between isoenzymes of the carbonic anhydrase
family and cyclooxygenase-2 [75]. Convergent evolution in nature is commonly observed to reveal
similar enzyme active sites between proteins [76]. Likewise, divergent evolution can result in
shared ligand binding sites among proteins that have highly dissimilar overall structures [77].
Between proteins even of distant origin, similar ligand binding motifs containing conserved
consecutive residues can be found, indicating that it is quite efficient for nature to reuse localized
features to bind similar molecules, even when the functional relationships may not be clear.
The principle of protein subpockets requires definition at the level of individual amino
acids within a protein. Each residue is surrounded in three dimensions by other amino acid residues,
water molecules and/or metal ions. The resultant microenvironments create the recognition features
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Figure 1.1. Shared Subpocket Between Two Structurally Distinct Proteins. The conformation of
the adenine portion of ACP is conserved between two structurally and sequentially diverse proteins,
demonstrating a shared subpocket at the binding site (HSP90 N-terminal domain, yellow, PDB ID:
3T10; Chemotaxis protein CheA, blue, PDB ID: 1I5A). Figure is reproduced with permission: ©
2015 John Wiley & Sons A/S. doi: 10.1111/cbdd.12631.

for a particular chemical fragment, albeit with likely moderate ranges of affinities. These localized
environments created by the protein generally define what are termed “subpockets” within a
binding cavity. Even within the limits of 20 different standard amino acids and the amide backbone,
a substantial number of distinct subpockets with unique “fingerprints” are possible. These
subpockets differ by the relative proximity of specific amino acids to each other and distances
between chemical functional groups. The amount of chemical space covered by chemical fragments
is vast, but not all of them comprise preferable features for protein binding [78]. Therefore, any
given chemical fragment is not guaranteed to bind to a protein subpocket across the entire proteome.

1.2.1.2 Fragment Diversity and Protein Interactions

For a chemical fragment to bind with favorable free energy, it must have the appropriate overall
shape, proper spacing of its chemical functional groups and generally compatible hydrophobic
features to establish meaningful life-times within a subpocket. How these characteristics overlap
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with the physiochemical properties associated with the characteristics of drug-like molecules
warrants consideration. In principle, chemical fragments can represent high diversity in shape and
chemical features, but only a subset of compounds that could be classified as “fragments” are useful
for the purposes of screening against biological targets. A study by Zuegg and Cooper [79] analyzed
more than eight million unique compounds from more than 100 chemical vendors and found that
only 400,000 of these passed the fragment-like filter for the analysis of drug- and lead-likeness
based upon “the rule of three” (molecular weight < 300 Da, ClogP < 3, the number of hydrogen
bond donors and acceptors < 3, and the number of rotatable bonds < 3) [80]. A large number of
fragments are represented in this subgroup, but there is an argument for ignoring a majority of
commercially available compounds and enhancing practicality in a fragment-based screening
platform. Of course, rules often have exceptions, and there is evidence that simply adhering to “the
rule of three” for the design of a fragment library may preclude compounds that would otherwise
show up as hits [81].
To further facilitate the fragment library design process, there are a number of studies that
have examined the binding preferences of proteins for chemical fragments (Table 1.2). By
analyzing fragments from lead-like compounds in the PDB [73], Chan et al. found that particular
types of fragments are more likely to interact with specific amino acid side chains (Asp, Glu, Arg
and His) and engage in hydrogen bonding interactions [82]. Separately, through the use of a
developed algorithm, LigFrag-RPM, Wang et al. (2011) mapped the interaction profiles of 315
unique fragments—derived from 71,798 different PDB ligands—against 20 naturally-occurring
amino acids, also identifying the preferences of fragment-types for particular amino acids [83].
This map could be used to determine whether a given fragment is in a favorable or unfavorable
environment, and potentially guide the lead chemistry process.
While this may serve as a quick, efficient way to direct the design of ligand topology, the
orientations of individual amino acids have to be taken into account. Even when comparing the
same binding site between two crystal structures of the same protein, the microenvironments in that
site may differ significantly based on residue orientations, and this can substantially bias docking
studies. As an example, Cox, B. et al. [84] noted that although co-crystal structures had been
obtained of the G-protein-coupled receptor (GPCR) CXC-motif chemokine receptor 4 (CXCR4)
bound to the anti-HIV small molecule IT1t and peptide CVX15 [85], docking of IT1t back into the
CXCR4:IT1t crystal structure resulted in large RMSD values compared to experimentally solved
structures. Similarly, docking other small molecule antagonists into the crystal structure gave poses
that lacked critical interactions identified by site-directed mutagenesis [86,87]. It was observed that
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Table 1.2
Preferential Amino Acid Fragments
Residue

Examples of Fragments

Arginine

Aspartic Acid

Cysteine

Glutamic Acid

Histidine

Methionine

Phenylalanine

Threonine

Tryptophan

Tyrosine

Examples of chemical fragments that select amino acids interact with. [82,83]
Table is reproduced with permission: © 2015 John Wiley & Sons A/S. doi:
10.1111/cbdd.12631.
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the CXCR4:CVX15 (CVX15: cyclic peptide antagonist) crystal structure produced a result that
showed agreement between the computational binding pose of another small molecule CXCR4
inhibitor, AMD11070, and independent site-directed mutagenesis data. When analyzed in more
detail, the orientations of residues Gln200 and His203 in the interior of the binding pocket differed
substantially between the two co-crystal structures. Though the same amino acids are present at the
binding site, changes in side chain orientation can substantially affect predicted binding modes and
docking scores in virtual-compound screens, and may result in an unacceptably large false negative
rate, particularly when rigid protein docking approaches are used. Therefore, the most accurate
representations of protein subpockets must take into account multiple possible rotameric states of
amino acid side chains if binding site microenvironments are to be generalized as chemical spaces
represented by single “fingerprints”. This presents a potential problem for many approaches to
binding site comparison that make use of pre-existing ligand-bound data, since the amino acids that
make up the microenvironment surrounding a ligand fragment are already conformationally-biased
in a given crystal structure.
While particular amino acids are seen to favor certain chemotypes, there exist some types
of compounds that show relatively limited specificity and can negatively affect fragment-based
drug screening efforts. These molecules, being related to pan-assay interference compounds, are
often widely promiscuous in the number and types of interactions with proteins and serve as
artifacts, yielding false signals across many types of assays [56,88–92]. There are varied reasons
for the promiscuous nature of these compounds [93,94]; but, they represent a subclass of indirect
observations of the potential ‘fuzziness’ in protein microenvironments. In essence, these
compounds own a fragment chemical space that can recognize more general protein features that
have recurring characteristics which contribute to the high level of promiscuity. When considered
in this context, protein subpockets cannot always be rigidly defined by a size and shape boundary
since some chemical functionalities are seen to interact with less well-defined features.

1.2.2

Identifying Subpockets

In reality, defining what constitutes a ‘subpocket’ for fragment screening is not always a clear task.
A significant number of topological features on a protein could potentially be classified as being
part of a subpocket if one were to focus on the environment of a single amino acid. A common
approach for defining pockets is to focus on the proximity of protein atoms or residues to a bound
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ligand. There have been many studies dealing with the analysis of binding sites, ranging from
sequence comparisons, to overall binding site structural similarity and pharmacophore
(“fingerprint”) searching [59,95–105]. Until recently, the majority of the work in the field has
looked at the relationship between binding sites in the context of an entire defined pocket.
Traditional computational methods have attempted to reduce the representation of protein surfaces
in an effort to maximize the speed with which a search query can be performed (for examples, see
Jordan, et al. (2012) [106] and Xie, L. & Bourne, P.E. (2007) [107]). It is likely that higher degrees
of accuracy in predicting the similarity of binding sites can be obtained by taking into account more
in-depth features such as hydrophobicity, aromaticity and hydrogen-bonding capability at the level
of single amino acids. As a result, attention in the field has turned to studying local areas of protein
surfaces, with implications for traditional receptor binding sites as well as protein-protein
interaction interfaces. Table 1.3 highlights many of the currently available programs, methods or
databases used to screen binding sites; and while there is diversity between each of these, most can
be generalized into one of two groups: protein topology- and ligand interaction-driven approaches.

1.2.2.1 Using Protein Topology to Search for Binding Sites

A significant number of methods currently exist for comparing protein binding sites [98]. Some of
these detect locally conserved residue patterns in order to define similar topological features
between proteins and their probability of containing equivalent interaction sites. These approaches
can function independently of known ligand-binding data, since the protein structure drives the
query. A web server such as ProBiS [108] is useful for detecting either global or local similarities
between proteins and identifying structurally conserved binding sites on proteins of interest. This
tool takes into account geometric as well as physicochemical properties for aligning the local
structure of two proteins; a user can decide to compare the entire surface of a protein, or only a
selected surface patch, against a database of more than 35,000 non-redundant structures. The
program COFACTOR [109] is able to identify functional sites on a protein as well as predict its
biological function by comparing the local and global 3D structure of a protein against the large
BioLiP database [110]. Similarly, the IMAAAGINE web server [111] can be used to define an
arrangement of 3-8 amino acid residues that are converted into a search pattern to query the PDB
and identify structural motifs with equivalent localized environments amongst the arrangement of
amino acids within a defined tolerance distance (default of 1.5Å). These examples demonstrate
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Table 1.3
Methods or Tools for Analysis of Binding Site Similarity and Pharmaceutical Discovery
Method or Database

Publication or Software URL

CatSld [112,113]

http://catsid.llnl.gov

Description
Searches

for

matches

between

catalytic sites and proteins
CavBase (Relibase)

http://relibase.ccdc.cam.ac.uk

[114–118]

Uses 3D property descriptors to detect
similarities between protein cavities
that share little or no sequence
homology

COFACTOR [109]

http://zhanglab.ccmb.med.umi

Structure-based method for biological

ch.edu/COFACTOR

protein function annotation

http://nbcr.ucsd.edu/data/sw/h

Finds suitable fragments that match

osted/crystaldock/

protein pocket-lining residues

DoGSiteScorer

http://dogsite.zbh.uni-

Detects

[120–122]

hamburg.de

predicts site druggability

F-SPE-FP-PH3

http://www.ncbi.nlm.nih.gov/

3D

[123]

pubmed/20886466

environments surrounding fluorinated

CrystalDock [119]

protein

fingerprint

subpockets

descriptors

and

for

ligands in the PDB
FINDSITELHM [124]

http://cssb.biology.gatech.edu/

Homology modeling approach to

findsitelhm

flexible ligand docking

FragFEATURE

http://www.ncbi.nlm.nih.gov/

Predicts small fragments preferred by

[125]

pubmed/24762971

a target protein structure

GIRAF [126,127]

http://pdbj.org/giraf/source/dis

Searches and flexibly aligns protein

tr.tar.gz

ligand binding interfaces

http://pubs.acs.org/doi/abs/10.

Uses known protein-ligand binding

1021/ci300178e

site data to predict/design a ligand for

G-LoSA [128]

the target protein
HOMOLOBIND

http://pibase.janelia.org/homol

Identifies residues that are similar to

[129]

obind/

structurally characterized binding site

IMAAAGINE [111]

http://mfrlab.org/grafss/imaaa

Searches 3D arrangements of amino

gine

acids in PDB structures
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KRIPO [104]

http://www.ncbi.nlm.nih.gov/

Quantifies subpocket similarities to

pubmed/22830492

identify bioisosteres

http://medit-

Locates similar regions on protein

pharma.com/index.php?page=

surfaces that are linked to certain

med-sumo

chemical function

http://nucleos.bio.uniroma2.it/

Identifies

nucleos

based on nucleotide modularity

http://kiharalab.org/patchsurfe

Web tool for predicting binding

r2.0/

ligands for a protein

http://phosfinder.bio.uniroma2

Web server for the prediction of

.it

phosphate binding sites

PocketFEATURE

https://simtk.org/home/pocketf

Uses protein microenvironments to

[134]

eature

identify similar binding sites; method

Med-SuMo [130]

Nucleos [131]

Patch-Surfer [132]

Phosfinder [133]

nucleotide-binding

sites

is able to recognize distant protein
relationships
PocketAlign [135]

PoSSuM [136]

http://proline.physics.iisc.ernet

Generates structural superpositions of

.in/pocketalign/

binding sites

http://possum.cbrc.jp/PoSSuM

Enables rapid exploration of similar
binding sites between structurally
diverse proteins

PrISE [106]

ProBiS [108]

http://prise.cs.iastate.edu/inde

Predicts interface residues using local

x.py

surface structural similarity

http://probis.cmm.ki.si

Enables structural comparison and
local alignment of proteins

PROLIX [137]

RCSB PDB [73]

http://www.ncbi.nlm.nih.gov/

Mines protein-ligand interactions in

pubmed/22582806

large structure databases

http://www.rcsb.org/pdb/home

Worldwide repository of 3D structural

/home.do

information

of

large

biological

molecules
SA-Mot [138,139]

http://sa-mot.mti.univ-paris-

Extracts structural motifs of interest

diderot.fr

from protein loop structures
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SCOWLP [140]

http://www.scowlp.org

Enables individual and comparative
analysis of protein interactions

SiteBinder [141]

http://ncbr.muni.cz/SiteBinder

Allows the superimposition of large
sets of protein structural motifs

SiteComp [142]

http://sitecomp.sanchezlab.org

Compares binding sites, evaluates
residue contribution to binding and
identifies

sub-sites

with

distinct

molecular interaction properties
SubCav [143]

TargetHunter [144]

http://www.ncbi.nlm.nih.gov/

Similarity searching and alignment of

pubmed/23327721

protein subpockets

http://www.cbligand.org/Targ

Web-based target prediction tool

etHunter
TRAPP [145]

http://www.mcm.h-

Analyzes binding pocket variation

its.org/trapp/

along protein motion trajectory and
assesses the druggability of a target

TrixP [146]

http://www.ncbi.nlm.nih.gov/

Fast protein binding site comparison

pubmed/23390978

and function prediction

Wallach, I. & Lilien,

http://bioinformatics.oxfordjo

Uses pharmacophoric features to

R.H. algorithm [147]

urnals.org/content/25/12/i296.

predict subcavity binding preferences

full
Table is reproduced with permission: © 2015 John Wiley & Sons A/S. doi: 10.1111/cbdd.12631.
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larger-scale (whole-protein) methods of comparison that identify conserved features of binding site
topologies between proteins.
While these strategies can prove to be quite effective in certain circumstances, some of
these ‘globalized’ methods may not be able to recognize distant similarities, particularly in cases
where the dynamics of a protein allow a ligand to bind at sites that may be very structurally diverse.
Recent tools have been developed to approach protein comparisons and binding site identification
by taking a “subpocket-focused” approach. Based on the 3D coordinates of a protein,
DoGSiteScorer [120–122] is able to detect potential pockets on the surface and split each of them
into subpockets. The program uses properties such as volume, depth, surface, ellipsoid main axes,
site lining atoms and residues, as well as functional groups present to calculate the predicted
pockets. This tool scores each of these pockets for their potential druggability, yielding accuracies
of 88% when trained and tested against a dataset of 1069 different structures [121].
Among some of the other methods [135,148–150] used to compare binding sites are
CavBase [114–118] and PrISE [106]. CavBase derives 3D descriptors that characterize the surface
properties of a binding cavity. The individual amino acids lining a cavity are analyzed to form
descriptors of the localized chemical environment. Dummy atoms (“pseudocenters”) are placed on
the surface, representing the overall chemical property expressed by the surrounding exposed atoms
in that area. Therefore, cavities described by a series of pseudocenters are compared with a database
(Relibase [151]) of cavities from PDB protein structures. Similarity is determined through the
matching of 3D property descriptors (pseudocenters) between the different sites to provide a
“pharmacophore-esque” search that takes advantage of localized environments within a protein
binding cavity. Additionally, a new evaluation formalism for entries in Cavbase has recently been
reported that improves efficiency of large-scale mining for similar protein binding pockets [152].
Separately, PrISE is able to predict interface residues of protein-protein interactions by defining
structural elements consisting of a central amino acid residue and its surrounding residues on the
protein surface. PrISE deconstructs the surface of a query protein into its structural elements and
compares those to similar elements in a database that contains elucidated structural elements in
PDB format. Elements are labeled as interface or non-interface based on the characteristics of the
central residue. The labels are then used to predict whether the central residue of each structural
element of the query protein is an interface residue. Ultimately, although different, CavBase and
PrISE are able to use the chemical environment around a specific amino acid residue to predict the
similarity between sites of interaction on different proteins.
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For analyzing similarities between binding sites in terms of sub-cavities, the
PocketFEATURE algorithm [134] takes a modified approach by analyzing “microenvironments”
to assess overall similarity between proteins for prediction of shared ligands. The method does not
rely on the sequence or relative pattern of amino acids in a binding site. Instead, Liu & Altman
define a “microenvironment” as a local, spherical region within a protein structure that may
encompass amino acid residues that are discontinuous in sequence and structure. A set of 80
physiochemical properties [153] is calculated over six concentric spherical shells, centered on a
predefined functional center, with the total radius of the “microenvironment” being 7.5Å. Two sites
are compared using an adjusted Tanimoto coefficient based on the presence of similar properties.
Advantageously, this algorithm relies weakly on geometric requirements, instead using biophysical
and biochemical measurements to characterize a subregion of a binding pocket. This approach
allows for dynamic conformational changes in both the ligand at a binding site and the pocket itself.
In this way, the algorithm may most closely align itself with a true subpocket-type search when
compared to the aforementioned computational methods.

1.2.2.2 Ligand Interaction Approaches to Compare Binding Sites

As opposed to protein structure-driven approaches, ligand-driven approaches utilize known
interaction data of ligands (small molecules and chemical fragments alike) with proteins to develop
binding models that can be used to compare binding sites. Traditionally, many of these methods
analyze the environment surrounding a bound ligand in a protein’s binding site, encoding
physiochemical and/or geometric features to form a general pharmacophore. These descriptors can
then be screened against databases of known structures to detect similar sites. A program such as
G-LoSA [128] uses this general strategy to predict or design a ligand for a target protein given
known interaction data between ligands and predicted similar binding sites. The region surrounding
a bound ligand is compared to localized regions in other proteins, and those containing a large set
of aligned residues are identified. Similarly, GIRAF [126,127] utilizes a database of known ligandprotein structures to create an index of the geometric features of the surrounding atomic
environment. Similar ligand-binding sites can then be identified and aligned with the query
structure, independent of sequence homology, or protein fold. PROLIX [137] uses fingerprints of
ligand-protein interaction patterns to rapidly mine large crystal structure databases for similar
patterns. The PoSSuM database [136] enables the rapid exploration of similar binding sites between
proteins based on physiochemical and geometric similarities, sorted using the neighbor-search
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algorithm SketchSort [154]. Each of these methods is useful for finding similar binding sites to a
query protein in a small amount of time based on already-known interaction data, but these
generally take whole-site approaches as opposed to screening small microenvironments of the
binding site itself.
As with protein topology-driven approaches for binding site analysis, recent methods
utilizing ligand-bound data are advancing the analysis of subpockets. The web tool Patch-Surfer
[132] represents a binding pocket as a set of small, localized surface patches. Each of these patches
is further characterized using 3D Zernike descriptors [155], enabling the identification of
corresponding regions in pockets on other proteins, even if the overall pocket shapes are different.
This method is able to compare a queried pocket to known ligand binding pockets, and predicts
binding ligands for the query. In its most recent version, Patch-Surfer was tested against a large
dataset of more than 6000 non-redundant pockets, with 2707 different ligands, where it displayed
better predictive performance than many other currently available methods to predict protein
pockets. Another program, CrystalDock [119] is able to take a ligand-receptor complex, break the
ligand into its constituent molecular parts, use the microenvironments surrounding the ligand
fragments, and perform a geometric comparison to identify similar microenvironments in ligandbound PDB structures. This information can be used to predict chemical fragments that would bind
a site of interest. FragFEATURE [125] has a similar function in that it also compares the structural
environments within a target protein to those in databases to find statistically preferred fragments
at a binding site. KRIPO [104] is able to use microenvironment pharmacophore fingerprints to
identify similar binding sites between proteins, and potential bioisosteric replacements for queried
molecular fragments. Combining a sub-cavity comparison search with pharmacophoric analysis,
Wallach and Lilien developed a method [147] to cluster similar binding site sub-cavities to predict
patterns of binding between proteins that do not share any structural similarity with known systems.
Taking a modified approach to ligand-driven subpocket analysis, Kalliokoski, T. et al.
developed SubCav [143], a tool for comparing and aligning protein subpockets. In this method, a
modified version of the 3D pharmacophore fingerprint descriptor F-SPE-FP-PH3 [123] was used
to define pharmacophoric features of all protein atoms within 4.5 Å of a bound ligand. These atoms
were described according to eight different chemical features. Fingerprints composed of 7680
elements incorporating pharmacophoric features and the three dimensional triangular distances
between them, were generated for a grouping of subpockets within a binding site. Normalized
Tanimoto scores were then used to assess the similarity between two fingerprints. Subpockets were
aligned using the methodology described by Kabsch [156] implemented in BioPython [157]. An
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advantage of this method is that it can identify similar fragment binding sites independent of protein
structural or sequence similarity. This focus on local equivalent microenvironments enables more
comprehensive predictions of the pharmacological selectivity for on- and off-target binding events
for fragments in ligands.

1.2.3

Shared Subpockets in ATP Binding Sites and Relevance to Ligand Selectivity

A current challenge for small molecule lead development is represented by target site similarities
within the superfamily of human protein kinases. Major efforts for drug discovery targeting these
kinases have focused on their ATP binding sites. Although these proteins have evolved distinct
cellular functions and hence substrates, there exists a significant level of similarity at the ATP
binding sites. One of the challenges in developing inhibitors to these proteins is the optimization
of selectivity for one or more related kinases [158]. A study by Anastassiadis, et al. (2011) showed
that a large proportion of commercially available kinase inhibitors display significant levels of
cross-reactivity, with some having the ability to inhibit the catalytic activity by more than 50% in
nearly 30% of all tested kinases [159]. The clinical implications for these observations are not
always clear, but offers a platform for understanding the role of subpockets in rendering predictable
inhibitor kinase cross reactivity.
Within kinase ATP binding sites, there exists a conserved phenylalanine residue of the
Asp-Phe-Gly (DFG) motif that is buried in a hydrophobic pocket, which is positioned in a groove
between the two ‘lobes’ of the kinase. This motif is targeted by type I kinase inhibitors [160,161],
being generally more promiscuous than type II and III inhibitors, which typically take advantage
of an allosteric binding site that becomes available upon a structural change of the DFG motif [160–
162]. The idea of a protein subpocket finds significant application here given the large similarities
in the binding pockets for type I inhibitors. An example can be seen with the JNK3 human kinase,
where the residues Glu147, Met149 and Val196 form a microenvironment (Figure 1.2c) that
recognizes shared chemical features between a natural ligand, adenosine monophosphate (AMP)
[163], and a dihydroanthrapyrazole-based inhibitor [164], though their structures, overall, are quite
different.
These binding site subpockets are used advantageously when designing mimics of natural
ligands as inhibitors, but the similarities in these microenvironments between kinases can also give
rise to promiscuous chemical landscapes. Staurosporine is a classical ATP-competitive inhibitor
that is notoriously promiscuous [165], with there already being 48 crystal structures available in

Figure 1.2. Conserved Subpockets in Protein Kinases Contribute to their Inherent Promiscuity. (a) Staurosporine (shown as partially transparent)
is known to have inhibitory activity against a plethora of protein kinases from different families [164]. Conserved subpockets between the
TAO2 MAP3-level kinase (green loop) and serine-threonine kinase 16 (STK16) (blue loop) allow staurosporine to bind with comparable
affinities to both proteins (TAO2, PDB ID: 2GCD; STK16, PDB ID: 2BUJ). (b) The promiscuous RET tyrosine kinase (orange surface) contains
a binding site subpocket that allows for the binding of overall structurally distinct inhibitors. The red highlighted portion of each inhibitor
overlaps in the subpocket, shown with the red circle on the right (green, PDB ID: 2IVU ; blue, PDB ID: 2IVV). (c) Within the binding pocket
of JNK3 MAP kinase, residues Glu147, Met149 and Val196 form a microenvironment that binds comparable chemical features between a
natural ligand, adenosine monophosphate (AMP) (PDB ID: 4KKE), and inhibitors such as the dihydroanthrapyrazole-based antagonist shown
on the right (PDB ID: 1PMV). Figure is reproduced with permission: © 2015 John Wiley & Sons A/S. doi: 10.1111/cbdd.12631.
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the PDB that show it bound to a variety of human kinases. With roughly 32% sequence similarity,
the TAO2 and serine-threonine kinase 16 (STK16) kinases both bind staurosporine with good
affinity. The sequence of residues at the ligand binding site differs between the two proteins, but
TAO2 [166] and STK16 [167] both fold in a way that causes chemically similar amino acids to
overlap, forming shared subpockets that result in a favorable binding site for the competitive
inhibitor (Figure 1.2a).
There are additional proteins in this family that display high levels of promiscuity as well.
The RET tyrosine kinase has been observed to be significantly inhibited by a variety of competitive
inhibitors [159]. While many of these ligands have structurally distinct features and vary in size,
one conserved binding orientation [168] makes use of an overall hydrophobic subpocket
surrounding Val804, as can be seen in Figure 1.2b. Even though the inhibitors shown in this
example are not vastly dissimilar, they do demonstrate that when designing ligands, consideration
of the fact that some proteins recognize more generalized chemical features. This insight is
especially important when considering kinases as biological targets; but, importantly the example
is instructive to apply to other protein families as well. Furthermore, documented ligand-kinase
associations offer many cases to bench mark tests of methodologies to identify and utilize fragment
subpockets for the desired selectivity or cross-reactivity.

1.2.4

Consideration of Protein Interfaces and Cooperative Interactions

In contrast to the types of ligand interaction sites considered so far, protein-protein interaction (PPI)
interfaces give fewer clues on a residue by residue basis for what is required for a specific binding
event. Protein surfaces most often are relatively flat, and the interface at which two proteins engage
typically makes up a large surface area (1000-2000 Å2) with multiple contact points [169]. Drug
discovery efforts, particularly in the pharmaceutical industry, traditionally avoided exploring PPIs
as drug targets, considering them “undruggable” until recent challenges of this classification [170].
Within the last decade, research into targeting PPIs as a therapeutic strategy for multiple diseases
has continued to accelerate. Previous work has shown that not all of the residues at a PPI interface
are critical for the interaction. In the best studied cases to date, there exist regions of “hot spots”
that confer most of the binding energy [170]. These “hot spots” are adept at binding protein or
peptide-esque molecules and have been suitable targets for peptides and a number of mimetic
compounds [171]. However, the practical utility of the hot spot theory requires additional
consideration with respect to the design of specific protein ligand interactions.
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Previous studies have concluded that amino acids such as Ile, Leu, Met, Phe, Trp, Tyr and
Val appear more frequently at PPI interfaces relative to other amino acids, and their average
distribution throughout the genome [172,173]. Some residues at interface hot spots form “anchor
sites”, where they serve as critical recognition features that drive the binding process [174]. In this
way, these sites are analogous to the previously discussed concept of a subpocket in that the
localized environment and relative orientation of particular amino acids in anchoring sites are
important for the recognition of specific chemotypes. The feasibility of targeting anchor sites was
demonstrated when developing small-molecule PPI inhibitors [173]. The surface of the E3
ubiquitin-protein ligase MDM2 forms a natural binding groove that the Phe19, Trp23 and Leu25
residues of p53 favorably bind (Figure 1.3a). Even when visualizing the unbound form of MDM2,
the pocket where Trp23 of p53 ultimately binds is visible, suggesting that this site is important for
the recognition and binding of p53. Phe19 and Leu25, upon binding, appear to induce the formation
of hydrophobic pockets on MDM2 that result in favorable binding environments for the two
residues. In this case, the recognition features of a subpocket are not necessarily prearranged for a
meaningful binding event to occur. Rather, a molecular fragment may induce formation of a new
subpocket with optimal chemical environment for that fragment to bind, when it otherwise would
not if considered a static system.
In a similar fashion, proliferating cell nuclear antigen (PCNA) contains a region on its
surface that recognizes specific chemical features. PCNA acts as a homotrimeric scaffold protein
that binds many different proteins associated with DNA replication and damage repair [175]. Many
of these proteins contain a conserved eight-member sequence known as the PCNA-Interacting
Protein (PIP box) motif [176]. While four out of the eight amino acids in this sequence are highly
variable, the remaining four residues represent conserved chemical functionalities that are critical
for proteins to bind at the PIP box-binding site on PCNA (Figure 1.3b). The conserved aromatic
residues (tyrosine or phenylalanine) in the seventh and eighth positions of the PIP box are part of
a short 310 helix that binds in a highly flexible [177] hydrophobic pocket on the surface of PCNA.
This site generally recognizes hydrophobic molecular fragments exemplified by the discovery of a
small molecule, T2AA, that binds in that pocket and inhibits the interaction of PCNA with other
PIP box-containing proteins [178]. Upon comparison between the structures of PCNA bound to
p21 (PDB ID: 1AXC) [179] and T3 (an analogue of T2AA; PDB ID: 3VKX) [178], a subpocket
formed by Ile128, Tyr133, Tyr250, Pro234 and Val236 binds an aromatic fragment of both T3 and
p21’s PIP box tyrosine (Figure 1.3c). Furthermore, the inhibitor’s core iodine atoms induce a
structural widening of the binding pocket, exposing a larger hydrophobic surface, resulting in a
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Figure 1.3. Protein Interface Hotspots Contain Inducible Microenvironments that Bind Conserved
Fragments Between Molecule Types. (a) Three residues of p53 (F19, W23 and L25; green sticks)
become buried in the surface of MDM2 (blue surface), inducing the formation of hydrophobic
subcavities. Residue W23, in particular, likely acts as an anchoring residue, substantially
contributing to the binding affinity (PDB ID: 1YCR). (b) Four key residue positions (green sticks)
in the highly conserved PIP box sequence are essential for the binding of PIP box-containing
proteins (p21 shown as green loop) to PCNA (orange surface). The fifth, seventh and eighth
residues in the sequence bind at a surface pocket on PCNA made up of several hydrophobic
microenvironments (PDB ID: 1AXC). (c) Within the hydrophobic PIP box binding site on PCNA
(orange surface), the subpocket defined by the relative orientation of I128, Y133, Y250, P234 and
V236 to one another has affinity for an aromatic ring moiety, with a tyrosine residue (green sticks)
of p21’s PIP Box sequence (green loop) anchored in the same location as the tyrosine-analogous
fragment of the small molecule inhibitor T3 [178] (PDB ID: 3VKX, p21 peptide from 1AXC). (d)
Some receptors exist that themselves accept a variety of structurally diverse substrates, the best
example being the large family of GPCR olfactory receptor proteins. OR1G1, a member of this
family, becomes activated upon exposure to numerous diversified odorants [180]. Figure is
reproduced with permission: © 2015 John Wiley & Sons A/S. doi: 10.1111/cbdd.12631.
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stably bound planar orientation of the molecule. The ligand-dependence of the subpocket within
the PIP box binding region is another example of how the plasticity of protein interfaces must be
taken into consideration.
Because drug-like compounds are often composed of several segmental fragments, any one
substructure of a molecule could have affinity for a sub-pocket fingerprint shared between two or
more proteins. Of course, the observable binding affinity of the drug molecule depends on all of its
interacting components with a protein; a single interaction within a microenvironment may not be
nearly sufficient enough to stabilize a specific bound conformation to elicit a pharmacological
effect. However, protein systems do exist that have evolved to accept a variety of chemical
structures, whether through flexible binding sites, or weak requirements for a binding event to
produce a desired effect. The large family of GPCRs that make up the mammalian olfactory system
is one example. Many individual members of this group become activated upon interaction with a
plethora of different odorants [180–183] (Figure 1.3d), implicating the existence of ‘fuzzy
subcavities’ making up interaction sites. Receptor OR1G1, and others like it, thus exhibit flexible
recognition of general chemotypes, rather than a specific orientation of atoms.
The aforementioned examples demonstrate that PPI interfaces containing subpockets are
analogous to those found in traditional small ligand binding sites. However, these characteristics
indicate the transient aspects of these subpockets and articulate both opportunities and challenges
for discovery of selective ligands with useful pharmacological effects. Many cases highlight
limitations of structure-based virtual screening, and improved methods to achieve overall accuracy
continue to emerge [184–189]. Computational approaches to address the issues of ligand and
receptor dynamics has been an area of continued advancement [61,184,185,187,190,191]. The
distinctions are likely that induced-fit and conformational selection play more significant roles in
formation of subpockets and the resulting affinity of a molecule composed of multiple substructures
[61,192–194]. These mechanistic principles have recently been exemplified in the formation of
transient binding sites for protein interface inhibitors where evidence for both local conformational
selection and induced-fit pathways have been evaluated [192].
An understanding of how subpockets are influenced by other microenvironments in
proximity is a general characteristic for consideration in FBDD. When a fragment of a small
molecule binds in a given subpocket, the binding event can induce structural changes that modulate
the features of surrounding regions. This means that in a fragment-based screen, suitable binding
in a particular chemical microenvironment may not occur in the absence of nearby transient binding
events of other fragments, resulting in false negatives. A recent case study addressed how current
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FBDD methods are limited in detection of fragments that exhibit cooperative binding [195].
However, the deployment of these methods to provide improved accuracy in fragment-based
screens is less than complete.
Several computational approaches to meet these limitations are emerging and show
significant promise for expanding successes. Mahasenan, K.V. & Li, C. were able to develop an
approach that incorporates multiple protein conformers via ligand-directed modeling [196,197].
Substantial improvements for sampling and free energy scores in docking studies can be achieved
when taking into account multiple fragment-ligands simultaneously [198,199]. Novel inhibitors of
STAT3 and the IL-6/GP130 protein interface were discovered by considering multiple subpockets,
and simultaneous ligand screening [200–203]. Type II kinase inhibitors were also developed for
the MELK kinase by taking into account an induced conformational shift of the protein [204].
These examples implicate the importance for ligand-dependent subpockets when using FBDD
approaches; they may represent a general process that can allow for cooperative binding into
subpockets. The full extent to which this impacts current drug discovery efforts and computational
screening methods remains to be fully established, but opens avenues for improvement in the
utilization of computational and experimental approaches to discover multiple fragment sites at
protein interfaces.

1.2.5

Summary of Computational Approaches toward FBDD

There are an increasing number of computational tools available to complement experimental
fragment-based screens and ligand design. Advantages to these approaches are that they enable a
potential general solution to the challenges of optimal fragment selectivity and linkages but these
goals remain to be fulfilled. The prediction of protein structure microenvironments and dynamics
requires consideration and methodological advances are emerging. As previously highlighted, the
similarities of protein microenvironments between evolutionarily related or convergent proteins
could argue for increased chances of off-target effects. To the extent that this may be a concern at
protein interfaces still remains largely unknown [170,205]. However, the potentially unique
combinations of transient subpockets that arise upon the binding of a ligand may ultimately result
in higher degrees of selectivity.
The occurrence of subpockets in unrelated proteins is generally recognized as a potential
contribution to drug effects; however, an account of these features when selecting specific
fragments in drug development has been traditionally based upon empirical deduction.
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Experimental and computational approaches that can account for potential cooperative interactions
are subjects of considerable importance for structure-based drug design. It is increasingly feasible
using computational approaches to consider a classification process to stratify both risk and benefit
of new molecular candidates. These tools can also be applied to molecular fragments and their
associated libraries. As opposed to promiscuous scaffolds, fragments with high propensity for
subpocket interactions can be argued to represent important tools for lead identification when
considered in an appropriate knowledge framework. Whether fragment libraries can be qualified
on a proteome-wide scale remains a future challenge, but the combinations of experimental and
computational methods offers increasing promise.

1.3

Research Scope

The number of new drug applications over the past several years has paled in comparison to the
more than 40 per year that were observed during the late 1990’s. Though the human genome project
promised to usher in a new era of drug discovery, it has not completely lived up to its lofty goals.
Indeed, much of protein research still focuses on the 10% of proteins that were already known
before the mapping of the human genome [206]. Much of the difficulty in finding new drugs may
be associated with the content of libraries currently used for high-throughput and virtual screening,
since these libraries tend to be historically biased toward traditional drug targets [207–209].
Although much progress has been made in the elucidation of regulatory mechanisms of key
intracellular processes, such as the DDR, there remains a need to better understand the necessary
molecular features for conferring selectivity between major regulators of theses pathways.
Amongst the redundancies between alternative pathways in the DDR, DNA scaffolds play
key roles in that they recruit, stabilize and orient other repair-facilitating proteins that make up
complexes at sites of DNA damage. Due to specific conserved structural features between binding
partners of DNA scaffolds, it stands to reason that targeting the site of recruitment of these proteins
on a scaffold could produce a substantial pharmacological response in a given context. Proteinprotein interfaces, however, have proved to be challenging drug targets, and often require unique
classes of molecules as inhibitors [210]. Additionally, the high cost and often limited diversity of
high-throughput screening libraries both exist as prohibitory factors in many drug discovery efforts.
As a result, a method for pairing down the necessary compounds to screen would be beneficial,
particularly when little is known about a specific target’s ideal drug chemotype.
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PCNA serves as an interesting drug target given its importance in DNA replication and
damage repair. Studies have shown that the scaffold’s PIP Box binding site can be targeted using
small molecules to modulate its interactions with its natural binding partners. However, SAR
studies have been unable to significantly improve upon the relatively limited chemotype identified
that binds at that site. The first goal of this research is the development of a peptoid-based screening
platform that enables the reduction of cost and time in the initial synthesis of an early-stage
compound library that can be used to identify generic features of a protein-protein interaction
antagonist for a given site. This approach is used in the discovery of new inhibitors of PCNA-PIP
Box protein interactions. Understanding the key interactions that may be driving the propensity for
ligands to of bind at that site could be useful in creating more drug-like compounds that target
disease-specific complexes in order to control the progression of cancer.
The second goal of this research is to explore the differential modulation of signaling
pathways based on intracellular compartmentalization of known cancer therapeutics, and whether
this could serve as a viable strategy for targeting traditionally drug-resistant cancer types. It was
seen that with nuclear-targeted kinase inhibitors, phosphorylation of intracellular STAT3 was
preferentially modulated, as opposed to either ERK1/2 or EGFR. Alone, this may not have a
substantial improved effect over commercial gefitinib, but when used in combination with DNA
damaging agents or inhibitors of DDR-related processes, it could product a substantial phenotypic
response in drug-resistant tumor types reliant on abnormal expression or localization of EGFR.
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2. PEPTOIDS AS PROBES FOR DISRUPTING PCNA-PROTEIN
COMPLEXES

Integral to the majority of biological functions, protein-protein interactions (PPIs) mediate a large
number of important regulatory pathways. There are estimated to be around 400,000 different PPIs
within the human proteome [211] that are involved in various processes such as signal transduction,
cell metabolism, apoptosis, growth, membrane transport and cellular motility. PPIs are regulated
by various factors ranging from the simple affinity of binding between proteins or other ligands, to
things such as protein concentration, ligand concentration, presence of ions and covalent
modification, and these interactions can be classified as being either stable or transient. Over the
last couple decades, significant research has resulted in large-scale protein interaction networks
that have allowed a better understanding of pathway functionality, as well as the association
between genetic variation and disease states [212]. Research is still ongoing to understand how the
dysregulation of PPI networks leads to the formation of specific diseases, and this ultimately may
lead to the discovery of a generation of new drugs.
Study of the molecular structure of proteins can provide details on the site of interaction
between different proteins or at the interface between two substructures of the same molecule.
Assembly of protein complexes can result in the formation of homologous and heterologous
structures made up of potentially many different macromolecules. In the case of a molecule such
as PCNA, the protein itself forms a homo-oligomeric structure around chromatin-bound DNA, and
recruits many other regulatory factors to it that can make up large hetero-oligomeric complexes
implicated in DNA replication and damage repair [175]. Proteins generally contain structural
domains that allow for the recognition and interaction with specific amino acid sequences, or other
structural features, on other proteins. Common examples of these include PDZ, SH2, SH3, SAM,
LIM and PTB domains [213], and in the context of proteins that interact with PCNA, the PIP Box
[214] and AlkB homologue 2 PCNA interacting motifs (APIM) [215]. Because these structural
features are often heavily conserved among different proteins, their importance has long been
recognized, and some motif recognition factors are viewed as potential targets for therapeutic
intervention.

29
2.1

Protein-Protein Interactions as Therapeutic Targets

Traditionally, PPIs were seen as being “undruggable” by commercial practitioners, and drug
discovery efforts avoided these types of targets [216]. Typically, most endeavors comprised the
design of compounds that mimicked endogenous ligands of enzymes and other proteins [217]. A
typical protein-protein interface can encompass an area of 1,500-3,000 Ǻ2 with 750-1,500 Ǻ2 of
buried surface area [170,218], and a binding event between two proteins may involve multiple
points of contact, also referred to as “hot spots” [219]. Simply blocking one of these points of
contact may be insufficient to elicit a pharmacological response, though this would be heavily
context dependent. These features present significant challenges for developing inhibitors of PPIs
(iPPis), but the technological hurdles associated with PPI targets are becoming less daunting [220].
Various strategies are being explored to develop positive therapeutic outcomes for disease
by targeting PPIs, and these have mostly consisted of peptidomimetic and small molecule-based
approaches. iPPIs can be generally be classified as either orthosteric inhibitors, directly interfering
with the protein-protein interface, or allosteric inhibitors, which bind at some distal site and induce
or prevent some conformational change in the protein that hinders complex formation. Potentially
ideal inhibitors of macromolecular interactions would be stable peptides or peptidomimetics that
adopt a defined secondary structure. However, smaller peptides do not tend to form defined
conformations in solution. As a result, research on using peptides as iPPIs has focused on
developing analogue mimics of β-turns [221] as well as stabilized α-helical [222] and β-turn
peptides [223–225], and foldamers [226]. Other major strategies of developing iPPIs have involved
designing secondary structure and surface mimetics. Each of these approaches shows promise, and
the number of iPPIs discovered using these methodologies continues to grow, especially where
inhibition of large surface contact regions is necessary.

2.1.1

Targeting Protein Interfaces with Small Molecules

Similar to the case of more traditional drug targets, such as enzymes, small molecules have been
used as antagonists of protein-protein interactions. However, predicting a targetable site for
inhibition at a protein interface is not technically straight forward since all of the amino acids at
that site do not contribute equally to binding. Typically, only a small subset of the residues
contributes the majority of free binding energy to binding; these hot spots are defined as a
significant increase in the free energy of binding (∆∆Gbinding > 1.5 kcal/mol) when a residue is

Compound Name
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PCNA-I1

Targeted Protein-Protein
Interaction
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mutated to alanine [219]. Identified concave hot spot regions are often the subject of investigation
for their potential druggability, though other factors must be considered when targeting those sites
[236].
The major challenge of developing small molecular weight iPPIs, though, has been that
inhibition of PPIs typically requires coverage of a large number of surface contacts; but for a
compound to fall under the criteria for Lipinski’s guidelines [237], it may not possess the necessary
features that would make it a good iPPI. However, it is not clear that these guidelines, which
normally apply to small molecule-enzyme interactions, should be applicable to protein-protein
interfaces [238]. Studies have shown that iPPIs have unusual physiochemical properties when
compared to inhibitors of traditional targets (e.g. enzymes, surface receptors, etc.), such as higher
molecular weights, higher hydrophobicity and more aromatic rings [239,240]. Furthermore, iPPIs
typically demonstrate higher degrees of globularity, lower distribution of hydrophilic regions,
smaller proportions of exposed hydrophilic regions and stronger capacities to bind hydrophobic
patches at the core of protein-protein interfaces [210]. Due to these factors, conventional methods
used in drug discovery have proved unsuccessful for the most part in finding small molecule iPPIs,
but researchers have turned to alternative methods [220,241] that have thus far made progress in
discovering new inhibitors [238,242], with compounds currently in clinical trials for six different
targets [205].
While discovery of new iPPIs seems to be increasing, finding new inhibitors through
traditional screening methods has been limited by the chemistry available. One of the main
problems has been that high-throughput screening has often relied on compound libraries that are
biased toward previous drug discovery efforts (i.e. targeting enzymes and surface receptors), and
this has hindered the success of these screening efforts with PPIs [208,243–245], whose
chemotypes are generally not well-represented in current libraries [239,246]. Additionally, drug
discovery has been focused on a relatively limited number of targets [247–249], which as of 2006
stood at only 324 [250]. When contrasted with the approximately 400,000 predicted PPIs in humans
[211], the need for expanding the explored druggable space is clear.

2.2

Proliferating Cell Nuclear Antigen is Crucial for the Processes of DNA Damage
Repair and Replication

PCNA is a nuclear homotrimeric protein complex that encircles chromatin-bound DNA and acts as
a processivity factor in DNA damage repair and replication [251]. Functionally, it serves as a DNA
clamp in archaea and eukaryotes, and is composed of three PCNA molecules that associate to form
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a tight ring around duplex DNA. It is expressed in the nuclei of cells during the S phase of the cell
cycle [252], and serves as a topological site of recruitment on DNA for various proteins that are
necessary for DNA replication or repair, such as DNA polymerase δ [253]. Upon destabilization of
reservoir PCNA complexes, PCNA is loaded onto DNA in a replication factor C (RFC)-dependent
manner with subsequent cell cycle inhibition [254,255]. Once bound to chromatin, PCNA mediates
protein complex formation that is involved in the excision of DNA lesions, and promotes DNA
synthesis [175,176,256]. A large number of proteins are currently known to interact with PCNA,
implicating the involvement of PCNA in all facets of the DDR. In additional to being crucial for
the base excision, mismatch, nucleotide excision and translesion synthesis repair mechanisms,
PCNA acts as a regulator of cell cycle progression, chromatin remodeling and transcription [256].
Its expression is controlled by E2F transcription factor-containing complexes [257], with p53
playing a major role in helping to decide the ultimate fate of the cell [258]. Altogether, these
regulatory mechanisms protect the cell from increased levels of genetic instability, and guard
against uncontrolled proliferation.
2.2.1

PCNA Phosphorylation Controls Its Stability on Chromatin and is Associated with
Dysregulation of DNA Mismatch Repair

In order to modulate its functions, PCNA is post-translationally modified by multiple biochemical
events, each directing a different functional consequence. For example, in the context of DNA
damage repair, mono-ubiquitination at lysine-164 leads to activation of Rad6-dependent translesion
synthesis [259]. Extensions of this mono-ubiquitin chain are thought to activate the template switch
pathway; alternatively, modification by the Small Ubiquitin-like Modifier (SUMO) protein inhibits
the template switch pathway [259]. Separately, phosphorylation of PCNA at tyrosine 211 (Y211)
is associated with stabilization of chromatin-bound PCNA, and by extension, subsequent PCNAassociated functions. Recent observations suggest nuclear-located tyrosine kinases, epidermal
growth factor receptor (EGFR) and c-Abl, facilitate association of PCNA with chromatin and are
required for the formation of nuclear foci of PCNA in DNA-damaged cells [260–263].
PCNA has critical roles in the survival and proliferation of cells, and disease-associated
dysregulation of associated functions can have dire effects on genome stability [264]. Abnormally
high levels of PCNA expression are associated with various malignancies, ranging from nonHodgkin’s lymphoma to skin, laryngeal, ocular, prostate and breast cancers [265–272]. PCNA has
also proven to be a useful marker in the detection of increased levels of cellular proliferation and
overall prognosis in breast cancer patients [273–275]. PCNA Y211 phosphorylation (pY211) levels
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Figure 2.1. PCNA Structural Features and PIP Box Binding Site. (a) left: Cartoon representation
of human PCNA with the interdomain connecting loop (IDCL) and PIP box binding site highlighted
(PDB ID: 1AXC); right: surface rendering of S. Cerevisiae PCNA bound to DNA (PDB ID: 3K4X).
(b) The 310-helical structure of the p21 peptide’s (green) PIP box binds in a hydrophobic surface
patch on PCNA (tan surface; PDB ID: 1AXC). (c) The small molecule antagonist T3 binds in the
hydrophobic surface patch of the PIP box binding region on PCNA and disrupts the association of
PCNA with PIP box-containing proteins (PDB ID: 3VKX); the proximity of this “hydrophobic
binding site” to PCNA residue Y211 is shown (dark orange residue).
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correlate with disease, such as the observation that elevated levels of pY211 are found in half of all
human prostate cancers [261], and high levels of Y211 phosphorylation better correlate with poor
survival of patients with breast cancer than does the total level of PCNA [260].
As previously alluded to, controlling PCNA-associated processes is extremely important
for ensuring cell viability and proper growth control. The protein is post-translationally modified
in different ways at specific times during the cell cycle in response to a variety of cellular events,
and in this way its activity is tightly controlled. Disruption of these regulated, time-sensitive,
processes can have profound effects on the cell. A recent study by Ortega, et al. [276] showed that
high levels of EGFR, such as is seen in multiple cancers, can lead to abnormally high levels of
PCNA-pY211. The phosphorylation at Y211 alters PCNA’s interaction with mismatch-recognition
proteins MutSα and MutSβ, and interferes with the PCNA-dependent activation of MutLα
endonuclease. As a result, DNA mismatch repair becomes inhibited at the initiation step, suggesting
that PCNA-pY211 facilitates error-prone DNA replication by suppressing the mismatch repair
function, thus promoting cancer development and progression. Given that phosphorylation at Y211
is important for the stability of PCNA on chromatin, it can be seen that subtle disruptions of the
ideal levels of PCNA present in a specific form can have a substantial effect on a cell’s outcome.

2.2.2

PCNA as a Molecular Drug Target

PCNA has been identified as a potential target for the treatment of certain cancers. Recently, small
molecule antagonists of PCNA have shown useful pharmacologic effects when used either alone
or in conjugation with a DNA damaging agent [178,231,233,277]. Additionally, targeting the
phosphorylation event at Y211 has exhibited pharmacological relevance in breast and prostate
cancer cell lines, as well as in vivo [261,263]. Correspondingly, rationale for PCNA as a disease
target has emerged, but the nature of PCNA-protein interactions does not provide a traditional view
of a drug target and therefore generates motivation for a new approach to modulate PPIs. Perturbing
the association of PCNA with PIP (PCNA Interacting Protein) box-containing proteins, or
disrupting Y211 phosphorylation would ultimately impair the cell’s ability to repair or replicate
DNA. Four major strategies for affecting this system (Table 2.2) include inhibiting the association
of PCNA with its interaction partners [178,231,278–283], stabilizing the interaction between these
species [284,285], dysregulate the stability of the PCNA homotrimer [233,234], or disrupting the
ability of kinases to phosphorylate Y211 on PCNA [261,262,286]. It is hypothesized that a peptide
or peptidomimetic molecule that is analogous to the PIP Box of known PCNA binding partners
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Table 2.2
Methods for Dysregulating PCNA-Dependent Processes
Method
PIP Box antagonist

PPI stabilization

Description
small molecule or peptide that binds at
the PCNA PIP box binding site and
disrupts the association of PCNA with
partner proteins
modifying the interaction of PCNA
binding partners with PCNA's IDCL can
stabilize the binding event, dysregulating
time-dependent PCNA-critical processes

dysregulate stability of
PCNA homotrimer

small molecule that binds at the PCNA
monomer-monomer interface and
stabilizes PCNA trimers, reducing the
amount of chromatin-associated PCNA

disrupt Y211
phosphorylation

hinder tyrosine kinases from
phosphorylating PCNA residue Y211,
reducing PCNA’s chromatin stability

compete with PCNA for
binding to partner proteins

peptide constituting a small region on
PCNA mimics the protein and acts as a
competitive inhibitor, reducing the pool
of available PCNA binding partners

References
[178,231,281–283]ab

[284,285]c

[233,234]a

[261,262,286]b

[278–280]b

a

small molecule-based
peptide based
c
not yet demonstrated as a therapeutic strategy
b

could bind to PCNA with good affinity at the PIP Box binding site. This would be sufficient to
either block the association of PCNA with other proteins at that site, or the peptide/peptidomimetic
would act as an adhesive, securing another protein on PCNA. Either method would dysregulate
PCNA-dependent processes, and could be useful as therapeutic strategies when cell survival
depends on upregulated levels of DNA damage repair.

2.2.2.1 Targeting the PCNA PIP Box Binding Site

Evidence shows that the majority of proteins that bind to PCNA have a conserved sequence motif
known as the PCNA Interacting Protein (PIP) Box [214,287–290]. The sequence is composed of
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eight residues with the sequence QXXφXXΩΩ, with Q being glutamine, X being any amino acid,
φ being a hydrophobic residue and Ω being aromatic. These proteins bind at a shared site on PCNA,
the PIP Box binding domain. From this, it can be inferred that this is a critical site for the regulation
of various processes tied to PCNA. This is supported by observations that deletion of the PIP Box
within c-Abl disrupts the interaction of PCNA with c-Abl, and ultimately increases the nuclear cAbl apoptotic function in DNA-damaged cells [291]. Furthermore, peptides lacking the PIP Box
motif or specific critical residues within that sequence showed substantial decreases in overall
binding to PCNA [292–294].
Recently, it was demonstrated in vitro that a small molecule could be used to disrupt the
association of PCNA with a PIP Box-containing peptide [178,231]. When introduced to HeLa and
U2OS cells, the compound T2AA and some of its synthesized variants were able to decrease cell
growth and diminish DNA replication and translesion DNA synthesis. An obtained co-crystal
structure of T3 (additional 3’-iodo substituent, relative to T2AA) and PCNA showed that the small
molecule bound in the hydrophobic surface pocket of the PIP Box binding site (see Figure 2.1).
Using a fluorescence polarization assay, the interaction between the POGO Ligase (PL) peptide
and PCNA could be disrupted with low micromolar IC50 values for a number of variants of T2AA.
While this discovery provided an important proof of concept, there is still much potential
improvement to be made with the small molecules’ binding affinities and overall molecular surface
area covered.

2.3

Peptoids as a Fragment-Based Screening Tool

Peptoids, being analogous to peptides, make up a class of peptidomimetics where side chains are
appended to the backbone nitrogen atom, rather than the α-carbon. Because of this substitution
pattern, these poly-N-substituted glycines lack the amide nitrogen which gives rise to many
secondary structure elements in both peptides and proteins. The use of peptidomimetics is a popular
approach in certain drug discovery efforts due to the disadvantages associated with peptides such
as their proneness to proteolytic degradation and poor oral bioavailability [295]. Peptoids, as
opposed to peptides, have a generally better inherent ability to penetrate cell membranes, have
higher resistance to proteolysis, are more resistant to solvent, temperature and chemical
denaturants, and are generally cheaper to produce [296–299]. When synthesized using the submonomer method [300], thousands of commercially-available primary amines could be used for
incorporation into the backbone. To date, more than 200 different amines have been used as peptoid

Compound Name
Compound 12
P26
Compound Ia
CHIR29498

Drug Target

RNA Hairpin
(Apical loop of pre-miR-21)

α/β-Tubulin

Ubc13-Uev1
(Protein-Protein Interaction)

Cell Membrane
(Gram- +/- Bacteria)

MIC 6 µg/mL

Kd = 4.4 pM
(Ubc13)

IC50 = 5.7 ± 1.2 µM

Kd = 12 ± 11 µM

Affinity or Inhibition
Constant

Staphylococcus aureus cell death

Surface plasmon resonance

HeLa cell growth inhibition

Fluorescence

Methodology

Table 2.3
Examples of Peptoid-Based Small Molecule Inhibitors

[304,305]

[303]

[302]

[301]

References
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side chains [306], resulting in substantial chemical diversity at each substitution position. Peptoids
have been used in a number of different biomedical applications from drugs [307,308] (Table 2.3)
to synthetic lung surfactants [309], hydrophobic nanosheets [310,311] and antibody biomarkers for
Alzheimer’s Disease [312]. Peptoid-based small molecule-esque ligands have been discovered that
target proteins such as vascular endothelial growth factor receptor 2 [313], Src Homology 3 and
WW domains [314], Karopherins and Tubulin [302]. Additionally, peptoids have been useful as
antibiotics against both gram-positive and –negative bacteria [315–317]. Due to their versatility in
numerous applications, they have become a popular screening tool since large combinatorial
libraries of peptoids, of approximate molecular weights between 450-750 Da, can be created with
diverse types of chemical substitutions in relatively short fashion.
Peptoid screening has proven successful in identifying numerous types of ligands targeting
many types of protein targets. Many of these efforts make use of trimeric peptoid libraries, which
are generally small enough to be considered small molecule-like. Using iterative re-synthesis,
Zuckerman, et al. (1994) created a library of 3500 peptoid trimers that was utilized in the discovery
of nanomolar ligands for the opiate and α1-adrenergic receptors [318]. Screening of trimeric peptoid
libraries has also resulted in the discovery of antimicrobial compounds [305] and mimics of the
Agouti-related protein [319]. Positional scanning techniques have been used to discover
noncompetitive antagonists of the vanilloid receptor subunit 1 (VR1) [320] as well as inhibitors of
Karopherins and Tubulin [302]. Moreover, in certain cases, large tripeptoid libraries of more than
300,000 compounds have been used, and this has resulted in the finding of antagonists of the
nicotinic acetylcholine [321], melanocortin type 1 (MC1) and gastrin-releasing peptide/bombesin
receptors [322]. Because of their relative ease of synthesis, short peptoids can be valuable tools in
the discovery of molecules that may be useful inhibitors in and of themselves, or as screening hits
that can be further refined into lead drug-like compounds.

2.4

Rationale

Traditional chemotherapies and molecularly-targeted agents including protein kinases inhibitors
have not provided sustained clinical efficacy [46–49,323]. Selective inhibition of kinases has been
a major issue, with current inhibitors often showing high levels of cross-kinase inhibition [159]—
though, the pharmacological significance of this promiscuity remains unclear. Targeting upstream
processes in general has inherent limitations, since the activation of many proteins results in
propagation (signaling cascades) and redundancy of intracellular signals. As an alternative,
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targeting certain downstream proteins that function in the nucleus, such as PCNA, could have
significant advantages as a strategy, particularly when the protein is targeted at the same time as
other molecular targets, including proteins involved in the DNA damage response or signaling.
PCNA is known to interact with more than 200 different proteins that require binding to
PCNA in order to regulate specific pathways of DNA replication or the DDR. While PCNA has
been a subject of detailed investigation for more than a decade, there is still much that is not well
understood. Despite the gaps in knowledge, two types of inhibitors have been discovered that target
PCNA, as previously discussed in Chapter 1. Though high-throughput screening efforts led to the
discovery of the thyroxine class of antagonists that target PCNA’s PIP Box binding site [178],
structure-activity relationship studies were not able to yield substantial improvements to the
reported IC50 values [231]. Although these inhibitors demonstrate the potential for modulating
PCNA-protein interactions, it is clear that additional information on the molecular surface features
of PCNA is necessary in order to design higher affinity ligands.
A potential approach toward the rational design of inhibitors of PCNA-protein interactions
would be to use computational and biochemical screening methods to facilitate a fragment based
drug design effort. For the development of iPPIs, it would be advantageous to use a system where
molecular mimetics could rapidly map ideal surface binding interactions sites in tandem before
considering detailed conformations of an optimal drug-like ligand. While this challenge can be met
with large peptides, the translation to drug-like molecules is not clear. Structures of PIP Boxcontaining peptides/proteins in complex with PCNA solved to date indicate the core PIP Box
recognition sequence is involved in a 310-helix that binds in a hydrophobic surface pocket on
PCNA. However, small molecule mimics of this topology are not easily defined. It is hypothesized
that determining the chemical recognition features of PCNA-protein interactions would allow for
the design of small molecule inhibitors that could be used to target PCNA-associated processes of
the DDR. While various strategies currently exist for targeting DNA repair pathways, PCNA would
serve as a novel target in the inhibition of the DNA damage tolerance pathway, post-replication
repair [324], specifically disrupting RAD6-dependent translesion synthesis as well as the “template
switch” pathway [259]. The discovery of such an inhibitor would have potential as a sensitizing or
synergistic agent in the development of new combination therapies for the treatment of disease.
In this chapter, a versatile chemical platform based on moderate molecular weight peptoids
(450-1000 Da) will be evaluated and discussed for its application in the future development of
small molecule protein-protein interaction modulators [325]. This system of computational-driven
peptoid library design could be applied to other model protein systems where traditional screening

40
methods fail, or little is known about the protein(s) of interest. The advantages of such an approach
would be a reduction in cost and time by greatly reducing the number of compounds to be
synthesized, in lieu of creating large (>50,000) ligand libraries. Additionally in this analysis, key
PCNA-ligand interactions were identified; together with the apparent flexibility of the surface of
PCNA, this may indicate the adaptability of the protein toward multiple forms of antagonists. This
chapter will conclude with the discussion of how this information could be used in the design of
drug-like small molecules that target PCNA.

2.5

Experimental

2.5.1

Methodology

The process toward discovering peptoid-based inhibitors of PCNA-protein interactions was a mutistep system where PCNA was first interrogated computationally, followed by synthesis and
subsequent biochemical screening of each peptoid. The details of the methodology follow.

Step 1: Generate focused library of peptoid-based antagonists using computational tools. The PIP
Box binding site on PCNA was examined in an effort to gain basic information on favorable
chemical features of potential small molecule inhibitors. First, a set of 20 primary amines was
selected that represented variation in hydrophobicity, aromaticity, ability to form hydrogen bonds,
and contained substructures present in clinically available drugs. Many of the amines from this set
are commercially available, though some require different degrees of synthetic preparation. In
preparation for virtual screening, the CombiGLIDE application within Maestro (Schrödinger) [326]
was used to generate a virtual library of trimeric peptoids that contained each of the 20 primary
amines, plus hydrogen as a potential substituent, in a combinatorial fashion to give 9,261 total
compounds. The ligands were ionized (along with desalting and tautomeric generation) using Epik
to generate all possible states within a pH range of 7.0±2.0, and these were minimized using the
OPLS-2005 force field.
In general, using a single rigid protein structure for virtual docking tends to produce skewed
results due to geometric constraints and functional group directionality at the binding site. This is
exacerbated when taking into account a protein such as PCNA, which has a significant degree of
plasticity at the PIP Box site [177], since there are likely to be many false negatives when docking
rigidly. While a flexible docking method such as Schrödinger Maestro’s induced-fit [327] is more
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Figure 2.2 Development of Initial Virtual Library. (top) 20 commercially and non-commercially
available primary amines were selected for their variation in hydrophobicity, aromaticity, ability to
form hydrogen bonds, and/or whether they contained substructures present in clinically available
drugs. N* indicates the location of the –NH2 group, which is the position of substitution into a
peptoid backbone (bottom). R1, R2 and R3 indicate the three substitution positions in a resultant
tripeptoid, and are referred to here as the first, second and third positions, respectively. Hydrogen
was also considered as a potential substituent (Gly), and would therefore effectively constitute the
incorporation of a glycine amino acid at wherever hydrogen was to be ‘substituted’.
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ideal for screening ligands virtually, as there should theoretically be fewer false positives and
negatives, the considerable amount of computational time required for such a method makes it
impractical for screening more than a few ligands at a time, especially those will high degrees of
freedom such as linear peptides and peptoids. To partially compensate for this, instead of a single
rigid structure of PCNA used for screening, four crystal structures of PCNA bound to four different
ligands were selected, each having a significant degree of structural divergence surrounding the
PIP Box binding site. These structures included PCNA complexed to the C-terminal tail of p21
(PDB ID: 1AXC), PCNA complexed to residues 331-350 of FEN1 (PDB ID: 1U7B), PCNA
complexed with the T3 ligand (PDB ID: 3VKX) and PCNA complexed with a fragment of DNA
polymerase η (PDB ID: 2ZVK).
Each crystal structure of PCNA was prepared using the Protein Preparation Wizard in
Maestro, with each protein minimized in complex with its respective ligand/peptide using the
OPLS-2005 force field to an RMSD of 0.30Å. Cubic grid boxes were created using either T3
(3VKX), or a PIP Box peptide amino acid at the hydrophobic site on PCNA, as the centroid, with
a length of 30Å. The prepared ligands were flexibly docked into each form of PCNA using the
standard precision (SP) model in Glide [328], and the top 10% of the ligand hits from each docking
run were flexibly re-docked into the respective form of PCNA using the extra precision (XP) Glide
algorithm, which places harsher penalties on energy of solvation, solvent-exposed surface area and
buried charge. Upon completion of each docking exercise, the results were compiled for each of
the top 50 hits in each of the docking runs. The frequency with which a specific side chain was
present at a particular location along the tripeptoid backbone was tallied for each crystal structure
of PCNA, and the top 50 hits from each run were compiled into total list of 200 top hits.
To further explore the use of peptoids as antagonists of PCNA-PIP Box interactions, the
known PCNA inhibitor, T2AA, was investigated for its use as a peptoid fragment. Functional
groups on T2AA potentially allow the compound to be incorporated into a peptoid backbone with
the same basic methodology used for tripeptoid synthesis (i.e. submonomer peptoid synthesis
[300]). In this way, T2AA could serve as an anchoring residue, potentially helping to direct small
peptoid molecules to the PIP Box binding site on PCNA. To explore this possibility, a virtual
combinatorial library was created using the same methodology as previously discussed, with a set
of 37 peptoid side chains (17 new primary amines in addition to the original set) and two forms of
T2AA, with defined attachment points at either the primary amine or amide groups on the molecule.
This library was then systematically screened using the crystal structure of PCNA bound to the T3
ligand (PDB ID: 3VKX). All ligands were prepared in Maestro using the same previous
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Figure 2.3 Creation of a Virtual Library Containing T2AA as a Fragment. A list of 37 primary
amines, along with T2AA, was used to create a combinatorial virtual library of peptoid-based
compounds. N* indicates the location of the –NH2 group, which is the position of substitution into
a peptoid backbone. R1 and R2 indicate the two substitution positions in a resultant tripeptoid.
Blue labels denote new fragments.

44
methodology. The high throughput virtual screening (HTVS) algorithm in Glide was used to screen
the initial set of compounds. The top 50% best hit compounds were screened again using Glide’s
SP model, and the top 7,500 hits from the SP screen were docked again using Glides XP model.
As before, the frequency that a particular side chain was present at a given substitution location on
the peptoid backbone was tallied for the top 50 hits from the XP screen.

Step 2: Select and Synthesize Set of Tripeptoid Ligands. Based on the results from the virtual
docking study, particular side chains appeared to be favored at specific positions along the
tripeptoid backbone (see Figure 2.4). Amines that appeared in approximately 10% or more of the
top 50 hits at a given position were selected for incorporation via synthesis. Peptoids were
synthesized using traditional submonomer solid phase practices [300], purified by HPLC and
characterized by ESI mass spectrometry. Side chains that are not commercially available were
synthesized in-house using acid-labile protecting groups.

Step 3: Screen Synthesized Tripeptoids Using Fluorescence Polarization (FP). Synthesized
peptoids were formulated in DMSO at concentrations of 10 mM. Synthesized peptoids were
initially screened using a fluorescence polarization assay (see Experimental Materials and Methods
section for details) at concentrations of 1 mM and 250 µM. Ligands that demonstrated sufficient
ability to disrupt binding between PCNA and the PL peptide were identified, and then further
characterized by generating dose response curves for each compound to obtain IC50 and Ki values.

Step 4: Computational Analysis of Select Top-Hit Compounds. Peptoids that emerged as hits from
the fluorescence polarization assay were examined using molecular dynamic (MD) simulations to
identify key interactions that may be driving their affinity for PCNA. A principal component
analysis (PCA) of each trajectory was performed and compared to MD trajectories from several
peptides, as well as T2AA, all of which are known to bind to PCNA.

2.5.2

Experimental Materials and Methods

Reagents and solvents were purchased from Sigma Aldrich unless otherwise noted. Materials were
repurified via recrystallization or distillation as necessary before use. NMR experiments were
performed on Bruker (Bruker Corp., Billerica, MA) ARX300 (300 MHz), ARX400 (400 MHz) or
DRX500 (500 MHz) instruments. Low resolution electrospray ionization (ESI) and atmospheric
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pressure chemical ionization (APCI) studies were carried out on an Agilent 6320 Ion Trap (Agilent
Labs, Santa Clara, CA) mass spectrometer. High resolution mass measurements were obtained on
a LTQ Orbitrap XL mass spectrometer (ThermoScientific Corp.) utilizing electrospray ionization
(ESI). Molecular masses and sequences of peptides or peptoids were validated on an Applied
Biosystems (Framingham, MA) MALDI-TOF/TOF 4800 mass analyzer, or Applied Biosystems
Voyager DE PRO mass spectrometer using either 2,5-dihydroxy benzoic acid or α-cyano-4hydroxy cinnamic acid matrices. TLC analyses were performed on Merck aluminum-backed F254
silica gel plates. Protein and peptide concentrations were determined by UV absorbance at 280
nm. Fluorescent peptide concentrations were determined by absorbance at 494 nm. Stock solutions
of each polypeptoid were made by measuring the dry mass of each in pre-dried, pre-weighed screwcap vials, and adding the volume of DMSO necessary to give 10 mM solutions. Stock solutions of
compounds containing N-terminal 5-carboxyfluorescein were made by measuring the aborbance at
494 nm, using an extinction coefficient of 79,000 L mol-1 cm-1 and Beer’s Law (A=εbc) to calculate
concentration. Data analyses and graphical representations were performed in Microsoft Excel,
GraphPad Prism 6 or OriginPro 2015.

Ligation Independent Cloning of N-terminal His-tag PCNA Construct. Ligation independent
cloning compatible expression vector pEV-L8 containing an N-terminal His-tag and TEV protease
recognition site was linearized by digestion with Ssp1 (New England Biolabs), purified by gel
filtration, and treated with T4 DNA polymerase (Novagen) in the presence of dGTP (New England
Biolabs) for 30 minutes at 22°C, followed by heat inactivation at 75°C for 20 minutes. The PCNA
fragment was amplified by PCR from a template plasmid (Genecopeia) using a high-fidelity
polymerase Platinum Pfx DNA polymerase (Invitrogen). The resulting PCR products were treated
with T4 DNA polymerase in the presence of dCTP to generate 5’ overhangs necessary for
annealing. A total of 0.2 pmol of each insert was incubated with 0.01 pmol of pEV-L8 vector in 3
µL reaction mix at 22°C for 10 minutes followed by addition of 1 µL of 25 mM EDTA at 22°C for
5 minutes. Annealing reaction products were transformed into X10Gold competent cells
(Strategene) and plated on LB agar containing 50 µg/mL kanamycin. Individual colonies were
grown and the constructs were assessed by PCR for insert size and verified by sequencing before
propagating the plasmid.

Expression and Induction of N-terminal His-tag PCNA. 10 µL aliquots of chemically competent
BL21 (DE3) E. coli cells (Agilent) were transformed via heat shock with 1 µL of purified plasmid
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encoding the fusion protein, N-terminal (His)6-PCNA for 30 seconds at 42°C. The cells were then
immediately placed on ice for 2 min, and 140 µL of SOC medium was added. Transformed cells
were allowed to grow for 1 hour at 37°C before streaking on a LB agar plate containing 50 µg/mL
kanamycin. Single isolated colonies were picked and grown at 37°C to an OD of 0.7-1.0 in the
presence of 50 µg/mL kanamycin. Transformed cells were induced with 0.4 mM IPTG for 4 hours
at 37°C. Transformed cells were pelleted at 4,000 x g for 20 minutes at 4°C, and stored at -80°C
until lysis.

Purification of N-terminal His-tagged PCNA. Two pellets of transformed BL21 (DE3) E. coli cells
were each resuspended in 20 mL of ice-cold lysis buffer (50 mM Tris HCl at pH 8.0, 0.15 mM
NaCl), lysed by sonication at a 30% amp output for 3 minutes (20 second pulses), and centrifuged
at 4,000 x g for 20 minutes at 4°C. Each supernatant was decanted and combined. Recombinant
(His)6-PCNA fusion protein was then purified from the soluble fraction by affinity column
chromatography using Ni-NTA resin at 4°C. After charging the column resin with the entire soluble
protein fraction, the column was washed with 20 mM imidazole in Tris buffer at pH 8.0 to remove
nonspecific binding protein. (His)6-PCNA was then eluted with 10 mL of 1M imidazole in Tris
buffer at pH 8.0. The eluted protein was diluted two-fold with dialysis buffer (25 mM HEPES at
pH 7.4, 10% glycerol, 0.01% Triton X-100), DTT and EDTA were added to a final concentration
of 2 mM, and the entire solution was diluted two-fold with 2 M ammonium sulfate in 25 mM Tris
buffer at pH 8.0 to give a final (NH4)2SO4 concentration of 1 M. The solution was agitated for 1
hour at 4°C, and during that time (His)6-PCNA precipitated from solution. The precipitated protein
was pelleted by centrifugation (5,000 x g for 10 minutes), the supernatant decanted, and the protein
pellet dissolved into 10 mL of dialysis buffer. The protein concentration was immediately assessed
via measuring its absorbance at 280 nm (using an extinction coefficient of 16,000 M -1cm-1), and
the protein solution was diluted as necessary to give a stock concentration of 4 µM. This was then
dialyzed for 24 hours, swapping the dialysis buffer twice with fresh 25 mM HEPES at pH 7.4, 10%
glycerol, 0.01% Triton X-100. After dialysis, the protein concentration was re-confirmed by
measurement of its absorbance at 280 nm.

General Method for Synthesis of Synthetic Peptides. Peptides were synthesized via solid phase
synthesis using 0.10 mmol of Rink Amide AM or MBHA resin (EMD Millipore). Each synthetic
step was performed in a glass fritted peptide reaction vessel placed on an orbital shaker. Before the
addition of Fmoc-protected amino acids (Anaspec), the resin was first swelled with
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dimethylformamide (DMF) for 30 minutes, and deprotected with a solution 20% piperidine in DMF
for 30 minutes. Amino acids were coupled using standard peptide synthesis conditions (1 mmol of
Fmoc-protected amino acid, 2.1 mL of 0.45 M 2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3tetramethylaminium hexafluorophosphate (HCTU; Anaspec) in DMF and 500 µL of 4M N,Ndiisopropyltheylamine (DIEA) in N-methyl-2-pyrrolidone (NMP)) for one hour at room
temperature, and were deprotected using 20% piperidine in DMF for 30 minutes at room
temperature. Between coupling and deprotection steps, the resin was washed with DMF (6x) and
dichloromethane (DCM) (3x). Reaction progress was monitored using a ninhydrin (Kaiser) test for
the presence of primary amines. For fluorescent N-terminal labeling using 5-carboxyfluorescein
(5-FAM; Anaspec), Fmoc-6-aminohexanoic acid was coupled to the completed resin-bound
peptide and subsequently deprotected, followed by the addition of a solution of 2 equivalents of 5FAM, 1.95 equivalents of HCTU and 4 equivalents of DIEA dissolved in 2 mL of DMF, allowing
the resin to incubate at room temperature overnight in the dark. Peptides were cleaved from resin
using a solution of trifluoroacetic acid (TFA)/triisopropylsilane (TIS)/water (95:2.5:2.5),
incubating the resin at room temperature for either 1 hour, or 3 hours in the case of peptides
containing glutamine, arginine, tryptophan or histidine. They were then precipitated into ice cold
diethyl ether and collected by centrifugation at 4,000 x g for 10 minutes at 4°C. The peptides were
purified via HPLC (Beckman Coulter System Gold 166 or 168) using an increasing gradient of
acetonitrile (ACN)/water with 0.1% TFA (5:95) to (100:0) over 30 minutes on an Agilent
ZORBAX SB-C18 reverse phase semi-preparative column. Molecular masses and sequences were
validated via MALDI-TOF/TOF. Purities were determined by HPLC using absorbencies at 219 or
280 nm.

Synthesis of Fluorescein-labeled POGO Ligase Peptide (FAM-PL). POGO Ligase peptide
(sequence: SAVLQKKITDYFHPKK) was synthesized by GenScript USA Inc. and provided
uncleaved on Rink Amide MBHA resin. 0.10 mmol of this resin was transferred to a glass fritted
peptide reaction vessel and swelled in DMF for 30 minutes, followed by washing with DCM (3x).
Sufficient deprotection of the final amino acid residue was confirmed by a ninhydrin (Kaiser’s) test
for primary amines. An aminohexanoic acid linker was added (1 mmol Fmoc-6-Ahx-OH, 2.1 ml
of 0.45M HCTU, 500 µL of 4M DIEA in NMP; 2 hours at room temperature) to separate the
fluorescent dye from the peptide sequence. Following subsequent washing of the resin (DMF (6x)
and DCM (3x)) and Fmoc deprotection (20% piperidine in DMF; 30 minutes at room temperature),
the resin was again washed (DMF (6x) and DCM (3x)) and then transferred to a glass scintillation
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vial wrapped in foil. A solution of 75.3 mg of 5-FAM, 80.7 mg of HCTU and 46 mg of DIEA in 2
mL of DMF was added, and the resin was then placed on an orbital shaker overnight at room
temperature. After 20 hours of incubation time, the resin was washed with DMF (6x) and DCM
(3x), dried over vacuum, transferred to a glass scintillation vial and cleaved from resin using a
solution of trifluoroacetic acid (TFA)/triisopropylsilane (TIS)/water (95:2.5:2.5) for 3 hours at
room temperature in the dark. The 5-FAM-labeled POGO ligase peptide (FAM-PL) was then
precipitated into ice cold diethyl ether and collected by centrifugation at 4,000 x g for 10 minutes
at 4°C. It was purified via HPLC (Beckman Coulter System Gold 168) using an increasing gradient
of acetonitrile/water with 0.1% TFA (5:95) to (100:0) over 30 minutes. The molecular mass and
sequence were validated via MALDI-TOF/TOF. Purity was determined by HPLC using
absorbencies at 219 and 280 nm. HRMS (LCMS): calculated mass (C116H164N25O29) [M-H]1-:
2372.6980, mass found m/z: 2372.7221 [M-H]1-.

General Method for Synthesis of Peptoid Trimers. Trimeric peptoids were synthesized using an
adapted procedure for submonomer [300] peptoid synthesis. Briefly, 0.05 mmol of Rink Amide
AM or MBHA resin was transferred to a 25 mL glass fritted peptide reaction vessel and was swelled
with DMF for 30 minutes. The resin was then deprotected using two 2.5 mL portions of 20%
piperidine in DMF with incubation times of 15 minutes for each addition at room temperature.
Following washing of the resin with DMF (6x) and DCM (3x), deprotection was confirmed by a
ninhydrin (Kaiser’s) test for primary amines. A solution of 1.5 mL of 1 M bromoacetic acid (30
equiv.) in DMF and 230 µL (29.4 equiv.) of N,N’-diisopropylcarbodiimide (DIC) was added, and
the resin was placed on an orbital shaker for 1 hour at 37°C. At that time, the resin was washed
with DMF (6x) and DCM (3x), and a solution of 1 M respective primary amine (2 M for
commercially available primary amines) in DMF was added, with incubation on an orbital shaker
for 2 hours at 37°C. These steps were repeated with washing steps in-between to produce the
desired peptoid sequence. For the coupling of T2AA, peptoids were first synthesized up to the final
bromoacetic acid addition. A solution of 500 mg (19.5 equiv.) of T2AA and 34 µL (39 equiv.) of
DIEA in 2.5 mL of DMF was added, and the resin was incubated overnight at room temperature
on an orbital shaker. Peptoids were cleaved from resin using a solution of TFA/TIS/water
(95:2.5:2.5), incubating the resin at room temperature for either 1 hour, or 3 hours in the case of
peptoids containing NArg, NEal or NBal side chains. TFA was removed with a steady stream of
blowing air, and the remaining residue was dissolved in ACN/H2O (50:50) with 0.1% TFA, frozen
and lyophilized. The peptoids were purified via HPLC (Beckman Coulter System Gold 166 or 168)
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using an increasing gradient of ACN/H2O with 0.1% TFA (5:95) to (100:0) over 30 minutes on an
Agilent ZORBAX SB-C18 reverse phase semi-preparative column. Molecular masses were
validated via low resolution ESI or APCI experiments, and exact masses were obtained by high
resolution ESI or MALDI.
Fluorescence Polarization Z’-Factor Analysis. 10 µL of 20 nM FAM-PL in FP binding buffer (25
mM HEPES at pH 7.4, 10% glycerol, 0.01% Triton X-100) was combined with either 10 µL of 200
nM recombinant (His)6-PCNA protein in binding buffer or 10 µL of binding buffer in each of 48
wells on a ProxiPlate-384 F Plus (PerkinElmer) low volume, black, opaque plate (24 replicates for
each set). The plate was allowed to incubate at room temperature in the dark for 30 minutes prior
to fluorescent measurement. Fluorescence polarization and resultant anisotropy were measured on
a BioTek Synergy 4 Multi-Detection Microplate Reader using an excitation filter of 485 nm and an
emission filter of 530 nm, each with a 20 nm band-pass. The average of each control set was
calculated along with the standard deviation. The Z’-factor was calculated using equation 2.1,

𝑍′ = 1 −

3𝜎+ + 3𝜎−
|µ− − µ+ |

(2.1)

where σ+ is the standard deviation of the positive control (FAM-PL peptide in the presence of
PCNA protein), σ- is the standard deviation of the negative control (FAM-PL peptide in the absence
of PCNA protein), and µ+ and µ- are the mean anisotropy values of the positive and negative
controls, respectively.

Fluorescence Polarization Binding Assay. Increasing amounts of recombinant (His)6-PCNA
protein were prepared in FP binding buffer (25 mM HEPES at pH 7.4, 10% glycerol, 0.01% Triton
X-100), with an 11-step 2-fold dilution series, and a top concentration of 30 µM. 10 µL of each
solution was combined with 10 µL of 20 nM FAM-PL peptide formulated in FP binding buffer in
a single well of a ProxiPlate-384 F Plus low volume, black, opaque plate. Each concentration of
protein was plated in a replicate of four, and the plate was allowed to incubate at room temperature
in the dark for 30 minutes prior to fluorescent measurement. Fluorescence polarization and resultant
anisotropy were measured on a BioTek Synergy 4 Multi-Detection Microplate Reader using an
excitation filter of 485 nm and an emission filter of 530 nm, each with a 20 nm band-pass. The
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parallel and perpendicular intensity values for each sample (n=4) were used to calculate fractional
occupancy (FO) of the FAM-PL peptide bound to monomeric PCNA using equation 2.2.

𝑓𝑏 =

𝑟 − 𝑟𝑓
(𝑟𝑏 − 𝑟)𝑄 + 𝑟 − 𝑟𝑓

(2.2)

where
𝑄=

𝑞𝑏
𝑞𝑓

𝑞𝑓 = ∥𝑓 + 2 ∙⊥𝑓
𝑞𝑏 = ∥𝑏 + 2 ∙⊥𝑏
and fb is the fraction of FAM-PL bound to PCNA, r is the observed anisotropy value, rf is the
anisotropy of free un-bound FAM-PL peptide, rb is the anisotropy of FAM-PL peptide saturated
with PCNA protein, Q is the ratio of quantum yield of bound (qb) to free (qf) FAM-PL peptide, ∥f
and ∥b are the parallel intensities of free un-bound and saturated FAM-PL peptide, respectively,
and ⊥f and ⊥b are the perpendicular intensities of free un-bound and saturated FAM-PL peptide,
respectively.

FO values were analyzed using non-linear regression statistics in OriginPro 2015, representing
them as the mean ± standard error of the mean (Y), and plotting them as a function of the monomeric
PCNA protein concentration (X). From this, equation 2.3 was used to obtain a dissociation constant
(Kd) for FAM-PL.

𝑌 = 𝑌𝑚𝑎𝑥 ∙

𝑋𝑛
𝐾𝑑𝑛 + 𝑋 𝑛

(2.3)

where n is the Hill slope.

Fluorescence Polarization Competition Assay. Solutions of competitive ligand were formulated
from DMSO stocks (10 mM for tripeptoids, 20 mM for T2AA) into FP binding buffer (25 mM
HEPES at pH 7.4, 10% glycerol, 0.01% Triton X-100) at appropriate 2X concentrations, relative
to the desired effective screening concentration. 10 µL of each competitive ligand was combined
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with 5 µL of 4 µM recombinant (His)6-PCNA protein in binding buffer and 5 µL of 40 nM FAMPL in binding buffer into each well of a ProxiPlate-384 F Plus low volume, black, opaque plate, in
replicates of four. DMSO at an equivalent concentration in binding buffer to the concentration of
DMSO in the competitive ligand sample was used as a negative control; T2AA at 250 µM was used
as a positive control. The plate was allowed to incubate at room temperature in the dark for 30
minutes prior to fluorescent measurement. Fluorescence polarization and resultant anisotropy were
measured on a BioTek Synergy 4 Multi-Detection Microplate Reader using an excitation filter of
485 nm and an emission filter of 530 nm, each with a 20 nm band-pass. Anisotropy values were
converted to fractional occupancy using equation 2.2, and IC50 values were calculated by fitting the
data to equation 2.4.

𝑌 = 𝑌𝑚𝑖𝑛 +

𝑌𝑚𝑎𝑥 − 𝑌𝑚𝑖𝑛
1 + 10(log 𝐼𝐶50 −𝑋)𝑛

(2.4)

where n is the Hill slope.

Inhibition constants (Ki) for the competitive ligands were determined using equation 2.5, which is
a modified form of the Cheng-Prusoff equation, previously reported for fluorescence polarization
assays [329].

𝐾𝑖 =

[𝐼]50
[𝐿]
[𝑃]
( 𝐾 50 + 𝐾 0 + 1)
𝑑
𝑑

(2.5)

where [I]50 is the concentration of each competitive peptoid at 50% inhibition, [L]50 is the
concentration of the FITC-PL peptide at 50% inhibition, [P]0 is the concentration of monomeric
PCNA protein at 0% inhibition, and Kd is the dissociation constant calculated from equation 2.3.

Molecular Dynamic Simulations. In preparation for molecular dynamic simulations, selected hit
peptoids were flexibly docked into the PIP Box binding site of the co-crystal structure of PCNAPogo Ligase (PL) peptide (PDB ID: 1VYJ), with the peptide itself removed, using Schrödinger
Glide’s induced-fit docking model. The PCNA crystal structure was prepared using the Protein
Preparation Wizard in Maestro, with PCNA minimized in complex with the PL peptide using the
OPLS-2005 force field to an RMSD of 0.30Å. PCNA-peptoid complexes were solvated in
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Schrödinger’s Desmond [330] using the TI3P water model in the presence of 0.15 M sodium
chloride buffer to generate orthorhombic water boxes that contained a 10 Å buffer region. Each
system was then minimized with the OPLS-2005 force field to an RMSD of 0.30Å.
The molecular dynamic simulations were performed in the same way as described in
Pedley, et al. (2014) [177], using Desmond and the OPLS-2005 force field. In summary, longrange electrostatic interactions were determined using a smooth particle mesh Ewald method with
a grid spacing of 0.8 Å. For non-bonded van der Waals interactions, a cut off of 9.0 Å was set. All
simulations were performed for 5.0 ns, except in cases where simulations did not fully converge
after 5.0 ns (simulations were extended by 2.5 ns in those situations), using the Desmond NPT
method with a six step slow relaxation protocol prior to the molecular dynamics run: (i) 2000 step
limited-memory Broyden-Fletcher-Goldfarb-Shanno (L-BFGS) minimization with a loose
convergence restraint of 50 kcal/mol/Å; (ii) 2000 step L-BFGS minimization with a convergence
constraint of 5 kcal/mol/Å; (iii) a 12 ps Berendsen NVT simulation at a temperature of 10 K with
restraints on solute heavy atoms; (iv) a 12 ps Berendsen NPT ensemble at a temperature of 10 K
and pressure at 1.01325 bar with restraints on solute heavy atoms; (v) a 24 ps Berendsen NPT
ensemble at a temperature of 300 K and a pressure at 1.01325 bar with restraints on solute heavy
atoms; (vi) a 24 ps Berendsen NPT ensemble at a temperature of 300 K and a pressure at 1.01325
bar with restraints on residues beyond 15 Å of the restrained ligand. The 5.0 ns molecular dynamic
simulation run was performed using NPT ensemble. Temperature of the simulation was kept at 300
K using a Nosé-Hoover thermostat. Pressure was maintained at 1.01325 bar using the MartynaTobias-Klein method. Energy and trajectory data was recorded at every 1.2 ps and 5.0 ps,
respectively.
Upon completion of each simulation, PCNA trajectory data were processed in VMD [331]
after removal of each peptoid ligand. For each trajectory, the protein backbone Cα atoms were
aligned to the first frame of the simulation to generate RMSD and Cα fluctuations (RMSF) values.
Simulations were determined to be converged once RMSD values had stabilized (average slope of
the RMSD curve over the period of the final 0.5-1.0 ns ≈ 0). In preparation for principal component
analysis, trajectories for each PCNA-peptoid system were overlaid using the alignment tools in
VMD. Additionally, trajectories previously generated from Pedley, et al. (2014), including the
systems where PCNA is in complex with the Polymerase δ, PL, p85α, p21, Apo, Akt or Abl
peptides, were overlaid with the PCNA-peptoid trajectories for purposes of comparative analysis.
Principal component analyses were performed using the Bio3D package [332] in R to analyze the
conformational differences between the aligned trajectories over the period of the final 0.5 ns for
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each simulation (100 snapshots per PCNA-ligand system). The first two orthogonal eigenvectors
(principal components—PC1 and PC2) were plotted on the same set of axes. Average trajectory
coordinates for the final 50 frames of each simulation were performed in VMD to generate average
overall conformations of PCNA in complex with each peptoid.

2.5.3

Synthesis of Non-Commercially Available Primary Amines and T2AA

Scheme 2.1
Synthesis of NArg
Synthesis

of

N-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)-1H-pyrazole-1-

carboximidamide (1). 16.16 g (55.96 mmol) of 2,2,5,7,8-pentamethylchroman-6-sulfonyl chloride
(Combi-Blocks, San Diego, CA) was dissolved in dioxane (200 mL), and 9.07 g (61.88 mmol) of
1H-pyrazole-1-carboxamidine HCl dissolved in dioxane (200 mL) was added to the solution
followed by 22 mL (2 eq.) of DIEA. The reaction mixture was stirred at room temperature for 48
hours, at which time all of the 1H-pyrazole-1-carboxamidine HCl had been consumed as confirmed
via TLC. The dioxane was evaporated in vacuo and the remaining brown oil was redissolved into
200 mL DCM. The organic layer was washed with water (3 x 200 mL) and brine (200 mL). The
organic layer was mostly evaporated in vacuo, and the remaining mixture was poured over wet
silica gel to remove the polar impurity that appeared via TLC under conditions of ethyl
acetate/hexane (25:75), but could not be removed with liquid-phase extraction. After flushing the
silica gel through with ethyl acetate/hexanes (25:75), the filtrate was evaporated, and the resulting
solid was recrystallized from ethanol to give 13.17 g (64.9% yield) of 1 as a white crystalline solid.
H NMR (500 MHz, CDCl3) δ 8.21 (dd, J = 2.8, 0.7 Hz, 1H), 7.67 (dd, J = 1.6, 0.7 Hz, 1H), 6.40

1

(dd, J = 2.9, 1.6 Hz, 1H), 2.98 (s, 2H), 2.62 (s, 3H), 2.56 (s, 3H), 2.11 (s, 3H), 1.47 (s, 6H). 13C
NMR (126 MHz, CDCl3) δ 12.34, 17.86, 19.16, 28.48, 42.99, 86.67, 109.47, 117.74, 124.83,
128.92, 130.88, 132.98, 139.13, 143.44, 148.66, 159.41.

Synthesis of N-(N-(3-aminopropyl)carbamimidoyl)-2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran5-sulfonamide (2 ; “NArg”). 5.88 g (17.5 mmol) of 1 was dissolved into DCM (100 mL) and was
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added dropwise to 6.75 g (91.1 mmol; 5.2 equiv.) of 1,3-diaminopropane dispersed in DCM (100
mL) at room temperature while stirring. The reaction was allowed to stir for 24 hours, at which
time TLC showed that all of 1 had been consumed. The reaction mixture was washed with water
(3 x 100 mL) and brine (100 mL), the organic layer was dried over sodium sulfate, and the organics
were evaporated in vacuo to give an off-white solid. The product was recrystallized using ethyl
acetate/hexanes to give 3.57 g (59.7% yield) of 2 as a white solid. 1H NMR (500 MHz, CDCl3) δ
3.30 (t, J = 6.09 Hz, 2H), 3.25 (q, J = 6.20 Hz, 1H, NH), 3.20 (q, J = 6.65 Hz, 1H, NH), 2.93 (s,
2H), 2.88 (t, J = 7.63 Hz, 2H), 2.54 (s, 3H), 2.47 (s, 3H), 2.07 (s, 3H), 1.82 – 1.70 (m, 2H), 1.66 (t,
J = 6.66 Hz, 1H, NH), 1.45 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 158.71, 138.15, 132.32, 132.12,
124.62, 117.50, 109.22, 86.35, 43.10, 39.78, 37.98, 28.50, 19.23, 17.85, 12.39. HRMS (ESI):
calculated mass (C17H29N4O3S) [M+H]1+: 369.1961, mass found m/z: 369.1980 [M+H]1+.

Scheme 2.2
Synthesis of NBal
Synthesis of 2,2,2-trifluoro-N-(4-(hydroxymethyl)benzyl)acetamide (3). 20.0 g (132 mmol) of 4(aminomethyl)benzoic acid was dispersed in 100 mL of anhydrous THF, and 350 mL (2.65 equiv.)
of 1 M borane-THF in THF was added dropwise. The reaction mixture was heated to reflux for
eight hours, and then allowed to cool to room temperature. 100 mL of MeOH was added to quench
the remaining borane-THF, and the reaction was stirred for an additional 15 minutes. The reaction
solution was filtered over celite and evaporated in vacuo to give a light yellow solid. 250 mL of
DCM was then added to the reaction flask containing the crude intermediate product, followed by
37 mL (2 equiv.) of triethylamine. The reaction was cooled to 0°C, 21 mL (1.1 equiv.) of
trifluoroacetic anhydride was added dropwise and the reaction was allowed to stir overnight,
allowing it to gradually reach room temperature. After 22 hours of reaction time, all of the starting
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material had been consumed as evidenced by TLC. 250 mL of water was added to the reaction and
the organic layer was separated. The aqueous layer was extracted once more with 250 mL of DCM,
the combined organics were washed with water (100 mL), and were dried over sodium sulfate,
filtered and evaporated in vacuo to give a thick yellow oil. This oil was purified via automated flash
chromatography (EPCLC W-Prep 2XY, Yamazen Corp., Yodogawa-Ku Osaka, Japan) using
DCM/MeOH as the eluents. The fractions containing the desired product were combined and
evaporated to give 15.87 g (51.44% yield for both steps) of 3 as a white solid. 1H NMR (300 MHz,
CDCl3) δ 7.34 (d, J = 8.17 Hz, 2H), 7.26 (d, J = 8.16 Hz, 2H), 6.86 (s, br, 1H), 4.66 (s, 2H), 4.49
(d, J = 5.86 Hz, 2H), 2.02 (s, 1H).

Synthesis of N-(4-(((tert-butyldimethylsilyl)oxy)methyl)benzyl)-2,2,2-trifluoroacetamide (4). 15.68
g (67.24 mmol) of 3 was dissolved in DMF (200 mL), followed by the addition of 9.17 g (2 equiv.)
of imidazole and 11.29 g (1.11 equiv.) of tert-butyl dimethylchlorosilane. The reaction was allowed
to stir overnight at room temperature. After 20 hours of reaction time, the reaction mixture was
evaporated in vacuo to half of its original volume. 100 mL of water was added, and the solution
was extracted with ethyl acetate (2 x 200 mL), the combined organics washed with water (200 mL)
and brine (100 mL), dried over sodium sulfate, filtered and evaporated to give clear, yellow oil.
This oil was purified via automated flash chromatography (EPCLC W-Prep 2XY, Yamazen Corp.)
using ethyl acetate/hexanes as the eluents. The fractions containing the desired product were
combined and evaporated to give 20.9 g (89.5% yield) of 4 as a white solid. 1H NMR (300 MHz,
CDCl3) δ 7.34 (d, J = 8.26 Hz, 2H), 7.25 (d, J = 8.17 Hz, 2H), 6.83 (s, br, 1H), 4.74 (s, 2H), 4.49
(d, J = 5.80 Hz, 2H), 0.95 (s, 9H), 0.11 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 157.52, 141.83,
134.51, 128.03, 126.72, 117.90, 64.65, 43.81, 26.04, 18.53, -5.17.
Synthesis of (4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)methanamine (5; “NBal”). 20.8 g
(59.9 mmol) of 4 was dissolved in methanol (100 mL), followed by the addition of a 2 M aqueous
solution of potassium carbonate (27.1 g in 100 mL water). The reaction was heated to reflux for
seven hours, and then allowed to cool to room temperature. Methanol was evaporated from the
reaction mixture in vacuo, the remaining aqueous solution was transferred to a separatory funnel,
and was extracted with DCM (2 x 400 mL). The combined organics were washed with water (100
mL), dried over sodium sulfate, filtered and evaporated in vacuo to give a yellow oil. The crude
product was purified via automated flash chromatography (EPCLC W-Prep 2XY, Yamazen Corp.)
with an increasing gradient of MeOH:DCM w/ 1% TEA. The fractions containing the desired
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material were combined and evaporated to give 12.35 g (82.0% yield) of 5 as a clear oil, which
solidified upon storage at -20°C. 1H NMR (500 MHz, CDCl3) δ 7.28 (d, J = 8.58 Hz, 2H), 7.25 (d,
J = 8.14 Hz, 2H), 4.72 (s, 2H), 4.43 (s, br, 1H), 3.81 (s, 2H), 0.95 (s, 9H), 0.10 (s, 6H). 13C NMR
(126 MHz, CDCl3) δ 141.85, 139.83, 126.87, 126.18, 64.70, 46.16, 29.35, 25.90, -5.29. HRMS
(ESI): calculated mass (C17H27NOSi) [M+H]1+: 252.1784, mass found m/z: 252.1785 [M+H]1+.

Scheme 2.3
Synthesis of NBza
Synthesis of 4-((2,2,2-trifluoroacetamido)methyl)benzoic acid (6). 21.16 g (140 mmol) of 4(aminomethyl) benzoic acid was suspended in 450 mL of dichloromethane, followed by 42.0 mL
(301 mmol) of triethylamine. The reaction was then cooled in an ice bath, and 60.44 g (2.06 eq.) of
trifluoroacetic anhydride in 50 mL of dichloromethane was added dropwise over the course of 1
hour. The reaction was stirred for an additional three hours while being allowed to gradually warm
to room temperature. 500 mL of aqueous saturated sodium bicarbonate solution was then slowly
added to the reaction mixture in portions, and the solution was acidified with 4N HCl (pH < 3). The
resultant precipitate was collected via filtration, and the filter cake was washed three times with
water and twice with ice-cold ether. The solid was dissolved in ethyl acetate, dried over sodium
sulfate, filtered, transferred to a round bottom flask and evaporated to give an off-white solid. The
product was recrystallized from ethyl acetate/hexanes three times to give 24.63 g (71.19% yield)
of 6 as a white solid. 1H NMR (300 MHz, DMSO) δ 10.15 (t, J = 5.91 Hz, 1H), 8.13 (d, J = 8.36
Hz, 2H), 7.51 (d, J = 8.38 Hz, 2H), 4.52 (d, J = 5.97 Hz, 2H). 13C NMR (75 MHz, DMSO) δ 167.97,
162.96, 145.92, 131.66, 130.49, 128.91, 127.95, 43.27.

Synthesis of tert-butyl 4-((2,2,2-trifluoroacetamido)methyl)benzoate (7). 12.55 g (50.77 mmol) of
6 was dissolved in anhydrous THF (150 mL), and 135 mL of t-butanol and 6.20 g (50.75 mmol)
DMAP were added. The reaction was cooled to 0°C under argon, and 29.2 g (152 mmol) of EDCI
was added followed by an additional 50 mL of anhydrous THF to wash down the insides of the
reaction flask. The reaction was sealed and stirred under argon overnight, allowing it to gradually
reach room temperature. After 16 hours of reaction time, 200 mL of water was added to the reaction
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and the organics were evaporated in vacuo. The aqeuous solution was extracted with DCM (2 x
200 mL), and the subsequent combined organics were washed with 5% HCl (2 x 200 mL), 200 mL
of water and 200 mL of brine. The organic layer was dried over sodium sulfate and evaporated to
give a yellow oil. The product was purified using normal phase flash chromatography (EPCLC WPrep 2XY, Yamazen Corp.) with an increasing gradient of ethyl acetate/hexanes (10:90 to 100:0
over 60 minutes). The fractions containing the desired product were combined and evaporated to
give 10.78 g (70.0% yield) of 7 as a white solid. 1H NMR (300 MHz, DMSO) δ 1.53 (s, 9H), 4.46
(d, J = 5.94 Hz, 2H), 7.39 (dt, J = 1.78, 8.33 Hz, 2H), 7.89 (dt, J = 1.83, 8.33 Hz, 2H), 10.09 (t, J =
6.11 Hz, 1H). 13C NMR (75 MHz, DMSO) δ 27.75, 42.36, 80.63, 116.22, 127.40, 129.31, 130.45,
142.54, 156.56, 164.70.
Synthesis of tert-butyl 4-(aminomethyl)benzoate (8; “NBza”). 10.75 g (35.5 mmol) of 7 was
dissolved in methanol (45 mL), and 12.25 g (2.5 eq.) of potassium carbonate dissolved in water (45
mL) was added in one portion. The reaction was sealed and stirred overnight at room temperature.
After 18 hours of reaction time, methanol was evaporated from the reaction mixture and the
remaining aqueous solution was adjusted to pH > 10 with 4N NaOH. The aqueous layer was
extracted with DCM (3 x 200 mL), the combined organics washed with water (50 mL) and brine
(50 mL), and the organic layer dried over sodium sulfate. The organics were evaporated to give
7.10 g (96.7% yield) of 8 as a clear oil. 1H NMR (300 MHz, CDCl3) δ 7.91 (d, J = 8.30 Hz, 2H),
7.31 (d, J = 8.32 Hz, 2H), 3.86 (s, 2H), 1.69 (s, 1H), 1.55 (s, 9H). 13C NMR (75 MHz, CDCl3) δ
165.57, 147.58, 130.47, 129.60, 126.71, 80.76, 46.02, 28.12. HRMS (ESI): calculated mass
(C12H18NO2) [M+H]1+: 208.1338, mass found m/z: 208.1334 [M+H]1+.

Synthesis of 2-((tert-butyldimethylsilyl)oxy)ethan-1-amine (9; “NEal”). 6.11 g (100 mmol) of
ethanolamine and 13.62 g (2 equiv.) of imidazole were dissolved in DCM (100 mL) in a 500 mL
round bottom flask. 15.83 g (105 mmol) of tert-butyldimethylchlorosilane dissolved in DCM (50
mL) was added dropwise over the course of 20 minutes, and the reaction mixture was stirred for
one hour at room temperature. At that time, all of the starting material had been consumed as
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confirmed by TLC; 100 mL of water was added and the layers were separated. The aqueous layer
was extracted twice with DCM (2 x 100 mL), and the combined organics washed with water (50
mL), dried over sodium sulfate and evaporated to give 13.68 g (77.9% yield) of 9 as a clear oil. 1H
NMR (300 MHz, CDCl3) δ 3.57 (t, J = 5.36 Hz, 2H), 2.71 (t, J = 5.25 Hz, 2H), 2.08 (s, 2H, NH2),
0.84 (s, 9H), 0.00 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 65.13, 44.27, 25.96, 18.35, -5.27. HRMS
(ESI) calculated mass (C9H22NOSi) [M+H]1+: 188.1471, mass found m/z: 188.1495 [M+H]1+.

Synthesis of tert-butyl (4-aminobutyl)carbamate (10; “NLys”). 50.02 g (567.4 mmol) of 1,4diaminobutane was dissolved in chloroform (600 mL) and was cooled to 0°C. 13.17 g (6.03 mmol)
of di-tert-butyl dicarbonate dissolved in chloroform (300 mL) was added drop-wise over the course
of two hours and the reaction was stirred overnight, allowing it to reach room temperature. After
21 hours of reaction time, the entire reaction mixture was transferred to a separatory funnel and
was washed with water (8 x 200 mL), dried over sodium sulfate and evaporated in vacuo to give
10.71 g (94.3% yield) of 10 as a clear oil. 1H NMR (300 MHz, CDCl3) δ 4.84 (s, 1H), 3.04 (t, 2H),
2.64 (t, J = 6.7 Hz, 2H), 1.46 – 1.38 (m, 4H), 1.37 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 155.93,
78.82, 41.70, 40.30, 30.77, 28.32, 27.37. HRMS (ESI) calculated mass (C9H21N2O2) [M+H]1+:
189.1603, mass found m/z: 189.1601 [M+H]1+.

Scheme 2.4
Synthesis of NTrp
Synthesis of N-(2-(1H-indol-3-yl)ethyl)-2,2,2-trifluoroacetamide (11). 19.99 g (124.8 mmol) of
tryptamine was dissolved in DCM (300 mL) followed by the addition of 11.1 mL (1.1 equiv.) of
pyridine. This solution was cooled to 0°C and 19.4 mL (1.1 equiv.) of trifluoroacetic anhydride
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was added dropwise. After 22 hours of reaction time, all of the starting material had been consumed,
as evidenced by TLC; the reaction mixture was washed with 2N HCl (3 x 250 mL), water (100 mL)
and brine (100 mL), dried over sodium sulfate and evaporated to give a brown solid. This solid was
dissolved in a mixture of acetone and DCM and was absorbed onto silica gel. This was dry loaded
into an empty flash column, and the product was purified via normal phase flash chromatography
(EPCLC W-Prep 2XY, Yamazen Corp.) using an increasing solvent gradient of ethyl
acetate/hexanes (20:80 to 100:0 over 60 minutes). The fractions containing the desired product
were combined and evaporated to give 24.1 g (75.3% yield) of 11 as a white solid. 1H NMR (300
MHz, DMSO) δ 10.86 (s, 1H, NH), 9.55 (t, J = 5.56 Hz, 1H), 7.53 (d, J = 7.72 Hz, 1H), 7.34 (dd,
J = 1.05, 7.99 Hz, 1H), 7.16 (d, J = 2.35 Hz, 1H), 7.07 (td, J = 1.25, 7.55, 8.09 Hz, 1H), 6.98 (ddd,
J = 1.13, 7.10, 7.90 Hz, 1H), 3.45 (q, J = 6.82 Hz, 2H).

Synthesis of tert-butyl 3-(2-(2,2,2-trifluoroacetamido)ethyl)-1H-indole-1-carboxylate (12). 24.0 g
(93.7 mmol) of 11 was dissolved in THF (200 mL), followed by 30.76 g (1.5 equiv.) of di-tertbutyl dicarbonate with an additional 50 mL of THF to wash down the sides of the flask. 0.59 g
(0.052 equiv.) of DMAP was then added and the reaction was heated to 40°C for two hours. At that
time, TLC showed that all of the starting material had been consumed, so 250 mL of DCM was
added to the reaction and the organic solution was washed with water (2 x 100 mL), dried over
sodium sulfate and evaporated in vacuo to give a viscous brown oil. The product was purified via
normal phase flash chromatography (EPCLC W-Prep 2XY, Yamazen Corp.) using an increasing
gradient of ethyl acetate/hexanes (10:90 to 100:0 over 100 minutes). The fractions containing the
desired product were combined and evaporated in vacuo to give 17.27 g (51.7% yield) of 12 as a
white solid. 1H NMR (300 MHz, DMSO) δ 9.57 (t, J = 5.78 Hz, 1H), 8.05 (d, J = 8.20 Hz, 1H),
7.62 (d, J = 7.48 Hz, 1H), 7.50 (s, 1H), 7.33 (td, J = 1.39, 7.77, 8.28 Hz, 1H), 7.25 (td, J = 1.17,
7.44 Hz, 1H), 3.49 (q, J = 6.72 Hz, 2H), 2.91 (t, J = 6.98 Hz, 2H), 1.61 (s, 9H). 13C NMR (75 MHz,
DMSO) δ 156.51, 156.03, 149.02, 134.78, 130.13, 124.42, 123.18, 122.52, 119.07, 117.40, 114.74,
83.48, 39.07, 27.67, 23.53.
Synthesis of tert-butyl 3-(2-aminoethyl)-1H-indole-1-carboxylate (13; “NTrp”). 17.20 g (48.27
mmol) of 12 was dissolved in methanol (60 mL) followed by the addition of 16.75 g (2.511 equiv.)
of potassium carbonate dissolved in water (60 mL). The reaction flask was covered and the reaction
was allowed to stir overnight at room temperature. After 16 hours of reaction time, little progress
was seen with the reaction, so it was heated to reflux for seven hours. At that time, TLC showed
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that all starting material had been consumed. Methanol was evaporated in vacuo, and the remaining
aqueous solution was adjusted to pH >10 with 4N NaOH. The product was extracted with DCM (3
x 200 mL), and the combined organics were washed with water (100 mL) and brine (100 mL), dried
over sodium sulfate, filtered and evaporated in vacuo to give 7.05 g (56.1% yield) of 13 as a yellow
oil. 1H NMR (300 MHz, CDCl3) δ 7.60 – 7.46 (m, 1H), 7.46 – 7.36 (m, 1H), 7.34 – 7.17 (m, 3H),
3.54 (t, J = 7.74 Hz, 2H), 3.03 (t, J = 7.11 Hz, 2H), 1.66 (s, 9H), 1.64 (s, 2H, NH2). 13C NMR (75
MHz, CDCl3) δ 167.81, 135.55, 130.74, 124.17, 123.05, 122.72, 122.26, 118.98, 115.15, 83.27,
51.28, 28.17, 26.50. LRMS (ESI) calculated mass (C15H21N2O2) [M+H]1+: 261.1, mass found m/z:
261.1.

Synthesis of (4-(tert-butoxy)phenyl)methanamine (14; “NTyr”). 175 mL of 1 M (175 mmol; 2.6
eq.) lithium aluminum hydride in THF was added to a round bottom flask with a stir bar and was
cooled to 0°C. A solution of 11.83 g (67.5 mmol) of 4-(tert-butoxy)benzonitrile in 50 mL of
anhydrous THF was added to the stirring solution dropwise over the course of 30 minutes. The
reaction was then fitted with a reflux condenser and was heated to reflux for six hours, followed by
stirring overnight under argon, allowing the reaction to cool to room temperature. After 22 hours
of total reaction time, the reaction mixture was cooled to 0°C and was quenched with 7 mL of
water, followed by 6 mL of 15% NaOH (aq) and an additional 17 mL of water. The resulting
emulsion was filtered over celite, with the filter cake being washed with methanol (2 x 50 mL) and
DCM (2 x 50 mL). The filtrate was evaporated, and the resulting dark yellow oil was dissolved into
75 mL of water. The solution was transferred to a separatory funnel and was extracted with ethyl
acetate (4 x 150 mL). The combined extractions were washed with water (100 mL) and brine (100
mL), dried over sodium sulfate, and evaporated in vacuo to give a dark yellow oil. The oil was
separated using basic alumina chromatography and a solvent system of ethyl acetate/hexanes
(20:80 to 50:50). The fractions containing the product (as evidenced by TLC) were combined and
evaporated to give 5.71 g (47.2% yield) of 14 as a clear oil. 1H NMR (300 MHz, CDCl3) δ 7.19
(dd, J = 2.26, 6.46 Hz, 2H), 6.94 (dd, J = 2.32, 6.46 Hz, 2H), 4.38 (s, 2H), 1.31 (s, 9H). 13C NMR
(75 MHz, CDCl3) δ 153.80, 135.32, 128.26, 124.27, 78.17, 54.93, 28.75. LRMS (EI) calculated
mass (C11H17NO): 179.26, mass found m/z: 179.
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Synthesis of (S)-4-(4-(2-amino-3-hydroxypropyl)-2,6-diiodophenoxy)phenol (15; “T2AA”). 7.55
mL of 1 M (15.1 mmol) lithium borohydride in THF was added to a 50 mL round bottom flask
followed by 5.2 mL of anhydrous THF and 5 mL of anhydrous dioxane. The solution was cooled
to 0°C under argon, and 3.85 mL (30.3 mmol) of chlorotrimethylsilane was slowly added. The
resulting solution was stirred for 15 minutes at 0°C, and 0.90 g (1.71 mmol) of 3,5-diiodo-Lthyronine (Combi-Blocks) was added in one portion with the aid of an additional 5.2 mL of
anhydrous THF and 5 mL of anhydrous dioxane. The flask was sealed and the reaction was stirred
overnight under argon while being allowed to slowly warm to room temperature. After 18 hours of
reaction time, the reaction was poured into 25 mL of ice-water, adjusted to pH >9 with 4 N NaOH
and was extracted with ethyl acetate (3 x 50 mL). The combined organic extractions were dried
over sodium sulfate, filtered and evaporated to give a light brown solid. This solid was dissolved
in a mixture of ACN/H2O (75:25) and was purified on an Agilent ZORBAX SB-C18 reverse phase
semi-preparative column on a System Gold 166 (Beckman Coulter) HPLC system, using a gradient
of ACN (0.1% TFA)/H2O (0.1% TFA) 0:100 to 100:0 over 30 minutes with detection at 254 nm.
The fractions containing the purified product were combined, frozen and lyophilized to give 460
mg (52.5% yield) of 15 as a fluffy white solid. 1H NMR (300 MHz, DMSO) δ 9.12 (s, 1H), 7.84
(s, 5H), 6.68 (dt, J = 2.30, 3.84, 9.08 Hz, 2H), 6.54 (dt, J = 2.30, 3.61, 8.98 Hz, 2H), 5.39 (t, J =
4.49 Hz, 1H), 3.56 (dd, J = 4.86, 7.97 Hz, 1H), 3.40 (dq, J = 5.48, 9.94 Hz, 2H), 2.87 – 2.69 (m,
2H), 2.07 (s, 1H). 13C NMR (126 MHz, DMSO) δ 152.65, 152.26, 148.83, 140.67, 137.48, 115.86,
115.82, 92.48, 60.07, 53.27, 40.02, 39.85, 39.78, 39.69, 39.52, 39.35, 39.19, 39.02, 33.06. HRMS
(ESI) calculated mass (C15H16I2NO3) [M+H]1+: 511.9220, mass found m/z: 511.9678 [M+H]1+.

2.6

Results

Various applications for trimeric peptoids have already been developed [302,305,318–322,333].
Three key regions at the PIP Box binding site are important for the recognition and binding of PIP
Box-containing peptides/proteins [177]. It was predicted that tripeptoids would be sufficient in size
to block these key areas. Furthermore, they fall within the general mass range of other inhibitors of
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PPIs, and they are small enough to enhance the ease of synthesis while lowering the cost and time
to completion. The general approach taken in this project represents a situation in which resources
are limited in both materials and time, and should be applicable to other situations where rapid
reduction of the size of a library to be synthesized is desired. In this way, this approach provides a
unique pathway to fragment-based drug discovery as multiple fragments are “tied” together in the
peptoid backbone, and are thus simultaneously screened together.

2.6.1

Preferences for Fragments along the Peptoid Backbone

As outlined in section 2.5.1, computational screens were used to drive the synthetic approach for
peptoid library creation. From the results of the screens, as expected, slightly different results were
observed for each crystal structure of PCNA (Appendix A, Figure A.1), and different results were
seen for each substitution position along the peptoid backbone (Figure 2.5). The 1st (N-terminal)
position generally showed a relatively limited preference for a set of several peptoid side chains
including NLys, NArg, NTyr, NGln, NEba and NBal. Six fragments were present in the 1st position
in at least 7% of the top hit list, which itself consisted of 200 compounds that were compiled from
the top 50 hits for each of the four PCNA crystal structures that were screened. The two fragments

Figure 2.4. Tripeptoids Dock at the PCNA PIP Box Binding Site. The combinatorial tripeptoid
library was screened against four crystal structures of PCNA. The top hit of the screen against
structure 3VKX (PCNA bound to T3) is shown above. The hydrophobic site is displayed in orange,
and the PIP Box glutamine binding site is displayed in blue.
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Figure 2.5. Percentage that Amine Fragments in the Initial Library Appeared in the Tripeptoid
Backbone. The top 50 hits from docking with each of the four PCNA crystal structures were
selected and compiled into a total group of 200 compounds; the number of times a specific amine
fragment was present at a particular position along the peptoid backbone was tallied. The fragments
are represented above as the percentage of the number of times that fragment was present in that
position, among the full list of 200 compounds. “1st”, “2nd” and “3rd” positions are as defined in
Figure 2.2.
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that stood out most significantly were NLys and NArg, each of which were present in over 20% of
the top hit list. Similar to the 1st position, the 2nd position did not show strong preference for a
limited number of fragments—rather, ten different fragments were present in the 2nd position in at
least 5% of the top hit list, though NArg did stand out with it being present in 15% of the top hits.
In contrast to the first two positions, the 3rd position in the peptoid backbone showed significant
preference for particular side chains, notably aromatic groups that contained functionalities that
allow for hydrogen bonding with protein amino acids. NBal especially stood out as 43% of all of
the top hit compounds contained that fragment in the 3rd position.
Given that there were 21 possible substituents at each of the three backbone positions, there
would theoretically be 9,261 total possible tripeptoids. With limited resources, this number of
compounds may be impossible to synthesize, and may present a non-trivial cost. If a cutoff was set
to where only fragments that appeared in 5% or more of the top hits at a given position were
considered, for example, the total list of compounds would be narrowed to just 240 (6 in the 1st
position x 10 in the 2nd position x 4 in the 3rd position). In principle, an even shorter total list of
compounds could be produced if the percentage cutoff for significance is raised (e.g. considering
only the fragments that appear in 10% or more of the top hits at a given position), and that was the
general strategy pursued here where less than 100 ligands were actually synthesized.

2.6.2

Virtual Incorporation of Second Generation Tripeptoid Ligands

As previously discussed, the small molecules T3 and T2AA have been demonstrated to physically
bind in the hydrophobic pocket of the PIP Box binding site [178,231]. Both compounds contain a
primary amine, as well as a carboxylic acid, potentially allowing them to be incorporated into a
peptoid backbone using submonomer peptoid synthesis. In doing this, either could serve as an
anchoring residue, helping to direct small peptoid molecules to the PIP Box binding site on PCNA.
Due to the enhanced thyroid activity and low solubility of T3, T2AA was selected as a better
candidate for investigation. Using T2AA as a fragment, a virtual combinatorial library was created
and virtually screened using similar methodology as described in section 2.5.1, with a larger set of
37 primary amine fragments and two forms of T2AA, itself having defined attachment points at
either the primary amine (NT2AA) or carboxylic acid group (CT2AA). Due to the significant
conformational difference in the PIP Box binding site between the co-crystal structures of PCNAT3 and PCNA-peptides, only the structure of PCNA bound to T3 was used (PDB ID: 3VKX) since
the hydrophobic pocket on PCNA would be able to accommodate the potential binding of T2AA.
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Figure 2.6. Percentage that Fragments Including T2AA Appeared in the Tripeptoid Backbone. The
top 50 hits from docking were selected and the number of times a specific amine fragment was
present at a particular position along the peptoid backbone was tallied. The fragments are
represented above as the percentage of the number of times that fragment was present in that
position, among the full list of 200 compounds. “1st”, “2nd” and “3rd” positions are as defined in
Figure 2.2.
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From the results (Figure 2.6), the 1st and 2nd positions along the peptoid backbone showed
strong preference for a small set of possible side chains, with T2AA, containing the amine
attachment point in the first position, and ethyl alcohol being by far the most favored in the second
position. It must be noted that overall, tripeptoids containing T2AA as a side chain docked with
much more favorable scores than peptoids that did not contain T2AA; though, based on the crystal
structure used for docking (PDB ID: 3VKX), PCNA was conformationally biased towards ligands
that took the shape of T3. In contrast, the third position did not show much preference for particular
side chains. This was presumably because, according to the docked structures, fragments in the
third position tended to be quite flexible and picked up a variety of interactions in the region
proximal to the PIP Box glutamine binding site. As a result, none of the third position fragments
individually picked up substantial stabilizing interactions with PCNA. Since NT2AA was the most
frequent fragment at the first position, it was decided that the most technically straightforward
approach would be for all second generation peptoids to have T2AA in the first position. This
would substantially increase the ease of synthesis since T2AA could be attached at the N-terminal
end of a resin-bound synthetic peptoid without the need for chemical protecting groups.

Figure 2.7. Second Generation Peptoid Ligands Dock at the PCNA PIP Box Binding Site. The
combinatorial tripeptoid library containing T2AA as a fragment was screened against the crystal
structure of PCNA bound to T3 (PDB ID: 3VKX). The top hit from the screen is shown above with
the T2AA fragment binding in the hydrophobic pocket site on the surface of the protein.
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2.6.3

In Vitro Screening of Synthesized Tripeptoids

Fragments that appeared in approximately at least 5% of each position on the tripeptoid backbone
were selected for incorporation. Among the top hit side chains were multiple that were not
commercially available, including NArg, NBal, NBza, NEba, NEal, NGln, NLys and NTyr.
Fragments that required protecting groups are shown in Appendix A, Figure A.5. Synthesis of NEba
and NGln with acid-labile protecting groups proved to be unexpectedly technically difficult, and to
avoid significant costs associated with further attempts at re-synthesis, focus was placed on
synthesizing tripeptoids containing the other top hit fragments. The total list of synthesized peptoids
can be found in Table A.2 of Appendix A. Some ligands were also synthesized that were not
predicted to be good biochemical hits for purposes of comparison to compounds that were predicted
to be PCNA-PIP Box antagonists.
Upon synthesis and purification, peptoids were screened in a fluorescence polarization
assay to find ligands that disrupted the interaction between His-tagged PCNA and FAM-PL. In the
design of the FP assay, the conditions from Pedley et al. [177] were used as a starting point.
However, customized conditions were needed given that the dynamic range between bound and
unbound FAM-PL using 10 nM peptide and 100 nM PCNA was small, though a Z’-factor analysis
[334] indicated the variability was small enough to quantitatively determine differences between
bound and unbound peptide (Appendix A, Figure A.2). To find a balance of PCNA to FAM-PL
that would produce a substantial dynamic range, and to determine the peptide’s Kd value, increasing
amounts of recombinant PCNA was added to a fixed concentration of the FAM-PL peptide (5 nM)
in a two-fold dose-response fashion (Appendix A, Figure A.3). Statistical analysis by non-linear
regression indicated that the dissociation constant for the peptide was 107 nM, which is similar to
what has been previously reported [335]. Because more than 80% of the peptide was bound at a
PCNA concentration of 1 µM, that concentration of protein was selected for use in subsequent
displacement assays. Ultimately, the protein being in that level of excess should greatly enhance
the dynamic range of the assay, and would thus increase the robustness in determining which
compounds are actually hits in disrupting the binding between PCNA and the PL peptide. After
developing conditions under which synthesized peptoids would be screened, 69 of the initially
synthesized compounds were screened by FP at concentrations of 1 mM and 250 µM to find any
general hits (Figure 2.8). T2AA was selected as the positive control since it is known to disrupt the
interaction between FAM-PL and PCNA, and would be the basis for comparison against the ligands
in this study.
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Figure 2.8. Initial Tripeptoid FP Screen. Many of the synthesized tripeptoids were screened using
fluorescence polarization at initial concentrations of 1 mM and 250 µM for their ability to disrupt
the binding between PCNA and FAM-PL. 1 mM T2AA serves as the positive control, and DMSO
(at the same concentration ratio of DMSO:binding buffer as the screened ligands, but with no
compound) serves as the negative control for binding disruption. FAM-PL and PCNA were at 5
nM and 1 µM, respectively. Error bars represent standard error of the mean, and dotted lines around
the controls represent the 95% confidence interval (α=0.05) for each. Lower anisotropy values
indicate disrupted binding of PCNA-PL. The full list of peptoids screened in this assay, listed by
peptoid number, can be found in Appendix A, Table A.3.

From the initial screen, five ligands—NLys-NPip-NBal, NLys-NTyr-NBal, NBal-NLysNTyr, T2AA-NEal-NPip and T2AA-Gly-NPip—were identified that were able to disrupt the
binding between PCNA and FAM-PL at 250 µM with comparable activity to the positive control,
T2AA. Series of two-fold dilutions of each hit (Figure 2.9) were performed to generate dose
response curves. Following the screen of the initial set of compounds, additional peptoid-based
ligands were synthesized that contained variations on the structure of the hits to see if inhibitory
nature of these ligands could be improved. One new fragment, NMba (see Appendix A, Figure
A.4), was selected to try in place of NBal due to its similarity in size and shape, but with the ability
to donate an additional hydrogen bond. Dose response curves were generated for these new ligands
as well (Figure 2.9). IC50 values were determined for each peptoid hit by performing non-linear
regression fits of each dose response curve using equation 2.4. K i values were calculated

Figure 2.9. Dose Response Curves of Peptoid-Ligand Hits. Two-fold dilution series of each hit compound, in addition to T2AA, were performed
to generate dose response curves. 1 mM T2AA serves as the positive control, and DMSO (at the same concentration ratio of DMSO:binding
buffer as the screened ligands, but with no ligand) serves as the negative control. Error bars represent standard error of the mean.
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Table 2.4
Hit Compound IC50 and Ki Values Measured by Fluorescence Polarization

*
†

Compound Name

IC50 (µM) *

Ki (µM) *†

T2AA

1.34 ± 0.33

1.27 ± 0.29

Gly-NPip-NBal

7.74 ± 3.41

6.84 ± 2.20

NBal-NLys-NTyr

> 600

> 900

NLys-NPip-NBal

1.94 ± 0.51

1.78 ± 0.44

NLys-NPip-NMba

12.93 ± 1.97

12.16 ± 1.71

NLys-NTyr-NBal

~ 165

~ 200

NMba-NPip-NBal

11.69 ± 2.55

10.49 ± 1.93

T2AA-Asn

7.20 ± 2.74

7.23 ± 3.69

T2AA-Gln

3.52 ± 1.65

3.32 ± 1.37

T2AA-Gly

2.91 ± 0.91

2.70 ± 1.08

T2AA-Gly-NBal

5.66 ± 1.67

5.38 ± 1.98

T2AA-Gly-NPip

16.17 ± 3.71

15.10 ± 3.04

T2AA-NEal-Gly

1.17 ± 0.37

1.08 ± 0.39

T2AA-NEal-NMba

1.18 ± 0.24

0.833 ± 0.439

T2AA-NEal-NPip

1.82 ± 0.37

1.73 ± 0.38

T2AA-NEal-NTyr

0.482 ± 0.328

0.521 ± 0.209

T2AA-NPip-NLys

6.13 ± 2.84

6.53 ± 1.92

Values are represented as the 95% confidence interval around the mean
Calculated using equation 2.5

(Structures of T2AA-containing ligands can be found in Appendix A, Figure A.7)
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from the resultant IC50 values using equation 2.5 (Table 2.4). As a control experiment, individual
fragments that make up the top hits, including NGln, NLys, NPip, NTyr, NBal, NBza and NEal,
were screened in the FP assay to determine whether they were individually capable of disrupting
PCNA-PL peptide binding (Appendix A, Figure A.6). However, none of the fragments showed any
evidence of inhibition.

2.6.4

Identification of Molecular Recognition Features of PCNA for Peptoid Ligands

In an effort to understand better the molecular features that may be driving the affinity of the
peptoids for PCNA, molecular dynamics simulations (MDs) were performed with each of the top
five initial hits—NLys-NPip-NBal, NLys-NTyr-NBal, NBal-NLys-NTyr, T2AA-NEal-NPip and
T2AA-Gly-NPip—in complex with PCNA. As discussed in section 2.5.2, each ligand was first
docked into the co-crystal structure of PCNA and PL-peptide (PDB ID: 1VYJ; Appendix A, Figure
A.8), with the peptide removed, using the Glide induced-fit model in Maestro. This was done to
give approximate starting points for the MDs, as well as to ensure that there were no conflicts on
an atomic scale due to Van der Waals clashing or unfavorable ionic contacts. Each simulation was
run on a 5.0 ns scale, or until it converged, as judged by the change in protein Cα and side chain
RMSD over time (see Appendix A, Figures A.9-A.13). Upon completion, simulation trajectories
were first aligned to the first frame of their own simulation, and then the simulations were aligned
to one another based on the position of their Cα atoms using VMD. The final fifty frames for each
MD were averaged to give an average final structure for each PCNA-ligand complex (Figure 2.10).
Upon analysis, it was clear that each of the resulting complexes differed significantly from the cocrystal structure of PCNA-PL. It has been previously reported that PCNA is quite flexible and can
adopt a variety of conformations to optimize ligand binding [177]. The results here suggest that
this principle is conserved given the large differences in the PIP Box binding region on the protein
between each MD. Regions on PCNA that appeared to drive the conformational difference between
each structure most substantially were between residues 80-86, 93-97, 104-111, 117-136, 162-166,
172-177, 181-194 and 251-257 (Appendix A, Figure A.14). Perhaps unsurprisingly, each of these
regions was found in either a β-turn or unordered loop structure, owing to the natural flexibility of
these secondary structure protein moieties. The PIP Box binding site itself is surrounded by four
distinct flexible regions comprised of β-turn residues 40-46, the disordered interdomain connecting
loop residues 117-136, β-turn residues 229-235 and disordered loop residues 251-257. It would
make sense that some of the most significant drivers of PCNA conformational change would be

Figure 2.10. Average Structures of the Final 50 Frames of Molecular Dynamic Simulations. The final 50 simulation trajectory frames for each
analyzed peptoid ligand were averaged using VMD, and the resulting structures visualized using Pymol. The hydrophobic pocket (orange) and
PIP Box glutamine binding site (blue) are highlighted in each.
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found in these regions.. Of the protein residues that looked to be the most important for direct
interaction with each peptoid ligand, His44, Pro129, Pro234, Ala252, Pro253 and Ile255 each
interacted with each peptoid ligand to various significant degrees in each of the MDs (Appendix
A, Figure A.15). Almost all of the significant contacts were shared with T2AA and the PL peptide,
indicating that the inhibitors occupy many of the ‘anchoring’ contacts between PCNA and PL,
enhancing their antagonistic activity.

Figure 2.11. Principle Component Analysis of PCNA Topology Variance. The final 100 frames of
each PCNA-ligand MD trajectory were aligned based on the position of the PCNA Cα backbone
atoms. A principle component analysis of the aligned trajectories shows differential clustering of
PCNA conformations (residues 1-257) when in complex with either a peptoid-based ligand or a
PIP Box-containing peptide. Principle components 1-3 (PC1, PC2 and PC3) for each structure were
clustered and plotted along with the proportion of variance for each principle component.
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To further visualize the differences between each MD output structure, a principal
component analysis (PCA) of the trajectory snapshots for the Cα atoms of each PCNA-ligand
complex was performed (Figure 2.11). In addition to the outputs from the MDs performed here,
trajectories of PCNA bound to various known binding peptides, as used in the study by Pedley, et
al. 2014 [177], were included in the PCA for comparison. In this additional set were trajectories of
PCNA in complex with the DNA polymerase δ, PL, p85-α, p21, Apo, Akt or Abl peptide. In a
PCA, the principle components, which are themselves orthogonal eigenvectors, describe the axes
of maximal variance of the distribution of structures. The percentage of variance of the fluctuation
of protein atom position in each dimension is characterized by a corresponding eigenvalue. By
clustering structures in principle component space, one can focus on the relationships between
different structures in terms of their major structural displacements. In the context of this work,
clustering along principle components 1, 2 and 3 allows for the comparison of the significant
structural differences between each conformation of PCNA that covers more than 50% of their
conformational variance (Figure 2.11, bottom right panel).
From the results of the clustering analysis, as predicted, the PCA indicated distinct
differences in the topology of the PCNA-ligand interaction sites. Of all the structures, PCNA-T2AA
was the most different from the rest, likely due to the fact that the inhibitor is much smaller than
the peptoid-based compounds and does not project outside of the hydrophobic pocket. Although
the structures were mostly separated from one another, there were some similarities in the
eigenvectors. For example, though PCNA-PL and PCNA-NLys-NPip-NBal were well separated in
clustering space, they both had nearly equivalent second principle components. Likewise, the
population distribution of PCNA-PL and PCNA-T2AA had nearly equivalent first principle
components. This would indicate that these conformations are very similar in certain dimensions.
The potential implications for predicting inhibitory efficiency from this PCA are not yet clear, but
this information could be useful for understanding how a ligand interacts with PCNA and how it
could be grouped with other similar compounds.
Analysis of the molecular dynamic simulations indicates that the peptoid inhibitors are
active due to their ability to disrupt key interactions between PCNA and the PL peptide (Figure
2.12). While in the most general sense they provide a geometric hindrance to PIP Box binding, it
is also significant that these compounds prevent PCNA from forming important contacts with PIP
Box residues. Computational results from Pedley, et al. (2014) suggest that the conserved amino
acids of the PIP Box—glutamine in position 1, a hydrophobic residue in position 4 and aromatic
residues in positions 7 and 8—act as anchoring residues that drive conformational stability of the

Figure 2.12. Peptoid Inhibitors Disrupt Key PCNA-PIP Box Interactions. (top) The competitive peptoid inhibitors, such as NLys-NPip-NBal
(yellow sticks), are projected to bind at the PIP Box binding site on PCNA (gray surface; PDB ID: 1VYJ), which overlaps with the PL peptide
(green cartoon and sticks). (bottom left) NLys-NPip-NBal overlays key contact points of the PL peptide’s PIP Box. Spheres represent PIP Box
amino acid residues. Colors indicate direct disruption of key (red) or non-key (orange) residues, and non-disruption of key (yellow) or non-key
(white) residues. (bottom right) Results from Pedley, et al (2014) demonstrating that residues 1, 4, 7 and 8 of the PL peptide’s PIP Box act as
anchoring residues. ** Changes in surface accessible surface area (SASA) were calculated with ANCHOR, measuring the differences between
bound and unbound forms of the PL peptide.
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complex between PCNA and PIP Box containing peptides/proteins. Disrupting these points of
contact would substantially weaken their interaction, and would effectively abolish binding.

2.6.5

Analysis of the Diversity and Chemical Classification of Peptoid Inhibitors

The original goal of the design of the tripeptoid library was to incorporate a set of fragments that
was reasonably chemically diverse so as to cover a sufficient screening space. To measure the
degree of dissimilarity, a clustering analysis was performed using Canvas [336] in Maestro (Figure
2.13) with the molecules shown in Figure 2.3, with the exception of the two variants of T2AA.
Fragments were first minimized using the OPLS2005 force field, and similarity was determined
with 64-bit precision in a linear fashion based on ring size (if present), aromaticity, hydrogen bond
donor/acceptor, ionization potential, whether terminal (in reference to functional group placement),

Figure 2.13. Similarity Clustering Analysis of Peptoid Ligands. A similarity clustering analysis
was performed for primary amine peptoid fragments using Canvas in the Schrödinger software
suite. Fragments were sorted and compared based on chemical features such as aromaticity,
ionization potential and the ability to form hydrogen bonds. Similarity is represented by a color
gradient with dark red being most similar, and dark blue being least.
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whether halogen and bond order. The Tanimoto similarity metric was used with an average linkage
method to calculate clustering. The clustering analysis indicated that there was a reasonable
separation in the chemical space, with there only being two small groupings of relative similarity.
This was due to the fact that a number of fragments contained a single aromatic ring, and a grouping
of others were linear. While there was a larger degree of diversity that could have been achieved,
this set of peptoid starting materials looked to be sufficient as a proof of concept for this study.
As discussed, inhibitors of protein-protein interactions have characteristics that distinguish
themselves from other traditional inhibitors in that they display such features as higher molecular
weight, higher hydrophobicity and a larger number of aromatic rings [239,240]. iPPIs also
demonstrate higher degrees of globularity, lower distribution of hydrophilic regions, smaller
proportions of exposed hydrophilic regions and stronger capacities to bind hydrophobic patches at
the core of protein-protein interfaces as compared to inhibitors of classical targets such as enzymes
[210]. Though peptoid-like molecules have been demonstrated to disrupt PPIs (Table 2.3), it was
not clear whether the library of compounds generated for this study would be predicted to be
classified as iPPIs prima facie. All of the fragments shown in Figure 2.3, including both variants
of T2AA, but not NVal due to its accidental omission, were used to create a combinatorial set of
tripeptoids in Schrödinger as before to give 54,862 total ligands.
The peptoids were characterized by implementing a Bayesian classifier method based on
the original findings by Morelli, X. et al (2011) [240]. The Bayesian categorization model is a
simple probabilistic classification model that is based on Bayes' theorem:

𝑃(ℎ|𝑑) =

𝑃(𝑑|ℎ)𝑃(ℎ)
𝑃(𝑑)

(2.6)

where h is the hypothesis or model, d is the observed data, P(h) is the prior belief (probability of
hypothesis h before observing any data), P(d) is the data evidence (marginal probability of the
data), P(d|h) is the likelihood (probability of data d if hypothesis h is true) and P(h|d) is the
posterior probability (probability of hypothesis h being true given the observed data d).

Bayesian statistics not only considers the likelihood of a model, it also takes into consideration the
complexity of the model. As a result, it automatically picks the simplest model that can explain the
observed data, and thus prevents overfitting. In this implementation of the Bayesian modeling, the
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learned models are created with a learn-by-example paradigm: the sample data that is of interest
(good) is marked, and then the system learns to distinguish them from background data. No tuning
parameters are required beyond the selection of the input descriptors from which to learn. The
learning process generates a large set of Boolean features from the input descriptors. It then collects
the frequency of occurrence of each feature in the good subset and in all data samples. To apply
the model to a particular sample, the features of the sample are generated, and a weight is calculated
for each feature using a Laplacian-adjusted probability estimate. The weights are summed to
provide a probability estimate, which is a relative predictor of the likelihood of that sample being
from the good subset. Ultimately, Bayesian categorization was used because it can process large
amounts of data, learns fast, and is tolerant of random noise [337–339]. The Laplacian-corrected
estimator is used to adjust the uncorrected probability estimate of a feature to account for the
different sampling frequencies of different features. The derivation is given below:



Assume that N samples are available for training, of which, M are active. An estimate of
the baseline probability of a randomly chosen sample being active, P(Active), is M/N.



Next, assume that feature F is contained in B samples, and that A of those samples are
active. The uncorrected estimate of activity P(Active|F) is A/B. As B becomes small, this
estimator tends to be less reliable. For example, if A = 1 and B = 1, P(Active|F) would be
1 (active), which seems overconfident for a feature that has been seen once. Most likely,
the estimator is poor because the feature is not sampled adequately, and further sampling
of that feature would improve the estimate.



It is possible to estimate the effect of further sampling by assuming that the vast majority
of

features

have

no

relationship

with

activity.

That

is,

if,

for

most

features, Fi, P(Active|Fi) is expected to be equal to the baseline probability P(Active).


If feature K is sampled additional times, P(Active)*K of those new samples are expected to
be active. This provides the information needed to estimate the corrective effect
of K additional samples: Pcorr(Active|F) = (A + P(Active)*K)/(B + K).



For K = 1/P(Active), this is the Laplacian correction. This stabilizes the estimator: as the
number of samples, B, containing a feature approaches zero, the feature's probability
contribution converges to P(Active), which is the expected value for most features.



The final step is to make the estimator a relative estimate by dividing by P(Active):
Pfinal(Active|F) = Pcorr(Active|F)/P(Active)
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For most features, logPfinal ~ 0. For features more common in actives, logPfinal > 0. For
features less common in actives, logPfinal < 0. The completed estimate for a particular
sample is derived by adding together the logPfinal values for all the features present in that
sample.

To perform the Bayesian classification, the 2P2I Hunter data set [240,340,341], which is a
library of molecules that contains 40 known iPPIs and 1018 small molecules that are not inhibitors
of PPIs, was first obtained. All 1058 compounds in that set were converted from 2D to 3D and
minimized using the Accelrys Discovery Studio 4.1 Visualizer [342]. Next, four descriptors were
calculated for each compound—globularity, CW2, EDmin3 and IW4 (for viewing the data, see the
file “2P2I Hunter Active Decoys” on the attached DVD at the end of the thesis). These descriptors
measure the following factors in a respective manner: 1) three-dimensional shape globularity; 2)
ratio between the surface of the hydrophilic regions calculated at −0.5 kcal/mol and the total
molecular surface (it is proportional to the concentration of hydrophilic regions [involved in weak
potential polar interactions] compared to the total surface area); 3) third lowest local minimum of
the interaction energy (in kcal/mol) of a dry probe (it measures the potential interaction energy of
the ligand with a hydrophobic object); 4) unbalance between the center of mass of a molecule and
the barycenter of its hydrophilic (IW) interacting regions (a high integy moment is a clear
concentration of hydrophilic interacting regions at one extremity of the compound).
In calculating the Bayesian cutoff, each sample was left out one at a time, and a model built
using the results of the samples, with that model used to predict the left-out sample. Once all the
samples had predictions, a ROC plot was generated, and the area under the curve (ROC AUC)
calculated (Appendix A, Figure A.16). Best Split was determined by picking the split that
minimized the sum of the percent misclassified for category members and for category
nonmembers, using the cross-validated score for each sample. Using that split, a contingency table
was constructed, containing the number of true positives, false negatives, false positives and true
negatives. Based on the resulting calculated cutoff of -0.188, 38 out of the 40 iPPIs as well as 244
out of the 1018 non-iPPIs were predicted to be true iPPIs (file “Bayesian Result on Decoy Set” on
attached DVD). With a more than 80% success rate at identifying true positives and negatives, it
was determined that the model was satisfactorily accurate.
Next, this same model was applied to the library of tripeptoid ligands, and the same four
descriptors were calculated for each molecule—globularity, CW2, EDmin3 and IW4. When
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Table 2.5
Peptoid Descriptor Statistics from Bayesian Model
Statistic

Globularity

CW2

EDmin3

IW4

Mean

0.123096

2.19173

-2.62519

1.99723

Median

0.11273

2.204385

-2.59537

1.91726

Minimum

0.027005

1.58044

-4.37756

0.059068

Maximum

0.654219

2.76792

-1.89029

6.11639

Skew

1.691743

-0.33117

-0.6282

0.488549

Table 2.6
iPPI Descriptor Statistics from Bayesian Model
Statistic

Globularity

CW2

EDmin3

IW4

Mean

0.11331

1.953635

-2.84006

2.699039

Median

0.079983

1.92631

-2.81911

2.54485

Minimum

0.013987

1.54225

-3.30688

0.525021

Maximum

0.45662

2.37198

-2.4452

5.5549

Skew

1.613415

0.248895

-0.48162

0.282107

Table 2.7
Non-iPPI Descriptor Statistics from Bayesian Model
Statistic

Globularity

CW2

EDmin3

IW4

Mean

0.055457

2.082103

-2.48144

2.579951

Median

0.037349

2.05015

-2.45079

2.440295

Minimum

0

1.26745

-3.51407

0

Maximum

0.356383

3.04432

-1.70217

8.53636

Skew

1.820263

0.377792

-0.55035

0.525307
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considering the entire set of the tripeptoids, both those that are predicted to be iPPIs and those that
are not, the statistics for the distribution of descriptor scores (Table 2.5; see Appendix A, Figure
A.17 for population distributions for each descriptor) indicate that those molecules are much more
similar in globularity to other known iPPIs (Table 2.6) than non-iPPIs (Table 2.7). For CW2, the
tripeptoids had a higher score than either iPPIs or non-iPPIs, likely due to the fact that these
peptoids, on average, have more exposed hydrophilic regions than what would be expected for
classical drugs. The peptoids were not able to be strongly associated with either iPPIs or non-iPPIs

Figure 2.14. Ligand Classification Based On Principle Component Analysis of Descriptors. A
principle component analysis of the four descriptors, globularity, CW2, EDmin3 and IW4, was
performed on the combined set of iPPIs and non-iPPIs from the 2P2I Hunter collection and 100
randomly selected tripeptoids that were predicted to be iPPIs. Red spheres indicate known noniPPIs, green spheres indicate known iPPIs, and blue spheres indicate peptoids.
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based on the EDmin3 descriptor, though there was very little separation between all three
populations. As a result, EDmin3 was not determined to be a good distinguishing factor in this
analysis. As might be anticipated based on the necessary number of hydrogen bond donors and
acceptors in the tripeptoid backbone, the average score of the final descriptor, IW4, was
significantly lower than both iPPIs and non-iPPIs since hydrophilic regions are generally more
spread out over an entire ligand, rather than being concentrated at one end.
Though these tripeptoids as an entire set may not be predicted to be classified as iPPIs
based on all factors taken together, aside from simply globularity, many of the ligands in the set
did adhere to the characteristics that would define them as inhibitors of protein-protein interactions.
From the analysis, 20,697 of the 54,862 peptoids were predicted to be iPPIs (results shown in the
file “Bayesian Classifier on Tripeptoid Set” on the attached DVD). One hundred of the peptoids
predicted as iPPIs by the Bayesian classifier were randomly selected from the set of 20,697, and
were combined with all 1058 compounds in the 2P2I Hunter set (file “2P2I and 100 Predicted
Peptoid iPPIs_combined” on the attached DVD). A principle component analysis of the descriptors
was performed in order to visualize the similarity/dissimilarity between tripeptoids and known
iPPIs/non-iPPIs. As can be seen in Figure 2.14, the differences between the three populations are
not obvious at face value, and in fact the principle component analysis did not reveal a substantial
separation between each of the three populations. As a result, the descriptors—globularity, CW2,
EDmin3 and IW4—were determined to be the better gauge of assessing whether a queried molecule
can be considered an iPPI.

Table 2.8
Descriptor Statistics for Experimentally Identified Peptoid Inhibitors
Peptoid Inhibitor

Globularity

CW2

EDmin3

IW4

Bayesian
Value *

NLys-NPip-NBal

0.195329

2.31062

-3.01837

1.61068

0.207156

T2AA-NEal-NPip

0.130552

2.29504

-2.8844

3.57786

0.471927

* Calculated output of the Bayesian classification model; values above -0.188 are predicted to
be iPPIs

Two of the experimentally confirmed inhibitors of PCNA-PIP Box interactions, NLys-NPip-NBal
and T2AA-NEal-NPip, were selected and assessed using the Bayesian classification model (file
“Bayesian Classifier on Active Peptoids” on attached DVD) for the four main descriptors (Table
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2.8). From the results, both peptoid-based inhibitors were predicted to be iPPIs, which is promising
for their potential use in the development of next-generation lead compounds for disrupting PCNAprotein interactions.

2.7

Discussion

Fragment-based drug discovery (FBDD) is a popular method of hit discovery and/or lead
development in both academia and industry due to its distinct advantages over traditional higher
molecular weight chemical libraries [53]. Multiple fragments can be screened simultaneously
against a single protein target, which greatly increases the throughput of a screening assay. This
would be useful in situations where one would be searching for fragments that could enhance the
inhibitory effect of a single fragment that has already been identified for a given site. Findings
ligands that enhance the inhibition could provide clues as to what chemical features may be
combined to form a single, larger molecule that binds with high affinity. However, when little is
known about the target site of interest, including more than one fragment at a time in a screen can
be problematic since there is typically no information on the fragments’ connectivity to one another.
It would be necessary to obtain an NMR or crystal structure of them in complex with their target
in order to elucidate how the fragments might be interacting with the protein at the binding site, as
well as their spatial proximity/orientation to one another. This is not always easy or even feasible
to perform based on the nature of the protein itself and the actual affinity of each fragment.
Therefore, having a way to know the relative positions of each small ligand to one another ahead
of time would be advantageous since favorable chemical features could theoretically be
incorporated into a larger molecule much more quickly.
As an alternative to traditional FBDD methodology, this study demonstrated that multiple
individual fragments could be tied together in a single peptoid-based backbone and be screened
both in silico and in vitro to find inhibitors of PCNA-PIP Box interactions. Though much attention
in the field of drug discovery is being paid to developing new inhibitors of protein-protein
interactions, PCNA itself would not be considered an easy drug target, and most research efforts
would shy away from it. PCNA does not have a traditional small molecule binding site, nor does it
have any visible deep binding clefts that would make targeting that site with a ligand obvious. Even
when compared to other protein-protein interfaces, such as the contact surface between MDM2 and
p53, there is not a clear binding groove—instead there is a shallow, relatively small surface pocket
where only a couple amino acids bind from PIP Box-containing proteins. However, other studies
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[178,231], in addition to this one, have been able to identify small molecules that are able to bind
at that site with enough affinity to disrupt the binding between PCNA and a PIP Box-containing
peptide. The next step in developing high affinity ligands for PCNA would be to expand upon the
chemical information gained from the tripeptoids that showed up as hits in experimental screens,
to create next generation ligands that take advantage of the molecular contacts identified in the
molecular dynamic simulations. This is discussed further in Chapter 4, section 4.1.
In addition to identifying inhibitors of PCNA, the other major goal of this research was to
develop a platform where a combinatorial screening library composed of ligands containing
multiple fragments could be quickly narrowed using computational analysis, ultimately saving time
and money in subsequent physical synthesis and experimental screening. Previous studies have
utilized peptoid-based libraries for identifying inhibitors, including tripeptoids [302,305,318–
322,333]. However, in many of those cases there was information already available on potential
ligands to fit the respective site of interest, which naturally narrows the number of molecular
variants to be made, and in other cases entire expansive chemical libraries were synthesized and
screened against their target(s). While the latter method can be effective for finding good hits, it
can be quite time consuming and expensive to synthesize tens of thousands or more compounds.
The approach developed here has the potential to be applied to numerous protein targets
where an ideal ligand would need a higher degree of globularity and would have to cover a
relatively large surface area. Although this method offers some potential versatility in screening
against different proteins, there are some natural drawbacks to the ligands. Due to the nature of the
peptoid backbone, and the way in which these compounds are cleaved from resin, there are amine
and carbonyl groups that are necessarily present, which may result in unfavorable interactions with
the target binding site, depending on the orientation of the ligand. Additionally, and perhaps most
significantly, because the individual peptoid side chains are tied together into a single backbone,
their degrees of freedom are substantially restricted, and this can mean that an individual fragment
may not be able to orient itself in the proper way to fully optimize a binding interaction.
Furthermore, because the entire library here consisted of peptoid trimers, a particular ligand may
maintain favorable interactions between only two of its side chains and the protein; forcing the
presence of the third side chain may curtail the overall binding affinity of the total ligand if the
individual interaction between that third fragment and the protein is unfavorable. There potentially
are also situations where to disrupt a particular protein-protein interaction, three peptoid residues
would be insufficient—four or more may be needed. These are all common dilemmas that are faced
with FBDD and/or drug screening efforts in that one must always be concerned with the chemical
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content and diversity of the compounds in the screening library. In that regard, this approach is not
unusual, but it does place limits on how this method can be used. Promisingly, the classification
analysis of peptoids that were experimental hits predicted them to be iPPIs. It is possible that ligand
selection can be further narrowed in the future by applying an additional filter based on whether
each compound is predicted to be an iPPI, but it may not be necessary for a peptoid to be classified
as an iPPI for it to efficiently inhibit a protein-protein interaction.
It is not yet clear whether in the context of PCNA-protein complex formation, directly
targeting PCNA alone would be sufficient to result in an efficacious treatment option. There is
some evidence that PCNA is implicated in some way with every pathway of DNA damage repair
given that key proteins in each of those pathways have PIP Boxes. However, many mechanisms in
cells are redundant and are capable of compensating for the loss of a single pathway regulator. It
may be that targeting PCNA will have utility only when other synthetically lethal [343] drugs are
present that target compensatory proteins for the processes of DNA replication and damage repair.
Additionally, it is not yet understood how the flexibility of PCNA would influence the efficacy of
a single drug targeting the PIP Box binding site. In addition to the study by Pedley, et al. [177], the
MD simulations performed in this work demonstrate that PCNA can adopt very different
conformations, depending on the ligand that is bound to it. The question remains as to whether a
given ligand would better inhibit the interaction between one PCNA-protein complex or another.
Due to the diversity in the binding partners of PCNA, it is possible that there are multiple binding
sites on PCNA; this is supported by the discovery of two different conserved PCNA-binding
sequence motifs in addition to the PIP Box: the KA Box and APIM [215,344]. Each of these
different motifs has been implicated in the ultimate function of complexes and the regulation of a
particular biological response. It may be that a ligand binding to PCNA at one site produces an
allosteric effect that would affect PCNA-protein complexes at other sites. The functional
consequences of this are not clear, but it could mean that attempting to stabilize a specific
conformation of PCNA to achieve a singular response is much more complicated than anticipated.
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3. NUCLEAR TARGETING OF KNOWN CANCER THERAPEUTICS

More than 500 genes coding for protein kinases have already been identified in the human genome,
and over 150 of these have been shown to be involved in the onset and progression of many
cardiovascular, neurodegenerative and inflammatory diseases, as well as cancer [345,346]. As one
of four members of the HER receptor tyrosine kinase family [347], epidermal growth factor
receptor (EGFR) serves as one of the most studied receptor targets in the fields of oncology and
drug development. It exists on the cell surface and becomes activated by the binding of one of its
various specific ligands. The activation of EGFR leads to the initiation of growth-promoting
signaling cascades that result in cellular activities such as DNA synthesis and proliferation.
A number of studies have focused on the link between EGFR expression and
tumorigenesis. Evidence strongly suggests that dysregulated EGFR expression and signaling plays
a major role in the onset and progression of various human cancers including head and neck
squamous cell carcinoma, lung, breast, colon, anal, pancreatic, ovarian, bladder and oesophageal
[348–353], while levels of the protein can be used as a prognosticator of patient outcome in certain
cancers [354]. This knowledge has resulted in a significant effort over the last few decades to target
EGFR as a therapeutic strategy for cancer. The tyrosine kinase inhibitors (TKIs) that have emerged
from this body of work have seen some success in the treatment of disease, but a number of
significant problems have limited their range of use.
Ample evidence exists for the utility of TKIs in both experimental and clinical practice.
The majority of small molecule TKIs explored to date act as competitive antagonists at the ATP
binding site and use a substituted quinoxaline scaffold [355]. Targeted therapies intended to inhibit
kinases have suffered from a lack of long-term effectiveness in patients [356], and achieving high
levels of specificity with kinase inhibitors has been difficult [159,357–362]. While the implications
for non-specificity of these drugs is not yet completely understood, this can ultimately result in
complications including a plethora of negative side effects and cardiotoxicity [363]. At the same
time, clinical benefit is often limited to only a fraction of treated patients, with factors related to
the genome of individual tumors contributing significantly to the observed responses [364], and
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acquired resistance to these drugs is a common occurrence in patients undergoing cancer therapy
[48,49,365–370]. In fact, all patients with colorectal, pancreatic, metastatic lung or head and neck
cancers that initially benefit from therapies that target EGFR eventually develop resistance to those
treatments, with a median progression-free survival time of less than one year [49].
Various intracellular kinases have been seen to translocate to the nucleus of cells through
endocytosis [371–382]. While the reasons for this are still unclear, EGFR/ErbB1 translocation to
the nucleus has been shown to promote cellular proliferation [377], and the phosphorylation state
of nuclear-located c-Src is correlated with patient outcome in ER-positive breast cancer [374].
Their overall role in resistant or poorly responsive tumor phenotypes is not yet completely
understood, but it is possible that targeting the nuclear-localized forms of these kinases could have
a pronounced and/or alternative effect relative to their normally targeted state. In any case, these
issues demonstrate the need for developing new therapeutics to overcome many limitations
associated with TKIs.

3.1

Targeting Mechanisms of Developed Resistance to Drug Therapies

There is evidence that an increase in the activity of ATP-dependent efflux pumps can reduce the
intracellular concentration of drugs, and this is correlated with acquired resistance of various
therapeutics such as imatinib (Gleevec), gefitinib (Iressa), doxorubicin (Adriamycin), daunorubicin
(Cerubidine), vinblastine, vincristine (Oncovin) and paclitaxel (Taxol) [365,383,384].
Additionally, a reduction in drug importation can lead to drug resistance [365,385,386]. More than
100 different mutations have been described that affect more than 70 amino acids, resulting in
different molecular mechanisms of resistance acquisition [387]. The most common mechanism of
developed resistance to TKI therapy is the presence of point mutations within the kinase domain.
Some of these mutations result in significant conformational changes at the binding site, inhibiting
the binding of TKIs due to steric hindrance. Other mutations may cause ATP to preferentially bind
the receptor, resulting in it outcompeting the inhibitors. In either case, these mutations impair the
apparent affinity of TKIs to these kinases, rendering this type of treatment ultimately ineffective.
There are examples abound of these types of mutations in various types of cancers. Some
examples are LYN D189Y in ER+ metastatic breast cancer [388], BCR-ABL T315I in chronic
myeloid leukemia [389], and KIT T670I in gastrointestinal stromal tumors [390]. In the case of
EGFR-mutant lung cancer, about 70-80% of these tumors contain a somatic mutation in the kinase
domain that responds to gefitinib. It has been seen that the drug binds EGFR 20-fold more tightly,
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compared to the wild-type protein, when it contains the L858R mutation—this produces a
substantial initial patient response [391]. However, all of these patients develop resistance to
gefitinib after a median period of 10-16 months. The most commonly observed causative
mechanism is the T790M “gatekeeper” mutation, which is seen in approximately 60% of patients
that develop TKI resistance [392]. Yet, secondary kinase mutations are a common occurrence in
various other cancers that display oncogenic addiction, and targeting this single mutation in and of
itself may not prove to be effective in staving off further development of resistance.
In reality, resistance to TKI therapies likely occurs through multiple interacting pathways.
The explosion of knowledge surrounding gene networks has demonstrated that central nodes of
specific gene interaction clusters undergo significant amounts of cross-talk with other nodes. This
is especially true of intracellular signaling cascades which rely on phosphorylative transfer, for
example. Disrupting the activity of a single enzyme or protein may not have a significant impact
on cellular function/viability since there can be compensatory parallel networks that can make up
for that loss. This can be accomplished by activating shared downstream targets (demonstrating
biochemical redundancy) [393], or by having other cellular functions cover for the initial loss (e.g.
multiple mechanisms of DNA damage repair). As an example, in the case of PARP1, the protein
typically has an important functional role in repair of single-stranded DNA breaks (SSBs), but can
also function in non-homologous end joining of double stranded breaks (DSBs) when Ku proteins
are lost [394], and homologous repair through interaction with MRE11 and ATM [395,396]. In the
absence of PARP1, SSB repair is impaired and DSBs subsequently tend to accumulate, but PARP1/-

mice remain viable and fertile, likely due to the compensating effect of PARP2 [397]. Only when

BRCA1/2 function is impaired does the organism lose viability. The BRCA1/2 proteins are
important for homologous recombination DSB repair, and studies have demonstrated the
synthetically lethal relationship between PARP1 and BRCA1/2 [398]. Compensatory relationships
between genes have long been studied [399], and the strategy of targeting synthetically lethal
proteins has become an interesting approach to treating specific types of cancer [292,400–402].
However, while pursuing synthetic lethality as a therapeutic strategy shows promise, these
new drugs show variable clinical benefit in patient populations in both single-agent and
combination therapies, and often are associated with dose limited toxicities such as
myelosuppresion [398]. Furthermore, there still exist the problems of downstream effector targets
being activated by alternative mechanisms that become upregulated in response to an intracellular
drug-induced insult, as well as the promotion of protein isoform development, which itself can
render a particular drug ineffective. These are contributing factors as to why no anti-RAS
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therapeutic has been clinically approved, for example [403,404]. The field has recognized these
issues, and ongoing research aims to improve our understanding of targeting downstream effectors.
What actually defines a “downstream” target is very context dependent, and not all effectors may
serve as efficient drug targets themselves, but the role of these proteins in the development of
resistance to targeted therapies is being explored for proteins such as EGFR [405–409].
In addition to EGFR’s role as an initiator of phosphorylation signaling cascades, it
functions as a transcription factor and enhancer of cellular proliferation in the nucleus
[260,373,410–412], where it can directly phosphorylate targets such as proliferating cell nuclear
antigen (PCNA), enhancing cellular growth [260,276]. Levels of nuclear EGFR (nEGFR) are also
used as a prognostic factor in various cancers [413–415], and its subcellular nuclear distribution
has been associated with acquired resistance to cetuximab in non-small cell lung cancer [416], and
gefitinib in triple negative breast cancer and epithelial carcinoma [384,412,417]. The total
mechanistic role of nEGFR in the progression of disease and development of drug resistance is not
completely understood, but it has been proposed that nuclear translocation of the protein allows it
to bypass typical downstream effectors, acting directly on the eventual downstream signal
recipients [286,418]. This would have obvious implications for the development of resistance since
TKI therapies may depend on their targets being accessible at the cell surface, or in the cytoplasm,
and cells that upregulate the nuclear import of receptors may be removing these proteins from the
targetable pool.

3.1.1

Subcellular Targeting as a Therapeutic Strategy

Traditionally, the pharmaceutical industry has focused on optimizing general molecular parameters
such as molecular weight, logP, and capacity to participate in hydrogen bonding as a way to balance
target specificity and bioavailability [419]. Upon reaching the organ or tissue of interest, a drug
will bind to its target molecule, given that this target is located at the cell surface. However, if the
target is located in an intracellular compartment, the drug may not be able to efficiently reach its
target, impeding the activity of the drug itself. Practitioners have turned to addressing this issue by
designing more membrane-permeable variants, but these may also have their own set of problems
related to non-specificity if the drug is able to freely diffuse throughout the cell. To address these
crucial obstacles, various methods have been developed to subcellularly target drugs to specific
regions within the cell where the drug target of interest exists [420].
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A diverse number of drug types such as pepducins, antitumor drugs, antioxidants, Shiga
holotoxin and cholesterol drugs have been targeted to different subcellular compartments including
the cell membrane, early/late endosomes, endoplasmic reticulum, Golgi, cytosol, mitochondria and
nucleus [420]. There are multiple methods through which these have been achieved, ranging from
things such as myristoylation and palmitoylation, to the use of lipophilic cations, drugencapsulating nanoparticles and cell-penetrating peptides [420]. The nucleus itself is an interesting
target given that it contains many cancer-related proteins involved in processes such as DNA
replication and damage repair. Strategies for targeting molecules to the nucleus arose from
observations of the mechanisms of action of various DNA viruses; in fact, viruses themselves have
been used as delivery vehicles for gene therapy [421,422], but issues with lack of specificity,
toxicity and immune response have limited their range of use. Instead, alternative delivery methods
are being explored that lack pathogenic components, but make use of specific viral machinery such
as peptide-based sequences.

3.1.1.1 Peptides and Peptoids as Cellular Uptake or Nuclear Targeting Sequences

Nuclear localization sequences (NLSs), often consisting of, but not limited to, short peptides
derived from viruses such as Human Immunodeficiency Virus 1 or Simian vacuolating virus 40
[423–428], have been used to target various types of molecules to the nucleus of cells. These
peptides can be attached to other molecules that range in size from small, drug-like molecules
(MW<500) to mesoporous silica nanoparticles that act as high-payload drug delivery transporters;
this has been shown to increase the efficiency of drug delivery and improves the respective desired
effect [420,429–431]. These peptidic regions can also be more broadly characterized as “cell
penetrating peptides” (CPPs). CPPs tend to be either amphipathic or contain arginine-rich stretches
that enhance cellular uptake through proposed mechanisms of cytoskeletal remodeling and actinencapsulated vesicle endocytosis [432], or through clathrin and dynamin in the case of
polyarginine,[433] though this has been disputed [434]. Other various forms of molecules exist that
enhance cellular uptake such as β-peptides [435], homochiral cyclic peptides [436] and peptoids.
As discussed in Chapter 2, advantages that peptoids have over peptides are their generally
better inherent ability to penetrate cell membranes, higher resistance to proteolysis, resistance to
solvent, temperature and chemical denaturants, and generally cheaper cost to produce [296–299].
The two most commonly used kinds of peptoids for enhancing cellular uptake are amino- and
guanidinium-based, containing between five and nine residues [437–439]. Guanidinium-peptoids
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are often taken into cells at a higher rate than amino-peptoids, and amino-peptoids are typically
localized to the cytoplasm, whereas guanidinium-peptoids are trafficked to the nucleus [437]. Both
types are characterized by multiple positively charged residues, but the fact that they are sorted
differently indicates that their uptake kinetics and subcellular destination are dependent on the
chemical nature of the side chains themselves. Similar to these molecules, polyarginine, -lysine and
-histidine peptides have been used to enhance cellular uptake as well. Among these, polyarginine
shows a much higher efficiency for uptake than polylysine or –histidine [299,444]. Furthermore, it
has been observed that a D-amino acid variant of polyarginine is more effective than the L- form
at being taken into cells [299]. Ultimately, however, none of these peptidic polycationic molecules
are as effective at enhancing cellular uptake as polyguanidinium-based peptoids [299].

3.2

Rationale

The use of peptide and peptoid-based carriers has long been proposed to enhance the uptake and
subcellular targeting of a host of molecular agents [420]. Studies have also shown that peptides
tagged with NLSs are able to more effectively act on their target. The utility of this strategy has
been established for peptides, proteins, oligonucleotides and nanoparticles alike, and is currently
being further explored for use in disease therapeutics. Interestingly, this approach has also been
validated for the targeting of small drug-like molecules. Hodoniczky, J. et al. demonstrated that the
antiproliferative effect of the antiandrogen drug, bicalutamide, was greatly enhanced when the drug
was conjugated to a peptide consisting of the cell permeable penetratin and nuclear localizing SV40
sequences [429]. Albeit, not all drugs may be amenable to incorporation through attachment via
disulfide or thio-ether linkages, as with that compound, but it provides an important example of the
effect of this strategy.
Subcellular drug targeting could potentially have broad applications for various disease
types, particularly in cases where the target of interest resides in cellular compartments such as the
nucleus. Because upregulated nuclear distribution of EGFR is associated with resistance to cancer
therapies [48,49,384,412,416–418], it may serve as a prime subject for this approach [445]. A
recent study demonstrated that a peptide derived from PCNA, which was tagged with TAT and
binds to EGFR, was able to disrupt phosphorylation at PCNA residue Tyr 211, and subsequently
inhibited the growth of human breast cancers cells both in vitro and in vivo [286]. The implicated
reason for this is that nEGFR has been shown to bind to and directly phosphorylate PCNA to control
its stability on chromatin [260,261]. Targeting it to the nucleus with TAT enables it to compete
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with PCNA for binding to nEGFR, suppressing the phosphorylation of PCNA and resulting in a
loss of PCNA stability on chromatin—potentially restoring DNA damage mismatch repair
[276,446]. Used in a combination therapeutic regimen, this method of targeting nuclear proteins
that are implicated in vital cell survival functions may prove to be very effective in the treatment
of disease.
It is important to note, as was demonstrated by the bicalutamide [429] and peptoid-based
[438] studies, the presence of a cell penetrating sequence alone may be insufficient in enhancing
the specific localization of a compound into the cell, and may instead lead to a general cytosolic or
vesicular distribution. The addition of a NLS instead upregulates nuclear uptake and can
substantially improve a drug’s activity. However, the question of whether simply enhancing
cellular uptake or specifically targeting a molecule to the nucleus is more effective is very
mechanism dependent, and will completely depend on the therapeutic context. Regardless, being
able to direct the nuclear uptake of an inhibitor may prove to be a solution to acquired drug
resistance, given that it would bypass “downstream” effector proteins, and would avoid issues
associated with receptors being taken in to the nucleus [429]. In this study, a strategy was explored
to determine whether, through the incorporation of either a NLS, CPPo or both, gefitinib’s activity
or mechanism of action could be modulated in triple negative breast cancer cell models and murine
tumor cells that irregularly express EGFR. To our knowledge, this study reports for the first time
the targeting of a commercially available TKI to the nucleus of cells, and the subsequent enhanced
effects, demonstrating a useful strategy for the targeting of traditionally drug-resistant cancer types.

3.3

Experimental

3.3.1

Methodology

A series of peptoid-based conjugates were synthesized using the methodology outlined in Scheme
3.1. These molecules consist of either amino- (NLys) or guanidinium- (NArg) based polycationic
cell-penetrating peptoid (CPPo) sequences, with half of the total set also containing a peptide-based
SV40 nuclear localization sequence. With the exception of negative controls that contained no drug,
the conjugates were N-terminally tagged with either piperazinyl gefinitib (synthesis outlined in
Scheme 3.2) or 5-FAM. The CPPo, NLS and drug/dye were each separated by a 6-carbon spacer.
The CPPo sequences were synthesized using submonomer peptoid synthesis [300] due to the

Scheme 3.1
Synthesis of Peptide-Peptoid
Gefitinib Conjugates
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relatively low cost of reagents, and ease of synthesis. The NLS was synthesized, and piperazinyl
gefitinib/5-FAM coupled, using standard peptide coupling procedures.

3.3.2

Experimental Materials and Methods

All chemical reagents and solvents were purchased from Sigma Aldrich, Combi-Blocks Inc. or
Fisher Scientific, unless noted otherwise. Materials were repurified via recrystallization or
distillation as necessary before use. NMR experiments were performed on Bruker (Bruker Corp.,
Billerica, MA) ARX300 (300 MHz), ARX400 (400 MHz) or DRX500 (500 MHz) instruments. All
H chemical shifts (δ) are relative to residual protic solvent (CHCl3: δ 7.26, DMSO-d6: δ 2.50,

1

CD3OD: δ 3.31 ppm), and all 13C chemical shifts (δ) are relative to the solvent (CDCl 3: δ 77.23,
DMSO-d6: δ 39.52, CD3OD: δ 49.00 ppm). Low resolution electrospray ionization (ESI) and
atmospheric pressure chemical ionization (APCI) studies were carried out on an Agilent 6320 Ion
Trap (Agilent Labs, Santa Clara, CA) mass spectrometer. High resolution mass measurements were
obtained on a LTQ Orbitrap XL mass spectrometer (ThermoScientific Corp.) utilizing electrospray
ionization (ESI). Molecular masses and sequences of peptides or peptoids were validated on an
Applied Biosystems (Framingham, MA) MALDI-TOF/TOF 4800 mass analyzer, or Applied
Biosystems Voyager DE PRO mass spectrometer using either 2,5-dihydroxy benzoic acid or αcyano-4-hydroxy cinnamic acid matrices. TLC analyses were performed on Merck aluminumbacked F254 silica gel plates. Stock solutions of each non-dye-containing compound were made
by measuring the dry mass of each in pre-dried, pre-weighed screw-cap vials, and adding the
volume of DMSO necessary to give 10 mM solutions. For mass measurements, molecular weights
were calculated based on their TFA salt form. Stock solutions of compounds containing N-terminal
5-carboxyfluorescein were made by measuring the aborbance at 494 nm, using an extinction
coefficient of 79,000 L mol-1 cm-1 and Beer’s Law (A=εbc) to calculate concentration. Data
analyses and graphical representations were performed in Microsoft Excel, GraphPad Prism 6 or
OriginPro 2015. Characterization of synthesized materials is outlined in Appendix B, Table B.2.

General Method for the Synthesis of Conjugate Peptoid Segments. The peptoid portion of each
molecule was synthesized using an adapted procedure for submonomer [300] peptoid synthesis.
Briefly, 0.100 mmol of H-Rink Amide-ChemMatrix resin (PCAS Biomatrix Inc., Quebec, Canada;
loading: 0.51 mmol/g) was transferred to a 25 mL glass fritted peptide reaction vessel and was
swelled with DMF for 30 minutes. The resin was then deprotected using two 2.5 mL portions of
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20% piperidine in DMF with incubation times of 15 minutes for each addition at room temperature.
Following washing of the resin with DMF (6x) and DCM (3x), deprotection was confirmed by a
ninhydrin (Kaiser’s) test for primary amines. A solution of 1.5 mL of 1M bromoacetic acid (30
equiv.) in DMF and 230 µL (29.4 equiv.) of N,N’-diisopropylcarbodiimide (DIC) was added, and
the resin was placed on an orbital shaker for 1 hour at 37°C. At that time, the resin was washed
with DMF (6x) and DCM (3x), and a solution of 1M respective primary amine in DMF was added,
with incubation on an orbital shaker for 2 hours at 37°C. These steps were repeated with washing
steps in-between to produce the desired peptoid sequence. Following the addition of the final
primary amine, a six-carbon linker (aminohexanoic acid) was coupled to the N-terminus as a spacer
between the peptoid and peptide portions of each conjugate. Fmoc-6-aminohexanoic acid was
coupled using standard peptide coupling conditions (89 mg (2.5 equiv.) Fmoc-6-Ahx-OH, 103 mg
(2.49 equiv.) HCTU and 65 mg (5 equiv.) DIEA dissolved up to 2.5 mL with DMF), with incubation
on an orbital shaker at room temperature for 16 hours. The resin was Fmoc-deprotected using two
2.5 mL portions of 20% piperidine in DMF with incubation times of 15 minutes for each addition
at room temperature.

General Method for the Synthesis of Conjugate Peptide Segments. The peptide segment of each
hybrid was constructed using standard solid phase peptide synthesis conditions and Fmoc-protected
amino acids (Anaspec Inc.). Amino acids were coupled by incubating the resin with a solution of
2.1

mL

0.45M

HCTU

(O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate) in DMF (9.45 equiv.), 500 µL 4M N,N-diisopropylethylamine in NMP (20
equiv.), and 1 mmol (10 equiv.) of each respective amino acid on an orbital shaker for one hour
(incubation time for arginine was extended to two hours) at room temperature. Fmoc deprotection,
subsequent to each amino acid coupling, was performed using two portions of 20% piperidine in
DMF with incubations on an orbital shaker at room temperature, 20 minutes for each addition. For
difficult deprotections, in-between the two additions of piperidine was added 2.5 mL of 3% w/v
1,8-Diazabicyclo[5.4.0]undec-7-ene in 20% piperidine/DMF. This was heated to 45°C for three
minutes, and the resin was promptly washed with DMF (6x) and DCM (3x). Fmoc-amino acid
couplings and Fmoc-deprotection steps were alternated with washing steps (DMF (6x) and DCM
(3x)) in-between to produce the desired peptide sequence. Following the addition of the final amino
acid, and subsequent Fmoc-deprotection, a six-carbon linker (aminohexanoic acid) was coupled to
the N-terminus as a spacer between the peptide and piperazinyl gefitinib or 5-carboxyfluorescein.
Fmoc-6-aminohexanoic acid was coupled using standard peptide coupling conditions (89 mg (2.5
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equiv.) Fmoc-6-Ahx-OH, 103 mg (2.49 equiv.) HCTU and 65 mg (5 equiv.) DIEA dissolved up to
2.5 mL with DMF), with incubation on an orbital shaker at room temperature for 16 hours. The
resin was Fmoc-deprotected using two 2.5 mL portions of 20% piperidine in DMF with incubation
times of 15 minutes for each addition at room temperature. FAM-TAT was synthesized using
standard peptide synthesis conditions outlined in Chapter 2.

Coupling of Piperazinyl Gefitinib or 5-Carboxyfluorescein to Conjugates. Piperazinyl gefitinib and
5-carboxyfluorescein were coupled using standard solid phase peptide synthesis conditions. 63 mg
(0.125 mmol ; 1.25 equiv.) piperazinyl gefitinib and 51 mg (0.1249 mmol) of HCTU were dissolved
in 2.5 mL of DMF, followed by 32 mg (0.25 mmol; 2.5 equiv.) of DIEA. The resin was then
incubated with this solution on an orbital shaker overnight at room temperature. For the coupling
of 5-carboxyfluorescein, a solution of 75.3 mg of 5-FAM, 80.7 mg of HCTU and 46 mg of DIEA
in 2 mL of DMF was added, and the resin was then placed on an orbital shaker overnight, in the
dark, at room temperature. After the coupling of either compound, the resin was washed with DMF
(6x) and DCM (3x), dried under high vacuum (< 1 mm Hg) and stored at -20°C until cleavage.

General Method for the Cleavage and Purification of Drug Conjugates. Resin-bound compounds
were cleaved from resin using a solution of trifluoroacetic acid (TFA)/triisopropylsilane
(TIS)/water (95:2.5:2.5), incubating the resin at room temperature for 3 hours. They were then
precipitated into ice cold diethyl ether and collected by centrifugation at 4,000 x g for 10 minutes
at 4°C. The peptides were purified via HPLC (Beckman Coulter System Gold 166 or 168) using an
increasing gradient of acetonitrile (ACN)/water with 0.1% TFA (5:95) to (100:0) over 30 minutes
on an Agilent ZORBAX SB-C18 reverse phase semi-preparative column. Molecular masses and
sequences were validated via MALDI-TOF/TOF (Applied Biosystems 4700 Proteomics Analyzer
196). Purities were determined by HPLC using absorbencies at 219 or 280 nm.

Methods Performed by Others (See Acknowledgements for Exact Roles)

Probing Phosphorylation Status by Western Blot. Cells were seeded in a 24-well plate, and grown
overnight in complete media (DMEM + 10% FBS, penicillin/streptomycin, insulin). The next
morning, the media was removed and replaced with serum-free media with inhibitors (1 µM in
DMSO). The cells were incubated for 6 hours, and EGF (25 ng/mL) was added. The cells were
incubated for 30 minutes, then the media was removed and lysis buffer was added (RIPA + PPIs,
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NaVO4, NaF, beta-glycerophosphate). After lysis, the insoluble fraction was removed, and the
protein concentration was normalized via a bicinchoninic acid assay. The lysates were separated
by PAGE and transferred to a PVDF membrane. The membranes were incubated with primary
antibody (pERK, pEGFR, pSTAT3, beta-tubulin) overnight at 4°C, then incubated with HRPconjugated secondary antibody for one hour at room temperature. The membranes were stripped
and re-probed if necessary (total-STAT3).

Fluorescent Imaging of Peptoid Conjugates. NME cells were seeded on a 12-well plate, and grown
overnight in complete media (DMEM + 10% FBS, penicillin/streptomycin, insulin). FAM-NArg
or FAM-SV40-NArg were added at a 10 µM concentration in PBS, and the cells were incubated
with the compounds for one hour at room temperature. Cells were then washed with PBS, fixed
with 4% formaldehyde in PBS, washed again with PBS, and the nuclei stained with DAPI in PBS.
Cells were imaged using the Nikon A1R-MP confocal microscope in the Purdue Bioscience
Imaging Facility.

MTT Proliferation Assay. MDA-MB-231 and -468 cell proliferation was measured using the MTT
(3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation reagent. Cells
were grown in DMEM (phenol-red free) supplemented with 10% FBS, 1% penicillin/streptomycin
at 37°C with 5% CO2. They were then plated on flat bottom 96-well plates at a density of 1 x 104
cells per 100 µL per well. Cells were allowed to attach for 4 hours and were then treated with 5
concentrations of each compound for 72 hours. 10 µL of MTT (5 mg/mL in DMEM phenol-red
free media) was added to each well at a final concentration of (0.5 mg/mL) for 4 hours at 37°C.
After the period of incubation, 100 µL of solubilization solution (10% Triton-X 100, acidic
isopropanol (0.1N HCl)) was added and the plates were sealed and stored from light for 3 days.
Absorbance was read at 570 nm and the percent cell growth was normalized by comparison to a
day zero control plate with no drug for each respective cell line. The day zero plate standardized
0% and 100% cell viability, with columns plated in triplicates with either 100 µL of DMEM alone,
or 1 x 104 cells in 100 µL of DMEM. No inhibitors were added; instead, 10 µL of MTT reagent
was added to each well after cells were allowed to attach for 4 hours. At the end 4 hours, 100 µL
of solubilization solution was added to the plate, and was it sealed and stored in the dark for 3 days.

Three-Dimensional (3D) Organotypic Growth Assay. 96-well plates were coated with Cultrex (50
μL/well) and cells were resuspended in DMEM supplemented with 10% FBS and 4% Cultrex (150
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μL/well). Luciferase-expressing cells were seeded at a density of 1 × 103 cells/well. Media
containing the indicated inhibitors and/or EGF was replaced every 4 days and organoid outgrowth
was detected by the addition of D-luciferin potassium salt (Gold Biotechnology) to induce
bioluminescence, which was quantified using a GloMax-Multi detection system (Promega).

Murine Cell Lines. Normal mammary epithelial (NME) cells were constructed from NMuMG cells
as previously described to overexpress EGFR [447]. These cells were then treated with
transforming growth factor beta (TGF-β) to induce metastasis, and were grafted into a murine
mammary fat pad. TGF-β-treated NME tumor cells that underwent metastasis were subcultured
from the lungs of mice—these cells displayed significantly enhanced primary tumor formation,
postsurgical recurrence and spontaneous pulmonary metastasis upon secondary mammary fat pad
engraftment. These subcultured cells were termed NME lung metastatic (LM1) [448]. Both cell
lines were cultured in DMEM + 10% FBS, penicillin/streptomycin, and insulin.

3.3.3

Synthesis of Primary Amines and Piperazinyl Gefinitib

Synthesis of “NArg” and “NLys” were performed in the same way as described previously in
Chapter two (see compounds 1, 2 and 10).

Synthesis of 6-Hydroxy-7-methoxyquinazolin-4(3H)-one (15): 6.23 g (30.2 mmol) of 6,7dimethoxyquinazolin-4(3H)-one, 5.40 g (36.2 mmol) of L-methionine and 42.6 mL (21.7 equiv.)
of methanesulfonic acid were added to a round bottom flask with stirring. The solution was heated
to 115°C and was stirred for 6 hours. The reaction mixture was poured onto crushed ice, and the
pH was slowly adjusted upwards with 40% NaOH, until a pH of 7. The white precipitate that
formed was filtered off and was washed with water, cold MeOH and diethyl ether. The solid was
dried overnight under high vacuum (< 1 mm Hg) to produce 5.54 g (95.4% yield) of 15 as a white
solid, which was used in the next step without any further purification. 1H NMR (300 MHz, DMSO)
δ 11.94 (s, 1H), 9.80 (s, 1H), 7.91 (s, 1H), 7.36 (s, 1H), 7.09 (s, 1H), 3.90 (s, 3H).

Synthesis of 7-Methoxy-4-oxo-3,4-dihydroquinazolin-6-yl acetate (16): 4.50 g (23.4 mmol) of 15,
28 mL (12.7 equiv.) of acetic anhydride and 28 mg (0.01 equiv.) of DMAP were added to a round
bottom flask with stirring. Upon filling the flask with argon, 5.6 mL (2.97 equiv.) of anhydrous
pyridine was added to the reaction mixture. The reaction became very viscous to the point of not

Scheme 3.2
Synthesis of Piperazinyl
Gefinitib
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stirring, so another 10 mL of acetic anhydride was added to the flask. The reaction was heated to
100-110°C and was stirred for 4 hours, at which point it was then poured onto crushed ice and
stirred vigorously for 30 minutes. The resulting white solid was collected via filtration and washed
with water, cold MeOH and small amounts of diethyl ether. The solid was dried under high vacuum
(< 1 mm Hg) overnight to give 3.07 g (56% yield) of 16 as a white solid, which was used in the
next reaction without further purification. 1H NMR (300 MHz, DMSO) δ 12.21 (s, 1 H), 8.09 (s,
1H), 7.75 (s, 1H), 7.27 (s, 1H), 3.91 (s, 3H), 2.30 (s, 3H).

Synthesis of 4-Chloro-7-methoxyquinazolin-6-yl acetate (17): 3.80 g (16.2 mmol) of 16 and 8.6 mL
(49.4 mmol) of DIEA were combined in a round bottom flask with stirring, and 2.27 mL (24.4
mmol) of phosphoryl chloride was added slowly. The reaction was heated to 80°C and stirred for
3.5 hours, after which the solvent and excess reagent were removed by roto-vap. The resulting
brown residue was used directly in the next reaction without purification or further
characterization.

Synthesis of 4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl acetate (18): The
crude product 17 was immediately resuspended in isopropanol (32 mL), and 2.60 g (17.9 mmol) of
3-chloro-4-fluoroaniline was added with stirring under argon. The reaction flask was fitted with a
reflux condenser, and the reaction was heated to reflux for 6 hours under argon. The reaction
mixture was cooled to room temperature, and the precipitated product was filtered and washed with
water, MeOH and cold diethyl ether. The product was dried overnight at reduced pressure to afford
4.57 g (77.9% yield for both steps) of 18 as an off-white powder. 1H NMR (300 MHz, DMSO) δ
11.51 (s, br, 1H), 8.94 (s, 1H), 8.77 (s, 1H), 8.01-8.09 (m, 1H), 7.70-7.78 (m, 1H), 7.48-7.55 (m,
2H), 4.00 (s, 3 H), 2.38 (s, 3H).

Synthesis of 4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-ol (19). 4.57 g (12.6
mmol) of 18 was dispersed in a mixture of MeOH (300 mL) and H2O (300 mL) at room temperature
with stirring. 1.01 g (42.2 mmol) of LiOH was added and the reaction was stirred at room
temperature for 45 minutes. The reaction mixture was neutralized to a pH of 7 with the addition of
10% acetic acid, and the resulting precipitate was collected by filtration, washed with water, MeOH
and cold diethyl ether. The product was placed under high vacuum (< 1 mm Hg) to remove all
traces of solvent, giving 3.38 g (83.7% yield) of 19 as a white solid. 1H NMR (300 MHz, DMSO)
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δ 9.79 (s, 1H), 9.47 (s, 1H), 8.45 (s, 1H), 8.13-8.20 (m, 1H), 7.70-7.85 (m, 2H), 7.38 (t, J = 10.2
Hz, 1H), 7.19 (s, 1H), 3.96 (s, 3H).

Synthesis of Ethyl 2-(4-(3-chloropropyl)piperazin-1-yl)acetate (20). 3.44 g (21.9 mmol; 1.5 equiv.)
of 1-bromo-3-chloropropane was added to 2.51 g (14.6 mmol) of ethyl 2-(piperazin-1-yl)acetate in
acetonitrile (90 mL) at room temperature with stirring. 4.1 mL (2 equiv.) of triethylamine was
added dropwise, and the reaction mixture was stirred at room temperature for 48 hours. At that
time, TLC showed that all of the starting material had been consumed, so the solvent was
evaporated in vacuo and the crude material purified by normal phase flash chromatography
(EPCLC W-Prep 2XY, Yamazen Corp.) using DCM/MeOH as the eluents. The the fractions
containing isolated product were combined and evaporated to give 1.9 g (52.4% yield) of 20 as a
light yellow oil. 1H NMR (300 MHz, CDCl3) δ = 4.14 (q, 2 H, J = 7.2 Hz), 3.55 (t, 2 H, J = 6.6
Hz), 3.17 (s, 2 H), 2.40-2.69 (m, 10 H), 1.88-1.97 (m, 2 H), 1.23 (t, 3 H, J = 7.2 Hz); 13C NMR (75
MHz, CDCl3) δ = 170.35, 60.76, 59.56, 55.47, 53.01, 43.27, 29.83, 14.38.

Synthesis

of

Ethyl

2-(4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-

yl)oxy)propyl)piperazin-1-yl)acetate (21). To a solution of 1.22 g (3.8 mmol) of 19 in 30 mL of
DMF were added 1.89 g (2 equiv.) of 20, 1.06 g (2 equiv.) of K2CO3 and 1.72 g (3 equiv.) of sodium
iodide. The reaction mixture was warmed to 60°C and was stirred for 96 hours. The solution was
then transferred to a separatory funnel, and the product was extracted with DCM (4 x 100 mL). The
combined organic layers were washed with water (2 x 100 mL) and brine (100 mL), dried over
anhydrous Na2SO4 and then evaporated to dryness. The crude product was separated using normal
phase flash chromatography (EPCLC W-Prep 2XY, Yamazen Corp.) with DCM/MeOH as eluents.
The fractions containing the desired compound were combined and evaporated to give 1.30 g (64%
yield) of 21 as a white solid. mp > 206°C (decomposes). 1H NMR (300 MHz, CDCl3) δ = 8.74 (s,
1 H), 8.66 (s, 1 H), 7.89 (dd, 1 H, J = 6.3, 2.4 Hz), 7.55-7.60 (m, 1 H), 7.45 (s, 1 H), 7.16 (s, 1 H),
7.08 (t, J = 8.7 Hz, 1 H), 4.17 (q, 2 H, J = 6.9 Hz), 3.98 (t, 2 H, J = 6.6 Hz), 3.87 (s, 3 H), 3.18 (s,
2 H), 2.40-2.69 (m, 10 H), 1.93-2.00 (m, 2 H), 1.27 (t, 3 H, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3)
δ = 170.56, 156.70, 155.18, 154.63 (d, J = 247.83 Hz), 153.46, 148.92, 147.31, 135.71, 124.31,
121.97 (d, J = 6.2 Hz), 120.81 (d, J = 18.4 Hz), 116.48 (d, J = 21.7 Hz), 109.32, 107.38, 101.84,
67.64, 60.83, 59.30, 56.17, 54.77, 52.82, 52.72, 26.08, 14.31.

F NMR (282 MHz, CDCl3) δ -

19

94.94. HRMS (ESI) Calculated mass (C26H32ClFN5O4) [M+H]1+: 532.2127, mass found m/z:
532.2128 [M+H]1+. IR: ṽ = 3289, 2940, 2821, 1743, 1624, 1579, 1526, 1500, 1472, 1428, 1397,
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1354, 1337, 1216, 1172, 1141, 1069, 1032, 1011, 931, 858, 821, 794 cm-1. UV/Vis: λmax = 246, 331
nm.

Synthesis

of

2-(4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-

yl)oxy)propyl)piperazin-1-yl)acetic acid (22; “piperazinyl gefitinib”). 1.30 g (2.44 mmol) of 21
was dispersed in 200 mL of 0.2 M LiOH (i-PrOH/H2O (1.2/1)), and the reaction mixture was stirred
at room temperature in the dark. After 7.5 hours, the i-PrOH was evaporated in vacuo, and 10%
HOAc was added dropwise to adjust the pH of the water layer to 5. A pale-white solid precipitated
during that time, and the solid was filtered, washed with water, MeOH and diethyl ether. The solid
was dried overnight under high vacuum (< 1 mm Hg) to remove residual water to afford 1.13 g
(92% yield) of 22 as a white solid. mp > 201°C (decomposes). 1H NMR (300 MHz, DMSO) δ 9.61
(s, 1H), 8.50 (s, 1H), 8.12 (dd, J = 2.57, 6.84 Hz, 1H), 7.88 – 7.71 (m, 2H), 7.44 (t, J = 9.11 Hz,
1H), 7.20 (s, 1H), 4.17 (t, J = 6.12 Hz, 2H), 3.94 (s, 3H), 3.16 (s, 2H), 2.81 – 2.58 (m, 4H), 2.08 –
1.88 (m, 2H).

13

C NMR (75 MHz, DMSO) δ 169.90, 160.71, 156.04, 154.51, 152.63, 148.35,

146.99, 136.88, 123.51, 122.40, 118.89, 116.67, 116.38, 108.81, 107.30, 102.52, 67.11, 58.72,
55.89, 54.30, 51.90, 26.16. 19F NMR (282 MHz, CDCl3) δ -120.13. HRMS (ESI) Calculated mass
(C24H27ClFN5O4): 504.1814, mass found m/z: 504.1838 [M+H]1+. IR: ṽ = 3368, 2952, 2838, 1625,
1581, 1500, 1473, 1429, 1400, 1247, 1234, 1218, 1144, 1004, 855 cm-1. UV/Vis: λmax = 249, 331
nm.

3.4

Results

Peptoid monomers, NLys and NArg, were prepared from 1,4-diaminobutane and 1,3diaminopropane, respectively, as described in Chapter 2, section 2.4.2 Experimental Materials and
Methods. These peptoids were selected based on previous evidence that they enhance cellular
and/or nuclear uptake, and were superior to L- or D-peptide sequences. Previous work indicates
that the number of residues in polycationic peptoids affects their uptake, with longer sequences
being taken into cells more rapidly [438]. To confirm this visually, two poly-lysine peptoids were
synthesized that contained either seven or nine residues. These were each N-terminally tagged with
FAM, separated by an aminohexanoic acid linker. MBA-MB-231 triple negative breast cancer cells
were then exposed to the 7-mer, 9-mer, FAM-tagged TAT peptide (sequence: GRKKRRQRRRPQ)
or FAM alone for three hours, fixed with paraformaldehyde and analyzed by confocal microscopy
(Figure 3.1). From the results, there was little indication that FAM alone was able to enter cells.
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Both the TAT sequence and peptoid sequences demonstrated enhanced cellular uptake, and
increasing the peptoid length from seven to nine residues appeared to increase the amount of
fluorescent compound taken up, as anticipated. Interestingly, the TAT sequence did not display

Figure 3.1. Enhanced Uptake of 5-Carboxyfluorescein Using a NLS or CPPo. MDA-MB-231 cells
were incubated with 10 µM (a) 5-carboxyfluorescein (FAM), (b) FAM-labeled TAT peptide, (c)
FAM-labeled NLys7 peptoid or (d) FAM-labeled NLys9 peptoid for 3 hours. Cells were then fixed,
stained with Hoechst 33342 and fluorescently imaged using confocal microscopy at 407 nm and
488 nm. Images generated by Jennifer Sturgis, Purdue University College of Veterinary Medicine.

much evidence of enhancing the nuclear localization of the dye, and the nine-member NLys peptoid
showed an equal or better proclivity for inducing cellular entry when compared to TAT. This may
not be surprising, though, given that the efficiency of uptake of CPPs can differ between cell lines
[449]. Concordant with previous studies, NLys peptoid entry was characterized by a punctate
intracellular distribution, being present inside vesicles. Because the amino-based peptoids did not
show any evidence of nuclear uptake, it was decided to pursue the use of poly-arginine peptoids,

Gef-SV40-NLys

Gef-SV40-NArg

Gef-NArg

NArg9

Gef-NLys

NLys9

Figure 3.2. Cell Penetrating Peptoid Sequences and Peptide-Peptoid Drug Conjugates Used in This Study. (a) Each peptoid-based compound
consists of a 9-member amino- (NLys) or guanidinium- (NArg) based polycationic sequence. (b) For compounds containing a conjugated drug,
piperazinyl gefitinib was coupled to either to a peptide-peptoid hybrid consisting of SV40 (NLS) and NLys9 or NArg9, or simply an NLys9 or
NArg9 peptoid sequence.

b)

a)
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Figure 3.3. NArg-Peptoid Conjugates Enhance Nuclear Uptake. Normal Mammary Epithelial
(NME) cells were incubated with either 10 µM FAM-NArg or FAM-SV40-NArg for one hour,
fixed and stained with DAPI. The cells were then imaged by confocal microscopy. (a) FAM-NArg
at 20X magnification (bars = 200 µm); (b) FAM-SV40-NArg at 20X magnification (bars = 200
µm); (c) FAM-SV40-NArg at 40X magnification (bars = 100 µm). Images generated by Wells
Brown, Purdue University College of Pharmacy.

given that they should theoretically increase the nuclear distribution of a tagged molecule [437].
Based on the observations of peptoid length-dependence on the efficiency of cellular entry,
guanidinium-based compounds were also synthesized with a length of nine residues (Figure 3.2a).
With the goal of further enhancing nuclear uptake, peptoids were also synthesized
containing the NLS from the simian virus 40 large T antigen (sequence: PKKKRKV). This
sequence, which is naturally found on the surface of certain proteins, promotes nuclear transport
through its recognition by importins, taking it through the nuclear pore complex [450]. The SV40
sequence was selected due to its relative ease of synthesis when compared to TAT. Following the
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submonomer synthesis [300] of each respective CPPo on Rink-amide resin, the NLS was assembled
using basic Fmoc-based peptide synthesis conditions. The NLS and CPPo were separated by a sixcarbon linker; an additional six-carbon spacer was placed on the N-terminus of the NLS, to which
either piperazinyl gefitinib (Pip Gef) or FAM would be attached (Figure 3.2b). To examine the
cellular distribution of the FAM-conjugated NArg9-containing molecules, normal mammary
epithelial (NME) cells, which were engineered to express elevated levels of EGFR, were exposed
to either FAM-NArg or FAM-SV40-NArg (Figure 3.3). Both FAM-NArg and FAM-SV40-NArg
were efficiently taken into the epithelial cells. From the results of imaging, FAM-NArg was
distributed inside the cytoplasm (Figure 3.3a), but the addition of the SV40 sequence seemed to
enhance the nuclear, and overall, uptake of these compounds, as expected (Figures 3.3b & c).
3.4.1

NLys-Based Conjugates Enhance the Anti-Proliferative Effect of Gefitinib in
Resistant Cells

Although Pip Gef is nearly identical to commercial gefitinib, with the exception of a piperazinyl
acetate moiety in place of the morpholino group, minor changes to its structure could have
substantial consequences for its affinity for EGFR, or could cause other issues due to changes in its
cellular uptake or solubility. To assess the two compounds for any difference in activity,
commercial gefitinib and Pip Gef were compared in 3D cell cultures of NME and LM1 cells (Figure
3.4). In both cells lines, gefitinib efficiently downregulated cell growth. In NME cells, PIP Gef did
not show as much of an antiproliferative effect, though at 10 µM the effect was similar to that of
gefitinib. In LM1 cells, however, the difference between gefitinib and Pip Gef was substantial, with
Pip Gef having comparable activity to the DMSO control. Because of the reduced potency of Pip
Gef, the next step was to assess whether incorporating the drug into a peptide-peptoid conjugate
could improve the observed activity. Due to the relative ease of synthesis and reduced cost of NLysbased peptoids as opposed to NArg, Gef-NLys and Gef-SV40-NLys were assessed for their ability
to negatively impact the growth of the tumor-based cell lines MDA-MB-231 and MDA-MB-468.
Both the 231 and 468 cell lines are derived from mammary gland/breast tissue that has
metastasized, and are classified as models for triple negative breast cancer (do not express estrogen
receptor, progesterone receptor or Her2/neu). Each line overexpresses EGFR [451,452], and
although 231 and 468 cells are relatively insensitive to gefitinib monotherapy when compared to
other breast cancer lines, MDA-MB-231 is especially resistant to the drug, displaying two-fold or
lower sensitivity than other triple negative cell types [453]. Furthermore, they show enhanced
resistance to other anti-tumor drugs including erlotinib, cetuximab, carboplatin, doxorubicin and
docetaxel. As anticipated, gefitinib had little effect on the growth of MDA-MB-231 cells, while

Figure 3.4. Activity of Commercial Gefitinib and Pip Gef in 3D Cell Cultures of NME and LM1. Luciferase-expressing cells were seeded on
96-well plates coated in Cultrex. Media containing gefitinib or Pip Gef, and/or EGF, was replaced every 4 days and organoid outgrowth was
detected by the addition of D-luciferin potassium salt to induce bioluminescence, which was quantified as percent relative growth. Data was
generated by Wells Brown, Purdue University College of Pharmacy.
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Figure 3.5. NLys-Based Drug Conjugates Negatively Impact Growth of Gefitinib-Resistant Cell Lines. MDA-MB-231 and -468 cell
proliferation was assessed using the MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation reagent. Cells were
plated on 96-well plates and were allowed to attach for 4 hours, followed by treatment with 5 concentrations of each compound and subsequent
incubation at 37°C for 72 hours. 10 µL of MTT (5 mg/mL in DMEM phenol-red free media) was added to each well at a final concentration of
(0.5 mg/mL) for 4 hours at 37°C. After the period of incubation, 100 µL of solubilization solution (10% Triton-X 100, acidic isopropanol (0.1N
HCL)) was added and the plates were sealed and stored from light for 3 days. Absorbance was read at 570 nm and the percent cell growth was
normalized by comparison to a control plate with no drug for each respective cell line. Data was generated by Ray Fatig, Purdue University
College of Pharmacy.
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PIP Gef had no measurable activity after three days, even at concentrations up to 50 µM (Figure
3.5). However, when PIP Gef was coupled to either NLys or SV40-NLys, a significant decrease in
cell growth was observed. At the same time, NLys and SV40-NLys peptoid sequences with no drug
conjugate (Ahx-NLys and Ahx-SV40-NLys, respectively) did not show any antiproliferative
activity (data not shown). In MDA-MB-468 cells, Gef-NLys and Gef-SV40-NLys also negatively
impacted growth—Gef-NLys had comparable activity to Pip Gef, though all of the test compounds
were inferior to gefitinib, with the apparent exception of Gef-SV40-NLys at a concentration of 50
µM. Given that NLys-based compounds do not appear to get taken into the nucleus (Figure 3.3),
the ability of the peptoids to improve the potency of gefitinib in resistant cells may be due to
enhanced cellular uptake, though it is not yet mechanistically clear why some cell lines would be
more sensitive to this effect than others.

3.4.2

Drug-Peptoid Conjugates Alter the Phosphorylation Status of STAT3

Because the peptoid conjugates demonstrated that they are taken into cells, and that they produce
a phenotypic growth effect, the next step was to examine the effect of gefitinib-tagged conjugates
on EGFR as well as downstream intracellular proteins. The phosphorylation statuses of EGFR,
extracellular-signal-regulated kinases 1/2 (ERK1/2) and signal transducer and activator of
transcription 3 (STAT3) were probed to observe the effect of the conjugates on signaling pathways
known to be activated in part by EGFR. ERK proteins exist within the family of classical MAP
kinases, and are involved in various intracellular signaling processes that regulate mitosis, meiosis
and postmitotic events in cells. They are activated by a plethora of upstream stimuli, including
growth factors, ligands for heterotrimeric GPCRs, cytokines, mitogens and carcinogens [454]. ERK
is naturally located in the cytoplasm, where it can translocate to the nucleus upon phosphorylative
activation. STAT3, on the other hand, which is a transcription factor that is activated in response
to various cytokines and growth factors, is able to translocate into and out of the nucleus
independently of phosphorylation, and maintains a prominent nuclear presence [455,456].
Furthermore, evidence exists that STAT3 physically interacts with nuclear EGFR, leading to the
activation of its transcriptional control [457,458].
To observe the effect of the conjugates on EGFR, ERK1/2 and STAT3, two murine tumor
cells lines, termed NME and LM1, were exposed to either gefitinib or erlotinib (Tarceva), or one
of the test compounds. As previously discussed, NME cells overexpress EGFR in the whole cell;
in LM1 cells, however, the level of EGFR is near normal, but the protein is disproportionally

Figure 3.6. Effect of Nuclear-Targeted Conjugates on Phosphorylation Status of EGFR, ERK1/2 and STAT3. NME (top) and LM1 (bottom)
cells were incubated with erlotinib, gefitinib or the NLys- and NArg-based drug conjugates at concentrations of 1 µM in the presence or absence
of EGF (25 ng/mL). Cells were lysed and probed for p-EGFR, p-STAT3 (residue Y705), p-ERK1/2, total STAT3 (t-STAT3) and/or β-tubulin.
Data generated by Wells Brown, Purdue University College of Pharmacy.
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Figure 3.7. Analysis of the Phosphorylation Status of ERK1/2 and STAT3 in MDA-MB-468 Cells. As performed previously with the NME and
LM1 lines, cells were incubated with erlotinib, gefitinib or the NLys- and NArg-based drug conjugates at concentrations of 1 µM in the presence
or absence of EGF (25 ng/mL). Cells were lysed and probed for p-STAT3 (Y705), total STAT3 (t-STAT3), p-ERK1/2 and total ERK1/2 (tERK1/2). Data generated by Wells Brown, Purdue University College of Pharmacy.
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located in the nucleus, as opposed to the rest of the cell (see Appendix B, Figure B.1). In the NME
line, cell lysates were probed for the phosphorylation status of EGFR (p-EGFR), STAT3 (pSTAT3) and ERK1/2 (p-ERK1/2), with the total level of STAT3 (t-STAT3) used as both a loading
and internal control (Figure 3.6 (top)). Erlotinib and gefitinib, both clinically established inhibitors
of EGFR, abrogated the phosphorylation of EGFR and STAT3; both antagonists had a negative
effect on ERK1/2 phosphorylation, with gefitinib nearly completely abolishing it. Pip Gef had
relatively little effect on the phosphorylation of EGFR, and no noticeable effect on STAT3 or
ERK1/2. It was also observed that attaching the SV40 nuclear targeting sequence to Pip Gef seemed
to hurt the activity of the drug. Interestingly, the NLys- and NArg-based drug conjugates had a
more profound effect on STAT3 phosphorylation than on EGFR, and each of the conjugates did
not have a measurable effect on ERK1/2. Of the compounds, Gef-SV40-NArg had the overall most
significant impact. LM1 cell lysates were also probed for p-STAT3 and p-ERK1/2 (Figure 3.6
(bottom)), and as with the other cell line, NLys- and NArg-based drug conjugates disrupted
phosphorylation of STAT3, but had little effect on ERK1/2.
Because murine cells lines showed a differential effect of the compounds on STAT3 and
ERK1/2, the human cell line MDA-MB-468, derived from a mammary gland adenocarcinoma, was
investigated (Figure 3.7). As was seen with the NME and LM1 lines, the NLys- and NArg-based
compounds decreased the levels of p-STAT3, but did not affect p-ERK1/2. Moreover, Gef-SV40NArg was again the most potent compound. To assess the distribution of phosphorylated STAT3
in the cell, MDA-MB-468 cells were cultured in the presence of EGF or bovine serum albumin
(BSA), and were imaged using immunofluorescence (Figure 3.8). t-STAT3 showed distribution
throughout the entire cell, both inside and outside the nucleus. When the cells were treated with
DMSO, p-STAT3 appeared to be restricted to the nucleus; but on exposure to Gef-SV40-NArg, the
cells showed little to no trace of STAT3 phosphorylation. Overall, it was not clear from the results
of the previous assays why Gef-SV40-NLys had little to no effect on EGFR, STAT3 and ERK1/2.
A potential explanation could be the aggregation or formation of unanticipated secondary/tertiary
structures in solution, but this issue was not pursued any further.

3.4.3

NArg-Based Compounds Disrupt STAT3 Phosphorylation in a Dose-Dependent
Manner

Based on the results from the Western blots, Gef-NArg and Gef-SV40-NArg were the most
effective compounds at disrupting STAT3 phosphorylation. Given that commercial gefitinib
effectively downregulated p-STAT3 as well as p-ERK1/2, it was investigated whether the NArg-
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Figure 3.8. Gef-SV40-NArg Disrupts Nuclear Accumulation of Phosphorylated STAT3. MDAMB-468 cells were seeded onto glass coverslips and cultured overnight in the presence of DMSO
or Gef-SV40-NArg (1 µM), and BSA or EGF. The coverslips were washed with PBS, the cells
fixed with PBS plus 4% formaldehyde for 20 minutes at room temperature, and then the cells
permeabilized with PBS plus 0.1% Triton X-100 for 20 minutes at room temperature. The cells
were washed with PBS, followed by PBS plus 2% BSA, and were incubated overnight at 4°C with
primary antibody (anti-STAT3 or –p-STAT3) in PBS plus 2% BSA. After incubation, the cells
were washed and again incubated for one hour at room temperature with secondary antibody
(donkey anti-mouse Alexa Fluor® 488) in PBS plus 2% BSA. The cells were washed with PBS plus
2% BSA, PBS alone, followed by incubation with DAPI in PBS for 5 minutes at room temp. The
cells were washed in PBS three more times, then mounted to a glass slide using Prolong Gold antifade reagent. Images were acquired using a Nikon A1R-MP confocal microscope. Images
generated by Wells Brown, Purdue University College of Pharmacy.

Figure 3.9. Dose Response of Gef-SV40-NArg against STAT3 and ERK1/2 in NME and LM1 Cells. NME and LM1 cells were exposed to
increasing concentrations of Gef-SV40-NArg in the presence of EGF (25 ng/mL). (a) Cell lysates were probed for p-STAT3 (Y705), t-STAT3,
p-ERK1/2 and t-ERK1/2. (b) Densitometry analysis was performed for each Western blot using the Biorad Chemidoc touch imaging system to
determine relative levels of p-STAT3 in each cell line at given concentrations of the drug conjugate. Data generated by Wells Brown, Purdue
University College of Pharmacy.
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based drug conjugates would effect ERK1/2 phosphorylation when the concentration of each
compound was increased. NME and LM1 cells were exposed to two-fold increasing concentrations
of Gef-SV40-NArg up to 10 µM (Figure 3.9a). In each line, the level of p-STAT3 decreased in a
dose-dependent manner, while p-ERK1/2 was not affected. The results also indicated that in LM1
cells, which have upregulated levels of nuclear EGFR, p-STAT3 was more sensitive to modulation
upon exposure to the drug conjugate than in NME cells. A densitometry analysis of the amount of
p-STAT3, normalized to the amount of total STAT3 in each cell line, further demonstrated the
higher sensitivity of LM1 cells to Gef-SV40-NArg (Figure 3.9b).
In the previous set of experiments, at 1 µM gefitinib eliminated the phosphorylation of
STAT3 and ERK1/2. However, it was unknown whether p-STAT3 would be fully abrogated before
p-ERK1/2 levels were affected at lower concentrations. To investigate this possibility, MDA-MB468 cells were exposed to Gef-NArg, Gef-SV40-NArg or gefitinib in a two-fold series of
concentrations up to 1 µM for gefitinib, or 5 µM for each peptoid conjugate (Figure 3.10). From
the results, it was seen that gefitinib nearly eliminated p-STAT3 at a concentration of approximately
125 nM, and increasing gefitinib four-fold to 0.5 µM abrogated p-ERK1/2. Gef-NArg and GefSV40-NArg both disrupted p-STAT3, with the latter abolishing the protein’s phosphorylation at
between 150 and 300 nM. However, even when the concentration of Gef-SV40-NArg was
increased more than ten-fold to 5 µM, there was no evidence of p-ERK1/2 being affected. This
could suggest that gefitinib and the peptoid-drug conjugates are acting through different
mechanisms. If the difference in STAT3 phosphorylation between gefitinib and Gef-SV40-NArg
was simply due to the differential affinity of the two compounds for EGFR, it would be expected
that as the concentration of the NArg-based ligand continued to be increased, levels of p-ERK1/2
would eventually begin to decrease. In effect, a dose response curve of the peptoid compounds
would be shifted to the right, relative to gefitinib. However, this was not observed, as gefitinib
inhibited p-ERK1/2 at four times the concentration of p-STAT3 inhibition, but Gef-SV40-NArg,
the most potent drug conjugate, did not inhibit p-ERK1/2 at even more than ten times the
concentration of p-STAT3 abrogation.

3.4.4

Drug-Peptoid Conjugates Downregulate EGFR-Dependent, but not JAK-Dependent
STAT3 Phosphorylation

As discussed, STAT3 is a transcriptional activator that can translocate into and out of the nucleus,
where it mediates the expression of a variety of genes. In a canonical sense, STAT3 is most often
associated with activation by Janus Kinase 1 (JAK1), but it can also be activated through either
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Figure 3.10. Dose Response of NArg-Based Drug Conjugates in MDA-MB-468 Cells. 468 cells
were exposed to increasing concentrations of gefitinib, Gef-NArg or Gef-SV40-NArg in the
presence of EGF (25 ng/mL). Cell lysates were probed for p-STAT3 (Y705), t-STAT3, p-ERK1/2
and β-tubulin. Data generated by Wells Brown, Purdue University College of Pharmacy.
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Figure 3.11. Drug-Peptoid Conjugates Downregulate EGFR-Dependent Phosphorylation of
STAT3. MDA-MB-468 Cells were cultured in the presence of either EGF (25 ng/mL) or IL-6 (20
ng/mL), followed by exposure to 1 µM Gef-NArg, Gef-SV40-NArg, gefitinib or the JAK1 inhibitor
ruxolitinib. Cell lysates were probed for p-STAT3 (Y705), t-STAT3, p-ERK1/2 and β-tubulin. Data
generated by Wells Brown, Purdue University College of Pharmacy.

direct interaction with EGFR or downstream pathways of EGFR [457–460]. To investigate whether
the drug-peptoid conjugates were affecting JAK-dependent STAT3 phosphorylation, MDA-MB468 cells were exposed to either EGF or IL-6 to activate EGFR- or JAK-dependent signaling
cascades, respectively. Gef-NArg, Gef-SV40-NArg, gefitinib and the JAK1 inhibitor ruxolitinib
were added to determine the effect on levels of p-STAT3 and p-ERK1/2 (Figure 3.11). As before,
in the presence of EGF Gef-NArg, Gef-SV40-NArg and gefitinib disrupted the phosphorylation of
STAT3, while only gefitinib affected the levels of p-ERK1/2. Conversely, in the presence of IL-6,
none of the compounds had an effect on p-STAT3, with the exception of ruxolitinib. Additionally,
IL-6 exposure did not result in ERK1/2 phosphorylation, indicating that STAT3 and ERK1/2 do
not associate with one another under the conditions of interleukin-induced JAK activation.

3.4.5

Gef-SV40-NArg Has Strong Potential for Oral Absorption

To investigate whether the drug conjugates might make good drugs in and of themselves, a
permeability study was performed with Gef-SV40-NArg to see if it was able to be absorbed through
the gastrointestinal tract. Caco-2 epithelial colorectal adenocarcinoma cells were cultured in
DMEM and plated as a single layer in Corning 12-well 0.4 μm polyester Transwell filter supports
(see Appendix B for experimental methodology). In order to ensure an adequate acceptor
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compartment concentration, the ligand concentration was kept well over 100-fold higher than the
limit of detection. Gef-SV40-NArg permeability was measured with an initial concentration of 100
μM in 1% DMSO/HBSS in triplicate samples. All samples gave an area under the curve well above
background, and future studies could likely be conducted over a shorter time scale or up to 10-fold
lower concentration. A significant lag period of between 30 and 60 minutes was seen; however,
linearity was stable after 60 minutes. This lag could be caused by slow permeation and equilibration
across the cell monolayer, but a jump in dC/dt slope can also be indicative of cell toxicity. It should
be noted that while Caco-2 cells are immortalized, they are contact-inhibited, and monolayers are
fully differentiated and no longer dividing at the time of study. Permeability results for Gef-SV40NArg are shown below:

Table 3.3
Permeability of Gef-SV40-NArg in
Caco-2 Cells

*

Triplicate 1

6.72 x 10-6 *

Triplicate 2

6.29 x 10-6 *

Triplicate 3

5.98 x 10-6 *

Average

6.33 x 10-6

Deviation

3.68 x 10-7

Values are reported as the
permeability across the cell
monolayer in cm/s

(Experiment performed by Christopher Kulczar, Purdue University College of Pharmacy)

In the assay, the mass balance for the drug conjugate was nearly 100%, indicating that the
compound remained stable throughout the experiment. Based on the results, it was concluded that
the permeability rates were considered to be in the middle range, suggesting that the drug conjugate
would have reasonable absorption through the gastrointestinal tract when ingested orally.
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3.5

Discussion

This study establishes a strategy for subcellularly targeting a small molecule that aims to inhibit
receptors at the level of the nucleus. The direction of molecules to intracellular compartments has
been studied for at least a couple decades, but this work reports, to our knowledge, the first instance
of incorporating a tyrosine kinase inhibitor into a NLS or CPPo. This same approach is versatile in
that it could theoretically be used to target numerous small molecules that are agonists/antagonists
of various protein targets. Both the peptide and peptoid portions of these compounds are
synthesized without much difficulty, and chemical modification of the small molecules would
allow for facile conjugation to the sequences using basic conditions for solid-phase peptide
synthesis.
The NLS and CPPo sequences used in this work were selected based on their success in
trafficking small molecule fluorescent dyes into the cell [437–439]. The design of these compounds
to simultaneously contain both the peptide-based NLS and peptoid-based CPPo proved to enhance
their cellular uptake and activity, but the physical structure of the drug conjugates, as a whole, may
not be ideal for every situation. While the six-methylene linkers provide spatial separation of
approximately 10 Å between the drug and peptide/peptoid portion of these molecules, it is possible
that the targeting sequence still destabilizes the binding of the small molecule to its target due to
steric clashing between the sequence and the protein. Other methods of attachment could be
explored such as either disulfide or thioether-based covalent linkages [429], which could become
reduced upon cellular uptake, releasing the drug. This, however, may not be an ideal alternative for
targeting the nucleus since the constrained timeframe of cellular machinery transporting the ligands
to the nucleus would necessitate a non-labile linker.
A major finding of this work is the observation that the drug conjugates downregulate
phosphorylation of STAT3, but do not affect ERK1/2, whereas commercial gefitinib abrogates pERK1/2 as cells are exposed to increasing concentrations of the drug. Both ERK1/2 and STAT3
can be found downstream of EGFR, but the involvement of each in cellular processes is quite
different (see Figure 3.12). ERK1 and ERK2, also referred to as MAPK3 and MAPK1, respectively,
are both part of the well-studied MAPK/ERK pathway that acts as a mediator of signal transduction
from the surface of cells to the nucleus. ERK1/2 are found in the cytoplasm until they become
activated, upon which they dimerize and pass into the nucleus. STAT3, on the other hand, can be
found in both the cytoplasm and nucleus, as it can translocate back and forth independent of its
phosphorylation [455,456]. In order to perform its role as a transcriptional factor, it becomes
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Figure 3.12. Cytoplasmic and Nuclear Modes of EGFR Signaling. Signaling originating from
EGFR propagates through the cell via two major pathways—one occurring in the cytoplasm, and
the other in the nucleus. Upon EGFR activation at the cell surface, EGFR either: 1) activates
downstream signaling proteins such as PI-3K, PLC-γ, one of the STATs, or RAS; these
subsequently activate further downstream proteins, causing a signal cascade that eventually reaches
targets in the nucleus, activating various cellular growth- or survival-related processes. 2)
translocates to the nucleus where it binds with and activates proteins that then lead to the initiation
of cellular responses such as checkpoint regulation, proliferation and DNA repair.
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activated though phosphorylation at residue Y705 in response to a number of cytokines and growth
factors, and has been identified as one of the two most important members of the STAT protein
family for cancer progression [461–463]. Unlike ERK1/2, there is evidence that STAT3 physically
associates and colocalizes with EGFR in the cell nucleus following EGF stimulation [457]. This is
a compelling observation since it would imply that it is possible that the drug conjugates
downregulate STAT3 in the nucleus of each of the cell lines.
Interestingly, in the context of downregulating STAT3 phosphorylation, LM1 cells
displayed a higher sensitivity to Gef-SV40-NArg than did NME cells (Figure 3.9). As previously
mentioned, as opposed to what is seen in NME cells, EGFR is upregulated in the nucleus of LM1
cells (Appendix B, Figure B.1), though the overall whole-cell expression level of the receptor is
comparable to wild-type cells. This could provide an explanation for the enhanced sensitivity to
downregulation of p-STAT3, but some investigation is still needed. As of yet, there is still no proof
of direct inhibition of STAT3 activation by EGFR in the nucleus, though the evidence presented
here could suggest that is occurring. Future experiments involving alternative subcellular tags or
nuclear separation could help to answer that question.
Ultimately, the discovery of ligands that preferentially downregulate signaling proteins
downstream of EGFR could have important implications for the treatment of certain cancers.
STAT3 is an important signaling mediator in malignant disease, and it has been seen to be
persistently activated in 22-65% of all non-small cell lung cancers [464–466]. Previous studies
have demonstrated that suppressing signaling from EGFR-STAT3 [467], as well as STAT3
signaling in general [468–472], can result in tumor cell apoptosis in breast, melanoma, leukemia,
myeloma and lung cancer types. Because constitutive IL-6R/JAK1/STAT3 signaling has been
proposed as a major mechanism of resistance for EGFR-TKIs [473], using the nuclear-targeted
conjugates in combination with a IL-6R/JAK1 pathway inhibitor could be an effective treatment
for patients with TKI-resistant cancer [474]. Together with the observations that the gefitinibconjugated molecules curtail the growth of gefitinib-resistant cells more efficiently than
commercial gefitinib, and that they hold the potential for good absorptivity through oral
administration, demonstrating that these compounds are able to efficiently target specific segments
of signaling pathways could substantially increase their value as therapeutics for disease.
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4. FUTURE DIRECTIONS

The search for new therapeutics to treat human disease is constant. Although there is a steady
stream of new drug applications in the United States every year, the total number of these
applications pales in comparison to that seen just a decade and a half ago. Due to the ballooning
costs associated with the research and development of a new drug, which are further exacerbated
by the tremendous subsequent investment necessary to take the drug to market, many entities have
scaled back drug discovery efforts and generally focus on ‘safer’ targets. This unfortunately results
in the vast majority of research focusing on a relatively small set of proteins [206], and the
chemotypes present in many libraries used for high-throughput screening tend to be biased toward
traditional drug targets such as receptor tyrosine kinases and enzymes [207–209]. The work
presented here represents two unique strategies that diverge from prototypical drug discovery
efforts in that they aim to provide new avenues for the discovery of new drug chemotypes.
Ultimately, the initial discovery of compounds that inhibit PCNA-protein interactions or target
subcellularly-located protein receptors lays a foundation for future work that could result in second
or third generation compounds that are much improved, and could see broader application in the
research & development or clinical spaces.

4.1

Using Chemical Information from Peptoid Hits to Develop More Drug-Like
Inhibitors

In the analysis of the peptoids that inhibited the interaction between PCNA and the PL peptide,
there were similar chemical features that were shared between the top hits. A general weakness of
these compounds is that they each have many rotational degrees of freedom, which, among other
features, does not make them ideal lead drug candidates. It would be advantageous if the features
that contributed to the ligands’ individual affinities could be conserved, but incorporated into a
more rigid drug-like structure (Figure 4.1). Chemistry currently exists that allows for the
rigidification of peptoid structures on resin by causing ring closure of a portion of the peptoid’s
backbone. This could be used, as an example, in the pursuit of next-generation lead molecules.
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Figure 4.1. Shared Chemical Features Between Peptoid Hits Can Be Incorporated into Lead
Compounds. (top) The average output positions of NLys-NPip-NBal (green sticks) and T2AANEal-NPip (blue sticks) from their respective MD simulations with PCNA are shown overlaid.
(bottom) Overlapping chemical features between the two ligands are color coded in blue, pink, red
or green, and these can be incorporated into a more rigid, drug-like scaffold to create nextgeneration lead molecules.
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Along with combining chemical features to make better lead antagonists, the peptoid side
chain library could be expanded to include fragments that have been used in other various studies
[302,305,312,318,320,475], as well as different chemotypes in general. With the additional 46
fragments shown in Figure 4.2, the total combinatorial library of tripeptoids would increase to more
than 570,000 compounds, and more than 585,000 when T2AA is included as a potential substituent

Figure 4.2. Set of Fragments for Incorporation into Future Virtual Libraries. In order to expand the
chemical space covered by tripeptoid-based screening, peptoid fragments previously used in other
studies can be incorporated into the virtual screening library.
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in the first position. Given that their features are distinct from inhibitors of classical targets, and
that they typically share certain properties with other members of their own class of compounds, it
is likely that inhibitors of protein-protein interactions will not cover extensive chemical space.
However, protein interaction surfaces can be quite diverse from one another, with substantial
differences in polar and nonpolar surface area as well as size and depth of surface pockets. Covering
a much larger fragment space for the purposes of using tripeptoids as a base for screening would
be beneficial in this case giving that it would, of course, greatly increase the probability of
discovering hit ligands.
As a logical next step following biochemical validation of tripeptoids, the best hits would
be tested in human cell lines to determine whether they elicit a quantifiable growth phenotype.
Abnormal regulation of PCNA levels, as well as post-translational modification of the protein
complex, has been observed in a number of malignant cell types, particularly breast and prostate
cancers [260,261]. As a result, cell lines such as MDA-MB-231 (breast), MDA-MB-468 (breast),
LNCaP (prostate), PC3 (prostate) and DU145 (prostate) would likely be used as the models for
testing. Demonstrating that the tripeptoid ligands can inhibit the growth of tumor-derived cells
would be an important validation of this study’s general approach toward discovering inhibitors of
protein-protein interactions. However, a major factor that is not taken into consideration in the
computational or biochemical testing processes is the ability for these compounds to efficiently
cross a cell membrane and/or be taken up via pinocytosis. It may be that the tripeptoids synthesized
for this study do not have favorable features for allowing them to efficiently be taken into cells, but
this has not yet been fully assessed.
Other future studies would aim to further investigate the mechanism of action of the
tripeptoid antagonists, as well as gauge their in vivo activity. The ability of these compounds to
affect DNA translesion synthesis (TLS) could be assessed using published methodology [178],
where, in the presence of PCNA antagonist, nuclear excision repair-resistant cells would be
transfected with plasmid DNA containing an intrastrand cisplatin cross-link in a coding region of
the lacZ gene, and another plasmid lacking the cross-link would serve as a control. Following a
period of incubation, replicated plasmid would be recovered and analyzed for TLS via E. Coli
transformation/colony selection. DNA damage response would be further monitored through the
use of tumor cell lines incubated with antagonist, cisplatin, or both. Cells would be stained using
γH2AX, a biomarker for double-stranded DNA breaks [476], and analyzed with flow cytometry.
In parallel to those studies, questions of whether blocking the PIP Box binding site could have an
effect on PCNA post-translational modification (PTM), and whether levels of PTM have an effect

128
on binding affinity at the PIP Box site could also be pursued. These are interesting questions since
the plasticity of PCNA [177] may accommodate for a larger variety ligands that bind at the PIP
Box site, and this could have ‘long-range’ effects on the opposing face of the protein complex that
directly affects levels of PTM—thus potentially having an effect on overall levels of DNA damage
repair. Furthermore, demonstrating that PCNA ubiquitination has an effect on the affinity of ligands
to bind at the PIP Box binding site could have huge benefits for drug-target specificity.
In further validation of tripeptoid-based inhibitors as potential drug candidates, top lead
molecules could be further evaluated for their pharmacological properties in early ADME/tox
profile assays. Prior to any in vivo efficacy testing, acute toxicity studies can be executed on all
compounds deemed as leads for in vivo testing. Pharmacokinetic studies can also be pursued in
rodent models. Ultimately, experimental data obtained from the tripeptoid molecules could be used
in the design of compound formulations that enable the drug properties and hypothesis testing to
be conducted with new tripeptoid molecular entities. Additionally, it is possible that due to the
homotrimeric nature of PCNA, a nanotechnology-esque approach could be utilized where three PIP
Box antagonists are linked together to inhibit all three binding sites on PCNA simultaneously
(Figure 4.3)—thus greatly enhancing the specificity and potency of these compounds.

4.2.

Further Assessment of the Nuclear Effect of Subcellularly-Targeted Gefitinib, and
Exploring the Localization of Alternative Small Molecule Inhibitors

The study outlined in Chapter 3 showed the feasibility of incorporating the known tyrosine kinase
inhibitor, gefitinib, into a peptoid-based sequence in an effort to target it to the nucleus of cancer
cells. The results indicated that as opposed to commercial gefitinib, these peptoid-based conjugates
were able to downregulate the phosphorylation of STAT3 while not affecting the phosphorylation
of ERK1/2. Fluorescently-tagged variants of the conjugates were able to be taken up into cells, and
FAM-SV40-NArg in particular was taken into the nucleus; however, direct evidence of the
gefitinib-tagged molecules in the nucleus would be important to establish. The next major piece of
evidence for the justification of the use of these compounds would be showing that they have a
strong growth phenotype. A two-dimensional MTT assay was performed using Gef-NLys and GefSV40-NLys, but the experiment would need to be performed with the NArg-based ligands,
especially given that there was evidence of them being more effective in the disruption of p-STAT3,
as well as having enhanced cellular and nuclear uptake. In three-dimensional cell growth studies
using NME and LM1 cell lines, the peptoid-based conjugates did not show much evidence of
growth inhibition over a four week study (data not shown). However, when T2AA, which has been
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Figure 4.3. Simultaneous Targeting of the Three PIP Box Binding Sites on PCNA. Attaching three
of the same PIP Box antagonists, such as T2AA-NEal-NPip (shown here), together with a
polypropylene glycol linker could allow for the simultaneous targeting of all three PIP Box binding
sites of PCNA upon the formation of the protein homotrimer. PCNA is shown as a gray surface,
while the trimeric antagonist is shown as yellow sticks.
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seen to disrupt cell proliferation in the U2OS bone osteocarcinoma cell line, was introduced to both
NMEs and LM1s in the same 3D assay, an enhancement of growth was observed. As a result, there
are likely multiple factors that affect the sensitivity of these cell lines to different types of inhibitors,
and so a proper model system would need to be developed.
To further validate the activity of the inhibitors in the nucleus, a number of different
experiments could be performed. In contrast to the nuclear localization sequence that was used in
this study to target the molecules to the nucleus of cells, a nuclear exclusion signal could be
incorporated, which would instead target the compounds for export from the nucleus into the
cytoplasm [477–479]. The phosphorylation statuses of STAT3 and ERK1/2, as well as potential
growth phenotype data, could be compared between the two classes of compounds to see if the
targeting sequence has a true effect. Separately, it was established here that inhibition of STAT3
phosphorylation by the peptoid antagonists was dependent on EGF stimulation. While this would
make sense at face value given that the ligands should be inhibitors of EGFR, the downstream
mechanisms of this inhibition are not yet completely understood. As of yet, it has not been proven
whether the observed effect on p-STAT3 in NME, LM1 and MDA-MB-468 cells is due to the direct
interaction of STAT3 with nuclear EGFR, or if there is simply inhibition occurring at the cell
surface, and the downstream signal originating from EGFR gets disrupted. This would be a point
of emphasis in elucidating the mechanism of action of the gefitinib-peptoid conjugates in the
disruption of p-STAT3. Furthermore, the functional consequence of abrogating STAT3
phosphorylation would need to be assessed. The protein naturally acts as transcription activator
upon its phosphorylation, and in cancer types dependent on altered EGFR-STAT3 signaling,
abolishing STAT3 phosphorylation may prove to be an effective strategy for inhibiting
tumorigeneses [467].
It is not yet known whether the peptoid/peptide sequences have a negative impact on the
drug binding to its target. While a six-member methylene linker was used to separate the drug from
the peptide or peptoid portion of these conjugate molecules, if the ligands are not subjected to
intracellular proteolysis, which may subsequently cause the drug to be released from the targeting
sequence, the drug binding to its protein receptor would necessitate the remainder of the molecule
(including the peptide and peptoid portions) to either wrap around the surface of the protein, or
project freely out into solution. It is likely that there are non-zero penalties to solvation and desolvation energies, as well as potentially added steric clashes between these molecules and the
receptor, as opposed to the commercial drug alone. Therefore, it may be beneficial to design a
method for the drug to be released from the peptide/peptoid targeting sequence within the cell. One

Figure 4.4. Alternative Reducible Linkers for Drug-Peptoid Conjugates. It is possible that coupling drugs, such as gefitinib shown here, to
alternative reducible linkers could provide a way for the drug to be cleaved from accompanying peptoid-peptide sequences inside the cell. Two
versions of a simple reducible disulfide linker is shown here which allows gefitinib to be attached to either the N-terminus (top) or C-terminus
(bottom) of the targeting sequence.
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idea is to use a reducible linker that involves a disulfide bond (Figure 4.4). This is a strategy
currently used in the design of vintafolide, an anticancer drug currently in Phase IIb clinical trials
for the treatment of non-small-cell lung carcinoma. Variants of this spacer could be designed so as
to be able to attach a desired drug to either the N- or C-terminus of a targeting sequence.
In addition to gefitinib, other protein kinase inhibitors could be explored for their potential
for incorporation into peptide/peptoid-conjugates. In this way, the subcellular targeting strategy can
be pursued against alternative receptors. For example, Figure 4.5 shows other potentially
modifiable kinase inhibitors such as erlotinib, imatinib, dasatinib, crizotinib and lapatinib, which
are antagonists of EGFR, BCR-Abl, BCR-Abl, ALK/ROS1 or HER2/neu/EGFR, respectively. In
the original design of piperazinyl gefitinib, the morpholino group was chosen as the site for
modification since it is in a portion of the molecule that is easily substituted, and it projects out into
solution, away from the interior of the binding pocket on EGFR (see PDB ID: 2ITY). The
modifications proposed in Figure 4.5 were selected for the same reason, where in each case the
location of substitution projects outward from the interior of the binding pocket. In addition to
exploring other kinase inhibitors, alternative targeting sequences could be pursued. For example,
instead of the SV40 nuclear localization sequence, TAT may be used. Other subcellular
compartments could be targeted in the future as well, where drug-conjugates could be directed to
the nucleolus [480], mitochondria [481] or peroxisomes [482], or could be targeted for secretion or
retention in the endoplasmic reticulum [483,484]. This could prove to be a versatile strategy for
increasing the intracellular concentration of a drug molecule in a desired compartment of interest.
In further investigation of the significance of the nuclear-targeted ligands, future work
could be done to determine whether a possible connection to the processes of DNA damage repair
exists. nEGFR plays a very important role in DNA repair pathway activation, and previous studies
have shown increased localization of EGFR to the nucleus after ionizing radiation (IR) [485–487].
Additionally, nEGFR’s direct interactions with PCNA and DNA-PK are both heavily implicated in
DNA repair [276,446,485,487,488]. Along with the previously discussed importance of PCNA and
its relation to the MMR repair pathway, DNA-PK is an essential protein to both the HR and NHEJ
repair pathways that address double strand breaks, and it becomes activated by phosphorylation by
EGFR allowing it to carry out its function in either pathway. The increased levels of
phosphorylation of PCNA and DNA-PK in various cancer types could explain in part the high
resistance to genotoxic agents, such as cisplatin, and IR. The loss of phosphorylation of PCNA
would decrease both the amount of active PCNA and the amount that is bound to chromatin; both
of these effects have been implicated in cell cycle progression. The loss of active DNA-PK would
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Figure 4.5. Variants of Protein Kinase Inhibitors Can Be Incorporated into a Peptide/Peptoid.
Similar to gefitinib in this study, other protein kinase inhibitors can be modified so as to be able to
conjugate them to a peptide or peptoid. Here, the linkages are analogous to the one used for
gefitinib, with a six-member methylene spacer separating the drug from the targeting sequence.
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see wide reaching effects given that it has many interactors, but much of the DNA repair aspects
of DNA-PK can be supplemented by PARP1, which can also activate NHEJ pathway independent
of DNA-PK [489]. It is possible that the addition of a PARP1 inhibitor along with gefitinib could
cause a synthetic lethal relationship by inhibiting the alternate NHEJ pathway [490,491] in addition
to downregulating the phosphorylation of PCNA, which itself has been strongly correlated with
enhanced tumorigenesis [260,261]. In effect, both double strand break repair pathways could be
inhibited, and this could be further supplemented by the inhibition of PCNA-dependent
[175,176,256] repair mechanisms. Ultimately, this could prove to be an effective treatment for
multiple forms of cancer.
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A. Characterization of PCNA Peptoid Inhibitors

Table A.1
PCNA Crystal Structures Used for Computational Screening
PDB ID†
1AXC

Description
Structure of the C-terminal region of
p21(WAF1/CIP1) complexed with human PCNA

3VKX

PCNA complexed with the small molecule
antagonist T3 at the PIP Box binding site

1U7B

Structure of human PCNA in complex with a
peptide derived from residues 331-350 of flap
endonuclease-1 (FEN1)

2ZVK

Structure of human PCNA in complex with a
fragment of DNA polymerase eta

† All crystal structures were obtained from the RCSB Protein Data Bank
(http://www.rcsb.org/pdb/home/home.do)
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Figure A.1. Initial Peptoid Fragment Tally by PCNA Crystal Structure. The initial amine fragment
library consisting of 20 primary amines as well as hydrogen as a substituent (Gly) was screened
against four different crystal structures of PCNA—PDB IDs: 1AXC, 3VKX, 1U7B and 2ZVK. The
number of times a particular fragment appeared in a specific substitution position on the peptoid
backbone, in the top 50 hits for each crystal structure, was tallied. Each structure displayed slightly
different results. “1st”, “2nd” and “3rd” positions are as defined in Figure 2.2.
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Table A.2
Characterization of Screened Tripeptoids
Calculated Mass
[M+H]1+

Observed Mass b
(m/z)

% Yield c

Gly-NPip-NBal

443.1931

443.5391

7.19%

NAem-NArg-NPip

535.2948

535.2581

47.49%

NAem-NArg-NTyr

507.2999

507.3044

22.44%

NAem-NEal-NBal

466.2621

466.2658

15.51%

NAem-NLys-NPip

507.2887

507.3019

32.08%

NAem-NLys-NTyr

479.2938

479.2624

33.93%

NAem-NPip-NBal

556.2772

556.2767

22.40%

NAem-NPip-NBza

570.2520

570.2553

34.71%

NAem-NPip-NPip

570.2520

570.3911

73.95%

NAem-NPip-NTyr

542.2570

542.2764

50.28%

NAem-NTyr-NPip

542.2615

542.3094

40.60%

NAem-NTyr-NTyr

514.2621

514.3411

7.16%

NArg-NArg-NPip

521.2904

521.4318

32.30%

NArg-NIle-NBal

464.2986

464.2994

9.40%

NArg-NLys-NBza

493.2843

493.2887

32.32%

NArg-NLys-NPip

493.2843

493.5698

34.09%

NArg-NPip-NBal

542.2683

542.2703

29.86%

NArg-NPip-NBza

556.2475

556.1994

13.39%

NArg-NPip-NPip

556.2475

556.2516

8.29%

NArg-NPip-NTyr

528.2526

528.2560

3.31%

NArg-NTyr-NBal

514.2778

514.2761

10.11%

NArg-NTyr-NTyr

500.2577

500.2616

13.73%

NBal-NArg-NBal

528.2890

528.2910

12.43%

NBal-NEal-NBza

487.2193

487.2186

29.94%

NBal-NLys-NPip

514.2621

514.2656

29.10%

NBal-NLys-NTyr

486.2672

486.3338

10.92%

NBal-NPip-NBal

563.2462

563.1897

5.32%

NBal-NPip-NBza

577.2254

577.2296

19.10%

Peptoid Sequence a

a

N-substituted side chains listed from N-terminus to most C-terminal
as determined by high resolution electrospray ionization or MALDI-TOF
c
based on dry mass recovery after HPLC purification
b
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NBal-NPip-NTyr

549.2305

549.2338

46.74%

NBal-NTyr-NBal

535.2512

535.2536

12.01%

NBal-NTyr-NPip

549.2350

549.2787

26.26%

NBza-NArg-NBal

542.2683

542.2712

20.25%

NBza-NArg-NPip

556.2475

556.2506

49.91%

NBza-NLys-NBza

528.2414

528.2452

23.80%

NBza-NLys-NPip

528.2414

528.2443

49.19%

NBza-NLys-NTyr

500.2465

500.2509

27.46%

NBza-NPip-NBal

577.2254

577.2283

14.47%

NBza-NPip-NBza

591.2047

591.2075

14.18%

NBza-NTyr-NBal

549.2305

549.2157

10.93%

NBza-NTyr-NPip

563.2098

563.4002

17.49%

NEal-NEal-NBza

411.1836

411.3020

10.34%

NEal-NEal-NPip

411.1836

411.1878

22.09%

NEal-NEal-NTrp

420.2203

420.2237

28.15%

NEal-NLys-NPip

438.2308

438.2353

33.02%

NEal-NPip-NBza

501.1941

501.1979

1.71%

NEal-NPip-NPip

501.1941

501.1972

37.39%

NEal-NPip-NTrp

510.2353

510.2364

11.03%

NLys-NArg-NPip

493.2843

493.4769

29.45%

NLys-NBal-NPip

514.2621

514.2684

35.56%

NLys-NEal-NBza

438.2308

438.2353

7.50%

NLys-NEal-NPip

438.2308

438.2351

34.86%

NLys-NIle-NBal

437.2958

437.4813

0.82%

NLys-NLys-NPip

465.2781

465.5013

28.13%

NLys-NPip-NBal

514.2621

514.2656

8.62%

NLys-NPip-NBza

528.2414

528.3454

36.49%

NLys-NPip-NMba

513.2826

513.6709

6.75%

NLys-NPip-NPip

528.2414

528.3143

27.24%

NLys-NTyr-NBal

486.2672

486.2708

20.16%

NLys-NTyr-NBza

500.2465

500.2403

21.69%

NLys-NTyr-NPip

500.2465

500.2713

10.44%

NMba-NPip-NBal

562.2666

562.6433

23.68%
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NPip-NPip-NPip

591.2047

591.8057

3.97%

NTyr-NArg-NBal

514.2734

514.3009

11.59%

NTyr-NArg-NPip

528.2526

528.3313

3.44%

NTyr-NEal-NBal

459.2199

459.2245

16.40%

NTyr-NIle-NBal

471.2563

471.3852

12.99%

NTyr-NLys-NPip

500.2509

500.2503

47.78%

NTyr-NLys-NTyr

472.2516

472.1906

4.57%

NTyr-NPip-NBal

549.2350

549.6621

0.75%

NTyr-NPip-NBza

563.2098

563.2132

27.46%

NTyr-NPip-NPip

563.2098

563.2128

23.04%

NTyr-NPip-NTyr

535.2193

535.2186

45.90%

NTyr-NTyr-NPip

535.2149

535.2551

23.10%

T2AA-Asn

682.9864

682.9854

5.78%

T2AA-Gln

697.0021

697.0003

8.15%

T2AA-Gly

625.9649

625.9629

0.81%

T2AA-Gly-NBal

803.0439

803.0422

9.83%

T2AA-Gly-NPip

817.0232

817.0266

4.51%

T2AA-NEal-Gly

727.0126

727.0109

3.81%

T2AA-NEal-NBal

847.0701

847.0695

1.67%

T2AA-NEal-NMba

846.0861

846.8161

13.13%

T2AA-NEal-NPip

861.0450

861.0513

5.95%

T2AA-NEal-NTyr

833.0545

833.0562

15.00%

T2AA-NPip-NLys

888.0967

888.0983

9.41%

T2AA-NPip-NPip

951.0560

951.0586

4.95%
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Figure A.2. Z’-Factor Analysis. Polarization values for 24 replicate samples of both positive and
negative controls were used to evaluate the quality of the assay platform. 10 nM FAM-PL and 100
nM PCNA served as the positive control, while 10 nM FAM-PL in binding buffer served as the
negative control. Dashed lines indicate the mean value of each set of controls, and dotted lines
indicate the 95% prediction interval.

Figure A.3. PCNA Titration for Determining Affinity of FAM-PL. Increasing amounts of
recombinant PCNA were added to a fixed concentration of the FAM-PL peptide (5 nM) in binding
buffer. The data were fit to Equation 2.3 was used to determine the Kd value for the peptide (here,
the calculated affinity was 107 nM).
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Table A.3
Peptoid Number from Initial Tripeptoid FP Screen (Figure 2.8)
Peptoid Sequence
(1st – 3rd Position)

Peptoid Number

NAem-NArg-NPip

1

NAem-NArg-NTyr

2

NAem-NEal-NBal

3

NAem-NLys-NPip

4

NAem-NLys-NTyr

5

NAem-NPip-NBza

6

NAem-NPip-NPip

7

NAem-NPip-NTyr

8

NAem-NTyr-NPip

9

NAem-NTyr-NTyr

10

NArg-NArg-NPip

11

NArg-NLys-NBza

12

NArg-NLys-NPip

13

NArg-NPip-NBal

14

NArg-NPip-NBza

15

NArg-NPip-NPip

16

NArg-NPip-NTyr

17

NArg-NTyr-NTyr

18

NBal-NArg-NBal

19

NBal-NEal-NBza

20

NBal-NLys-NPip

21

NBal-NLys-NTyr

22

NBal-NPip-NBal

23

NBal-NPip-NBza

24

NBal-NPip-NTyr

25

NBal-NTyr-NBal

26

NBal-NTyr-NPip

27

NBza-NArg-NBal

28

NBza-NArg-NPip

29

NBza-NLys-NBza

30
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NBza-NLys-NPip

31

NBza-NLys-NTyr

32

NBza-NPip-NBal

33

NBza-NPip-NBza

34

NBza-NPip-NTyr

35

NBza-NTyr-NBal

36

NBza-NTyr-NPip

37

NEal-NEal-NBza

38

NEal-NEal-NPip

39

NEal-NLys-NPip

40

NEal-NPip-NBza

41

NEal-NPip-NPip

42

NLys-NArg-NPip

43

NLys-NBal-NPip

44

NLys-NEal-NBza

45

NLys-NEal-NPip

46

NLys-NLys-NPip

47

NLys-NPip-NBal

48

NLys-NPip-NBza

49

NLys-NPip-NPip

50

NLys-NTyr-NBal

51

NLys-NTyr-NBza

52

NLys-NTyr-NPip

53

NPip-NPip-NPip

54

NTyr-NArg-NBal

55

NTyr-NArg-NPip

56

NTyr-NEal-NBal

57

NTyr-NIle-NBal

58

NTyr-NLys-NBza

59

NTyr-NLys-NPip

60

NTyr-NLys-NPip

61

NTyr-NLys-NTyr

62

NTyr-NPip-NBza

63
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NTyr-NPip-NPip

64

NTyr-NPip-NTyr

65

NTyr-NTyr-NBza

66

NTyr-NTyr-NPip

67

T2AA-NEal-NPip

68

T2AA-Gly-NPip

69
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Figure A.4. Chemical Structure of NMba. After initial results from experimental screening, the
fragment NMba was selected for incorporation into peptoids as a substitute for NBal due to its
structural similarity, but ability to form an additional hydrogen bond. The fragment was purchased
as a Boc-protected amine (left), but the side chain becomes exposed upon incorporation into a
tripeptoid and subsequent cleavage with trifluoroacetic acid (right). N* denotes a peptoid backbone
nitrogen.
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Figure A.5. Necessary Protecting Groups on Peptoid Fragments. Some of the fragments selected
for incorporation into either the virtual or synthetic libraries require protecting groups on reactive
species. N* indicates the location of the –NH2 group, which is the position of substitution into a
peptoid backbone.

Figure A.6. Dose Response Curves of Individual Peptoid Fragments. The fragments present in hit tripeptoid molecules were screened
individually in the FP assay to determine if they could individually disrupt the binding between PCNA and the PL peptide. None of the small
fragments showed any evidence of inhibition. T2AA was selected as the positive control, and DMSO as the negative control. Error bars represent
the standard error of the mean.
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T2AA-Asn

T2AA-NEal-Gly

T2AA-Gln

T2AA-NEal-NMba

T2AA-Gly

T2AA-NEal-NPip

T2AA-Gly-NBal

T2AA-NEal-NTyr

T2AA-Gly-NPip

T2AA-NPip-NLys

Figure A.7. Structure of T2AA-Conjugates. For second generation peptoid inhibitors of PCNA,
T2AA was coupled to the N-terminus of peptoids or peptides anchored on solid phase resin to
generate the molecules shown above.

Figure A.8. Co-Crystal Structure of PCNA-PL Peptide (PDB ID: 1VYJ).
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Figure A.9. PCNA-T2AA MD Simulation Ouput. (a) Average structure of the final 50 frames of the PCNA-T2AA MD simulation. (b) RMSD
diagram demonstrating simulation convergence. (c) Ligand interaction diagram showing molecular contacts over the course of the simulation.
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Figure A.10. PCNA-NLys-NPip-NBal MD Simulation Ouput. (a) Average structure of the final 50 frames of the PCNA-NLys-NPip-NBal MD
simulation. (b) RMSD diagram demonstrating simulation convergence. (c) Ligand interaction diagram showing molecular contacts over the
course of the simulation.
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Figure A.11. PCNA-NLys-NTyr-NBal MD Simulation Ouput. (a) Average structure of the final 50 frames of the PCNA-NLys-NTyr-NBal MD
simulation. (b) RMSD diagram demonstrating simulation convergence. (c) Ligand interaction diagram showing molecular contacts over the
course of the simulation.
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Figure A.12. PCNA-T2AA-NEal-NPip MD Simulation Ouput. (a) Average structure of the final 50 frames of the PCNA-T2AA-NEal-NPip
MD simulation. (b) RMSD diagram demonstrating simulation convergence. (c) Ligand interaction diagram showing molecular contacts over
the course of the simulation.
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Figure A.13. PCNA-T2AA-Gly-NPip MD Simulation Ouput. (a) Average structure of the final 50 frames of the PCNA-T2AA-Gly-NPip MD
simulation. (b) RMSD diagram demonstrating simulation convergence. (c) Ligand interaction diagram showing molecular contacts over the
course of the simulation.
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Figure A.14. MD Simulation Cα Atom RMSD Fluctuation by Residue Number. RMSD diagrams of each PCNA-peptoid MD simulation
are shown. Peaks indicate areas of the protein that fluctuate the most during the simulation. Alpha helical and beta-strand regions are
highlighted in orange and blue, respectively. Contacts between the ligand and PCNA residues are represented as green lines projecting
upward from the x-axis.
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Figure A.15. MD Simulation Interaction Diagrams. Interactions between PCNA amino acids and peptoid ligands or the PL peptide were
monitored over the course of each MD simulation. The number of trajectory frames in which an interaction occurred was recorded and listed
as a fraction of the total number of possible simulation frames. Numbers larger than 1.0 indicate that during the simulation, two or more
simultaneous interactions between a given protein residue and the ligand were taking place.
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Figure A.16. Enrichment Plot for Bayesian Model Prediction of the 2P2I Hunter Compound Set. A
leave-one-out cross-validation of the Bayesian model for the 1058-ligand 2P2I Hunter set was
performed, an enrichment plot was generated, and the percentages of true category members
captured at particular cutoff percentages were listed. From this, a best split value was calculated as
-0.188 for the Bayesian score.
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Figure A.17. Distribution of Peptoid Descriptor Statistics. After characterizing each peptoid from
the virtual library of 38 fragments (36 side chains and two variants of T2AA that can be
incorporated into a peptoid backbone), four descriptors for each ligand were calculated—
globularity, CW2, EDmin3 and IW4. Histograms showing the distribution of scores for each
descriptor amongst the entire set of peptoids are shown.
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B. Supplementary Information for Nuclear-Targeted Therapeutics and Cell Lines

Supplementary Materials and Methods

Imaging of NME and LM1 Cells by Immunofluorescence. Cells were seeded onto glass coverslips
and cultured overnight. The coverslips were washed with PBS, the cells fixed with PBS plus 4%
formaldehyde for 20 minutes at room temperature, and then the cells permeabilized with PBS plus
0.1% Triton X-100 for 20 minutes at room temperature. The cells were washed with PBS, followed
by PBS plus 2% BSA, and were incubated overnight at 4°C with primary antibody (anti-EGFR) in
PBS plus 2% BSA. After incubation, the cells were washed and again incubated for one hour at
room temperature with secondary antibody (donkey anti-mouse Alexa Fluor® 488) in PBS plus 2%
BSA. The cells were washed with PBS plus 2% BSA, PBS alone, followed by incubation with
DAPI and phalloidin (Alexa Fluor® 594) in PBS for 5 minutes at room temp. The cells were washed
in PBS three more times, then mounted to a glass slide using Prolong Gold anti-fade reagent.
Images were acquired using the Nikon A1R-MP confocal microscope in the Purdue Bioscience
Imaging Facility.

Assessing Oral Absorptivity of Gef-SV40-NArg with Caco-2 Cells. Caco-2 Cells were obtained
from ATCC (Manassas, VA). Dulbecco’s Modified Eagle’s Medium (DMEM), Fetal Bovine
Serum (FBS), Penicillin/Streptomycin (P/S), Non-Essential Amino Acids (NEAA), L-Glutamine,
Hank’s Balanced Salt Solution (HBSS), Phosphate Buffered Saline (PBS), Trypsin-EDTA, Type I
rat tail collagen, culture flasks, Corning 12-well 0.4 μm polyester Transwell filter supports, and all
other supplies were purchased form Sigma-Aldrich (St. Louis, MO). Caco-2 cells were cultured in
DMEM supplemented with 10% FBS, 1X P/S, 1X NEAA, and 2mM L-Glutamine in T-75 flasks
at 37oC in 5% CO2 and 90% RH. Media was changed every other day. Cells were passaged at a
ratio between 1:3 and 1:5 at 80-90% confluence. Cells were grown for at least 2 weeks after
removing from cryopreservation before studies were conducted.
Permeability studies were conducted in triplicate on Corning 12-well 0.4 μm polyester
Transwell filter supports. Transwells were pre-treated with 65 μL of 1 mg/mL Type I rat tail
collagen in 60% ethanol. Transwells were left overnight to evaporate ethanol prior to plating.
Passage 41 Caco-2’s were plated at a density of 70,000 cells/cm2. After plating, media was changed
every other day for 28 days. To ensure monolayer integrity, TEER was measured with a WPI Inc.
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EVOMX Volt-Ohm meter. All Transwells were above 400 ohm*cm2. Prior to studies, cells were
washed twice with PBS and then equilibrated for 30 minutes in HBSS, pH 7.4. After equilibration,
HBSS was removed and 0.5 mL of drug solutions were added to the apical chamber. Transwells
were then moved into well plates with 1.5 mL of pre-warmed HBSS. 200 μL samples were removed
from the basolateral compartment at 30, 60, 90, 120, 150, and 180 minute time points. After each
sample, 200 μL of HBSS was added to replace sample volume. Apparent permeability coefficients
were determined using the following equation:

𝑃𝑎𝑝𝑝 =

𝑉𝐴 ∗ (𝑑𝐶⁄𝑑𝑡)

(B.1)

𝑆𝐴 ∗ 𝐶0 ∗ 60

where Papp is the apparent permeability, VA is the volume of the acceptor compartment, dC/dt is the
change in basolateral compartment concentration over time, SA is the Transwell surface area, C0 is
the initial donor concentration, and 60 is a unit conversion from minutes to seconds.

The analysis was conducted on an Agilent 1100 HPLC with an Agilent Zorbax Eclipse XBD-C18
Column, 5 μm, 4.6 mm x 150 mm. Samples were kept in the autosampler at 4oC. A gradient method
was used and is shown below where A is water with 0.1% Trifluroacetic acid filtered through 0.22
μm nylon filters, and B is Chromsolv Acetonitrile with 0.1% Trifluoroacetic acid.

Table B.1. Solvent Gradient for HPLC Method
Time (min)

%A

%B

0

90

10

9

10

90

10

10

90

12

90

10

15

90

10

Flow was set to 1 mL/min with a column temperature of 40°C. Gef-SV40-NArg was measured at
345 nm. The retention time for the compound was 5.1 minutes. C0 and Donort-180 samples were
injected at 5 μL, while time point samples were 100 μL injections.
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Figure B.1. Localization of EGFR in NME and LM1 Cell Lines. Both cell lines were subjected to
analysis by immunofluorescence using a monoclonal antibody to detect EGFR. After
immunostaining, cells were stained with both DAPI and phalloidin (Alexa Fluor® 594) to detect
nuclei and actin, respectively. NME cells display upregulated whole-cell EGFR expression, while
LM1 cells show EGFR mostly localized to the nucleus. Images generated by Wells Brown, Purdue
University College of Pharmacy.
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Table B.2
Characterization of Subcellularly-Targeted Peptoid- or Peptide-Based Conjugates
Peptoid- or Peptide-Based
Conjugate a

a

Calculated Mass
[M+H]1+

Observed Mass c
(m/z)

Ahx-NArg

1534.0128

b

1534.4058

b

1.11 %

Ahx-SV40-NArg

2513.7174

b

2513.8523

b

1.29 %

FAM-NArg

1893.0684

b

1893.5849

b

0.45 %

FAM-NLys(7)

1383.8153

b

1383.9733

b

2.76 %

FAM-NLys(9)

1640.0053

b

1640.2131

b

2.11 %

FAM-SV40-NArg

2871.4355

b

2871.0960

b

1.15 %

FAM-TAT

2091.3680

b

2091.5021

b

3.46 %

Gef-NArg

2021.8010

2022.7603

2.62 %

Gef-NLys

1770.6882

1770.5853

0.34 %

Gef-SV40

1482.2582

1482.3820

3.61 %

Gef-SV40-NArg

2999.0735

2999.4851

0.47 %

Gef-SV40-NLys

2748.9687

2748.9822

3.20 %

naming conventions outlined in Chapter 3
calculated/detected as negative ion [M-H]1c
as determined by MALDI-TOF
d
based on dry mass recovery after HPLC purification
b

% Yield d

VITA
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